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CHAPTER 1




In the general population, cardiovascular disease (CVD) is a common cause of death[1,2]. Across 
Europe, CVD causes more than 4 million deaths each year, which accounts for almost 45% of 
all deaths[2]. Dietary and nutritional components are relevant players in the development 
and prevention of cardiovascular disease[3,4]. Fatty acids have been proposed as one of these 
components, which can be found in dairy (e.g. odd-chain fatty acids), fish (e.g. omega-3 fatty 
acids) and vegetable oils (e.g. Linolenic acid), common nutritional products of the Dutch diet[5].
Especially dairy products are an interesting source of investigation. First of all, the intake 
in the Netherlands is high. Additionally, it contains many different types of fatty acids, including 
both saturated and unsaturated, as well as both cis and trans fatty acids (see framework). Some 
of these fatty acids, such as the saturated odd-chain fatty acids as well as the trans fatty acids 
Vaccenic acid and Conjugated Linoleic acid, are thought to be rather unique for dairy products. 
Interestingly, recent research has suggested that the odd-chain fatty acids may reduce the risk 
to develop CVD[6-8]. Dairy fat is therefore an interesting target for further research to reduce 
cardiovascular risk in the general population.
Determining the precise effect of fatty acids from dairy products on health remains difficult. 
Current investigations rely mostly on dietary assessment tools, in which people record their 
daily consumption of products. These dietary assessment tools have their limitations. The data 
are not fully objective, and prone to bias and mistakes. Furthermore, dietary assessment tools 
only measure dairy fat intake, but do not take into account the uptake efficiency of the dairy 
fat into the human body and metabolism. To improve the reliability of the association between 
(dairy) fatty acids and cardiovascular health, new quantification methods are required, of which 
a direct measurement of fatty acids in blood samples represents an interesting example. Unique 
(combinations of) fatty acids present in blood can give insight in the consumption and uptake 
rate of the dairy products. In this thesis, we will explore the potential of different (combinations 
of) dairy fatty acids as potential biomarkers of dairy fat intake in the general population. In 




An introduction to fatty acids
Biochemistry
Fatty acids are rarely available as free fatty acid in nature. Most of the time they are the basic 
structural components of triglycerides, but they are also found as part of phospholipids or linked 
to cholesterol[9,10]. Naturally occurring fatty acids are typically composed of carbon chains with a 
methyl group at one end of the molecule, and a carboxyl group at the other end[11,12]. Fatty acids 
can be categorized according to chain length, number of double bonds, position of the double 
bonds (positional isomers) and configuration of the double bonds (geometric isomers)[13]. The 
most common fatty acids have chain lengths between 10 and 22 carbon atoms and are in large 
quantities present in plant oils and animal fats[11,12]. Fatty acids can be divided into saturated 
fatty acids (SFA), which are usually straight fatty acids with no double bonds, and unsaturated 
fatty acids, fatty acids with one (MUFA) or more double bonds (PUFA)[14]. Saturated fatty acids 
typically have an even number of carbon atoms (C12:0 – C18:0), but odd chain fatty acids can 
be found in nature as well (C15:0 and C17:0). These odd-chain fatty acids may either be de novo 
synthesized by some bacterial species using propionic acid or some other odd-short chain fatty 
acid as starter unit (instead of acetic acid), or by alpha-oxidation of even-chain fatty acids such 
as C16:0 (to C15:0) or C18:0 (to C17:0)[15]. Unsaturated fatty acids are either in cis- or trans 
configuration[14]. Well known cis fatty acids are the omega-3 fatty acids present in fish and some 
vegetables oils. Trans fatty acids are often produced during industrial hydrogenation (e.g. trans-
C18:1(n-9)), but can also be found in natural sources such as dairy (e.g. trans-C18:1(n-7))[16]. The 
trans fatty acids in milk derive from synthesis by the bacterial flora in the rumen of the animal.
Metabolism
The liver and adipose tissue are capable of synthesizing fatty acids de novo, particularly in the 
case of a carbohydrate rich diet. De novo lipogenesis (DNL) mainly produces palmitic acid (16:0), 
which can subsequently become elongated to stearic acid (18:0)[17]. 16:0 and 18:0 can then be 
desaturated into palmitoleic (16:1(n-7)) and oleic (18:1(n-9)) acids, respectively by Δ9-desaturase 
(also called stearoyl-CoA dehydrogenase (SCD))[18,19]. Two other fatty acid metabolic pathways 
that can be found in the human body are the omega-6 and omega-3 pathway. The omega-6 
fatty acid Linoleic acid (LA) and the omega-3 fatty acid alpha-linolenic acid (ALA) are two parent 
essential fatty acids that cannot be synthesized in the human body, and have therefore to be 
taken up from the diet (notably from vegetable oils, nuts and seeds). Subsequently, LA and ALA 
can undergo elongation and desaturation by Δ5 and Δ6-desaturase[20-22]. LA can be converted 
into arachidonic acid (AA), which is a precursor of prostaglandins, while ALA can be converted to 
eicosapentaenoic acid (EPA) and eventually to docosahexaenoic acid (DHA)[20-22]. The last step 




Fatty acids from dairy products
Worldwide intake of dairy products is high, particularly in developed countries such as North 
America and the European Union, including the Netherlands[23]. According to the Dutch Food 
Consumption Survey, intake of the Dutch adult population (age 31-50 years) is approximately 
283 and 253 g/d for respectively males and females[24]. Dairy contains more than 400 different 
fatty acids[25]. Seventy percent of the fatty acids present in milk are SFA, with palmitic acid 
(C16:0) (22-35wt%), stearic acid (C18:0) (9-14wt%) and myristic acid (C14:0) (8-14wt%) as the 
most prominent ones[25,26]. The odd-chain fatty acids pentadecanoic acid (C15:0 (1-2wt%)) 
and heptadecanoic acid (C17:0 (0.5-1.5 wt%)) can also be found in dairy products[26]. These 
are mainly produced from C16:0 and C18:0, under influence of microbial fermentation. This 
process is called α-oxidation and is considered rather unique for the bacterial flora of the 
rumen[15,27]. C15:0 and C17:0 are therefore thought to mainly originate from dairy fat[15,25,26]. 
Approximately 25% of the fatty acids in milk are MUFA, of which oleic acid (C18:1) is the main 
one (20-30wt%). Poly-unsaturated fatty acids, such as linoleic acid (C18:2) and α-linolenic acid 
(C18:3), account for around 0.5-3wt% of the total fatty acids in milk[25,26,28]. Approximately 
2.7% of the milk fats are trans fatty acids[25,29,30]. Dairy fat mainly contains the trans fats 
Vaccenic acid (trans-C18:1(n-7))[31-33] and Trans-palmitoleic acid (trans-C16:1(n-7))[34], which 
are formed by microbial fermentation in the rumen of the animal. Dairy products also contain 
conjugated linoleic acids (CLA) of which rumenic acid (cis-9, trans-11 CLA) comprises more than 
90% of the total CLA[30,32,35-37].
Intake of dairy fat and cardiovascular health
Total dairy intake and dairy fat intake have been proposed as nutritional components that may 
have a beneficial effect on cardiovascular health. For example, dairy intake may be associated 
with a reduced risk of coronary heart disease and stroke[38]. There is also evidence to suggest 
that higher intake of dairy is linked to a lower risk of type 2 diabetes[39,40]. In addition to 
total dairy intake, fat from dairy products may have beneficial effects on cardiovascular health 
and risk factors of cardiovascular disease[41-48]. These risk factors for cardiovascular disease 
include (1) traditional risk factors such as BMI, blood pressure and total triglycerides; (2) diabetes 
related risk factors such as fasting glucose and HbA1c%; and (3) non-traditional risk factors such 
as inflammation[49-52] (Figure 1). However, due to the presence of saturated and trans fatty 
acids in dairy, there is also skepticism about the potential protective effects and it has even been 
suggested that dairy fat is unhealthy[53,54]. Therefore, more research is warranted to unravel 
the association between dairy fat and cardiovascular health.
13
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Figure 1: The potential effects of fat from fish and dairy on cardiovascular risk factors.
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; Hs-
CRP, High-sensitive C-reactive protein; LDL, low density lipoprotein
Up till now, the most common method to measure the association between dairy (fat) intake and 
cardiovascular disease risk has been done by measuring dairy (fat) intake by dietary assessment 
tools such as food frequency questionnaires (FFQ), food diaries or 24h recalls. Of these dietary 
assessment tools, the FFQ is the most convenient one. This latter questionnaire is able to capture 
usual, individual, and long-term dietary intakes[55,56]. Although questionnaires and diaries are 
widely used, data are subjective and often biased. The methods are observational and based 
on self-report, which can lead to misclassification, underreporting and/or overreporting of 
intake[57]. A definite conclusion about the causality of the relationship between dairy fat intake 
and cardiovascular disease risks is therefore impossible to find. Researchers have therefore 
shown an increasing interest in biomarkers of dairy fat intake. Biological markers are considered 
to be more objective parameters of dairy intake.
Dairy fat biomarkers
The fatty acid compositions of plasma/serum (cholesterol esters (CE), triglycerides (TG), 
phospholipids (PL), free fatty acids (FFA), or a combination of the four), erythrocytes and adipose 
tissue have been shown to partially reflect the fatty acid composition of the diet[9,41,42,58]. 




serum are used to estimate short-term intake, in which triglycerides reflect intake of the past 
few hours, and cholesterol esters and phospholipids of the past few days[9,59].
Several fatty acids are to a large extent unique for dairy fat, and are therefore an interesting 
target for further research on dairy fat biomarkers. In short, C14:0, C15:0, C17:0 and Trans-
C16:1(n-7)) are commonly used dairy fat biomarkers[8,41-45,60,61]. And although these biomarker 
are widely accepted and used, interest in other potential dairy fat biomarkers is growing. For 
instance, trans-C18:1(n-7) and CLA have been suggested as potential dairy fat biomarkers, since 
these are also thought to mainly originate from dairy derived products[31,32,62,63]. In Chapter 
2, we aim to summarize the commonly used dairy fat biomarkers and investigate which fatty 
acids can serve as potential dairy fat biomarkers as well (Table 1).
Table 1: Fatty acids as biomarkers for nutritional intake in the general population
Animal Fat Industrial Fat
Dairy Fish




Potentially new biomarkers Trans-C18:1(n-7) C15:0
CLA C17:0
Abbreviations: C14:0, Myristic acid; C15:0, Pentadecanoic acid; C17:0, Heptadecanoic acid; C20:5(n-3), 
Eicosapentaenoic acid, C22:6(n-3), Docosahexaenoic acid; CLA, Conjugated Linoleic acid; Trans-
C16:1(n-7), Trans-Palmitoleic acid; Trans-C18:1(n-7), Vaccenic acid; Trans-C18:1(n-9), Elaidic acid
The less commonly investigated biomarkers trans-C18:1(n-7) and CLA have hardly been explored. 
Potentially, this might be because by difficulties to separate trans-C18:1(n-7) and other trans 
fatty acids in commonly applied measurement techniques. One of the trans fatty acid that is 
hard to separate from trans-C18:1(n-7) is trans-C18:1(n-9), or otherwise called Elaidic acid, an 
industrially produced fatty acid. To be able to investigate trans-C18:1(n-7) as a new potential dairy 
fat biomarkers, we aim to investigate a new method to separate trans-C18:1(n-7) from trans-
C18:1(n-9) (Chapter 3). Additionally, we aim to investigate the commonly and less commonly 
used dairy fat biomarkers in Chapter 4.
Dairy fat biomarkers and cardiovascular health
The commonly investigated biomarkers C15:0, C17:0 and to a lesser extent C14:0 and trans-
C16:1(n-7) may potentially have a positive influence on cardiovascular health[41-48]. Although 
this earlier research showed promising results, as of today some researchers question whether 
the association between the biomarkers C15:0 and C17:0 with cardiovascular health can only be 
15
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ascribed to dairy fat intake. Recently, C15:0 and C17:0 have also been suggested as biomarkers 
for fish fat intake[64-66]. In addition, both fish intake and fish fat intake are inversely related 
to cardiovascular diseases[67-69]. Consequently, associations of fatty acids such as C15:0 and 
C17:0 with cardiovascular health may as well be attributable to fish fat intake rather than to dairy 
intake. Therefore, in Chapter 5, we aim to investigate whether the commonly and less commonly 
investigated dairy fat biomarkers are solid biomarkers to predict dairy fat intake in the general 
population. Furthermore, we aim to investigate whether these fatty acids are related to good 
cardiovascular health, and so whether the potential cardiovascular health effects can be ascribed 
to dairy fat intake in the general population.
Intake of fish, omega-3 fatty acids and (cardiovascular) health
In observational studies both fish intake and fish fat intake have been found to be inversely 
related to the development of cardiovascular diseases and mortality[67,68,70,71]. Although 
these effects might be significantly associated with the fatty acids C15:0 and C17:0, the actual 
beneficial effects have predominantly been ascribed to the omega-3 fatty acids EPA and DHA[72-
74]. Several papers have suggested that EPA and DHA may cause a reduction in cardiovascular 
events[69,73,75,76]. Evidence suggest that this may be by influencing fatty acid ratios in the 
body (e.g. AA/EPA ratio)[77,78]. However, evidence from Randomized Controlled Trials are still 
confusing. In 2018 two studies were published on the association between omega-3 fatty acid 
intake and cardiovascular diseases[78]. One study (VITAL-Study) found that the intake of omega-
3 fatty acids was not associated with cardiovascular health benefits[79], while the other study 
(REDUCE-IT Trials) showed significant cardiovascular benefits[80]. Potentially, this might be due 
to the dose used in the RCTs (0.84 grams vs 3.8 grams of omega-3 fatty acids in respectively the 
VITAL-Trial and the REDUCE-IT Trials). From clinical trials and observational studies it has been 
demonstrated that omega-3 fatty acid consumption may have a favorable effect on traditional 
risk factors, such as serum triglycerides, systolic and diastolic blood pressure, but also on other 
risk factors such as inflammation[81-89] (Figure 1). Furthermore, in experimental animal studies 
EPA and DHA prevent the development of impaired glucose tolerance[90], while in humans 
it has been suggested to have a clinical significance in the prevention and reversal of insulin 
resistance[91,92].
Omega-3 fatty acids and (cardiovascular) health in renal transplant recipients
Renal disease patients are an important group that may particularly benefit from omega-3 fatty 
acid intake. Renal transplantation is the standard treatment for most renal disease patients[93,94], 
which improves survival. However, the survival of renal transplant recipients (RTR) continues to 
be significantly lower compared to the general population[95]. Importantly, one of the excessive 




protect against cardiovascular risk in the general population, supplements of EPA and DHA have 
been suggested to reduce all-cause and cardiovascular mortality in RTR[98]. Whether this is also 
true for the less investigated omega-3 fatty acid ALA is unknown. We therefore aim to explore 
the (cardiovascular) health associations of the omega-3 fatty acids EPA, DHA and ALA intake in 
RTR in Chapter 6 and 7.
While the association between the omega-3 fatty acid status and (cardiovascular) 
health can potentially be improved by the intake of the omega-3 fatty acids EPA and DHA, the 
association might be worsened by the use of drugs such as glucocorticoids (e.g. prednisolone)
[20,21]. Glucocorticoids are anti-inflammatory drugs commonly used to treat both acute and 
chronic inflammatory diseases[88,99], and are also commonly used in RTR to protect against 
graft failure[100-102]. From animal studies, it is suggested that glucocorticoids may negatively 
influence long chain omega-3 polyunsaturated fatty acid status, by inhibiting their formation 
through diminishment of delta-6 desaturase (D6D) activity[21,103]. Whether this is also the 
case in humans is unknown. Therefore, in chapter 8, we aim to investigate the dose-dependent 
influence of prednisolone on the EPA and DHA status, D6D activity, and the influence on 
cardiovascular risk factors in healthy young males.
Aims and outline of the thesis
In this thesis, we will explore commonly and less commonly investigated biomarkers for dairy and 
dairy fat intake in the general population. To explore the less commonly investigated biomarkers, 
we aim to develop a new method to separate the dairy-derived trans-C18:1 from other trans 
fats. Furthermore, to investigate whether the dairy fat biomarkers are solid markers for dairy 
fat intake in the general population, we aim to investigate whether the association between 
dairy fat biomarkers and dairy fat intake is independent of fish fat intake. A second aim of the 
thesis is to investigate the relationship of the commonly and less commonly investigated dairy 
fat biomarkers with (cardiovascular) health outcomes. Since the intake of omega-3 fatty acids 
also plays an important role in cardiovascular health, we aim to examine those as well.
First of all, we will explore fatty acids as biomarkers for dairy and dairy fat intake. In chapter 
2, a systematic review and meta-analysis is carried out to identify and validate the current 
biomarkers of dairy and dairy fat intake in the general population. The pros and cons of the 
current fatty acid biomarkers for dairy and dairy fat intake are summarized. Subsequently, new 
potential biomarkers are presented which will be further explored in our own dataset, the 
LifeLines Biobank and Cohort study.
Current evidence suggests that dairy fat biomarkers have positive effects on cardiovascular 
health. It has, however, been doubted whether associations of dairy fat biomarkers with 
17
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cardiovascular health are genuine. Firstly, most studies still use a suboptimal method to separate 
the trans-C18:1 fatty acids from each other, causing overestimation of the trans-C18:1(n-7) dairy 
fat biomarker. Therefore, in chapter 3 we describe a new method to separate the dairy-derived 
trans-C18:1(n-7) from the industrially-derived trans-C18:1(n-9). Subsequently, in chapter 4, 
we will try to confirm the commonly and less commonly used dairy fat biomarkers (i.e. trans-
C18:1(n-7) and CLA) in the LifeLines Biobank and Cohort study. Furthermore, a combination of 
biomarkers will be explored to investigate whether this is a better predictor for dairy fat intake 
compared to single markers.
Secondly, some researchers are concerned that the current biomarkers are not sufficiently 
explicit for the prediction of dairy fat intake, since some of these fatty acids, such as C15:0 
and C17:0, have also been identified as fish fat biomarkers. Consequently, associations of fatty 
acids such as C15:0 and C17:0 with cardiovascular health may as well be attributable to fish fat 
intake. Therefore, in chapter 5, we will investigate whether the dairy fat biomarkers are solid 
markers to predict dairy fat intake in the LifeLines Biobank and Cohort study. In addition, we 
will zoom in on the association between the identified dairy biomarkers and risk factors for 
cardiovascular disease.
In the general population, a reduction in cardiovascular risk has mainly been abscribed to fish 
fat intake and the omega-3 fatty acid supplements EPA and DHA. Cardiovascular disease is one 
of the excessive contributors to mortality in RTR. It has therefore been suggested that these 
omega-3 fatty acid supplements might as well reduce all-cause and cardiovascular mortality 
in RTR. Whether this is also true for the less investigated omega-3 fatty acid ALA is unknown. 
Therefore, in chapter 6 and 7, we aim to investigate the association of the intake of omega-3 
fatty acids EPA, DHA and ALA with (cardiovascular) mortality in RTR.
In contrast to the omega-3 supplements, drugs (i.e. glucocorticoids) have been thought 
to increase cardiovascular risk in RTR. Glucocorticoids are widely used in RTR to reduce 
inflammation. However, the drugs are believed to modify the plasma EPA and DHA status what 
may results in a worsened cardiovascular health status. We therefore aim to examine the impact 
of glucocorticoids on plasma EPA and DHA status, and its consequent effect on cardiovascular 
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Context: Dairy intake is commonly assessed using questionnaires, however, such data are often 
biased. Therefore, interest in dairy fat biomarkers is growing. An overview of fatty acids that 
can be used as biomarker for dairy fat intake is lacking. Objective: We performed a systematic 
review and meta-analysis of observational studies to identify circulating fatty acids as biomarkers 
total dairy and dairy fat intakes in the general population. Data Sources: We searched MEDLINE, 
EMBASE and Web of Knowledge for eligible studies until June 2017. Study selection: Articles 
were included when researchers assessed the correlation between circulating dairy fatty acids 
and total dairy (fat) intake as measured by dietary assessment tools. Data Extraction: Two 
independent reviewers extracted data and assessed the risk of bias. Data synthesis: Data were 
pooled with the random-effects model. Meta-analysis revealed that the fatty acids in plasma/
serum were significantly correlated with dairy (C14:0 (r [95%CI] = 0.15 [0.11 – 0.18]), C15:0 
(0.20 [0.13 – 0.27]) and C17:0 (0.10 [0.03 – 0.16]) and dairy fat intake (C14:0 (0.16 [0.10 – 0.22], 
C15:0 (0.33 [0.27 – 0.39]), C17:0 (0.19 [0.14 – 0.25]) and trans-C16:1(n-7) (0.21 [0.14 – 0.29])). 
Conclusions: This paper identified C14:0, C15:0, C17:0 and trans-C16:1(n-7) as biomarkers of dairy 
and dairy fat intake in the general population. Trans-C18:1(n-7) and CLA need more investigation 
because of suboptimal measurement techniques.
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INTRODUCTION
Dairy products contain numerous essential nutrients and can therefore be beneficial for almost 
all humans, including infants, adults and elderly people[1,2]. Bovine milk contains around 
87% water, 4.6% lactose, 3.4% protein, 4.2% fat, 0.8% minerals and 0.1% vitamins[3,4]. The 
composition and content of milk fat depends on several factors including bovine race, time of 
lactation, physiological status of the animal and type of diet[5,6]. Milk fat has been documented 
to contain more than 400 different fatty acids[4]. The fatty acids can be directly derived from 
the bovine diet, and indirectly from rumen microbial de novo lipogenesis, which can both be 
subject to rumen microbial fermentation[7]. Usually, feed of bovines consists of grass during 
summer and conserved forage (maize or grass silage and hay) during winter[8]. The type of 
feed influences the bacterial flora in the rumen, and thereby microbial de novo lipogenesis and 
ruminal fermentation[9,10]. The produced fatty acids are taken up from the rumen and can be 
extracted in milk[10].
By weight, seventy percent of the fatty acids present in milk are saturated fatty acids, 
with palmitic acid (C16:0) (22-35wt%), stearic acid (C18:0) (9-14wt%) and myristic acid (C14:0) 
(8-14wt%) as the most prominent ones[4,6]. Microbial de novo lipogenesis and microbial 
fermentation add to the fatty acids present in milk[9,10]. During microbial de novo lipogenesis, 
C16:0 and C18:0 are produced, with C16:0 as the dominant end product [9,10]. Ruminal microbial 
fermentation can in turn convert C16:0 and C18:0 into respectively the odd-chain fatty acids 
pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0). This process is called α-oxidation 
and is considered unique for the bacterial flora of the rumen[5,10]. C15:0 (1-2wt%) and C17:0 
(0.5-1.5 wt%) are therefore thought to mainly originate from dairy fat[5,6,10].This is in contrast 
to C14:0, C16:0 and C18:0, which also occur in high amounts in meat, including beef, pork and 
poultry, as well as fish and grain products[11,12]. Medium- and long-chain fatty acids produced 
by the cow’s mammary gland may be desaturated to their mono-unsaturated counterparts[4]. 
Approximately 25% of the fatty acids in milk are mono-unsaturated fatty acids, of which oleic 
acid (C18:1) is the most prominent one (20-30wt%). Poly-unsaturated fatty acids, such as 
linoleic acid (C18:2) and α-linolenic acid (C18:3), account for around 0.5-3wt% of the total fatty 
acids in milk[4,6]. Approximately 2.7% of the milk fats are trans fatty acids[4,13,14], which are 
synthesized via microbial fermentation of C18:0 unsaturated fatty acids[15,16]. Vaccenic acid 
(trans-C18:1(n-7)) is the most prominent trans fatty acid[15-17]. Trans-palmitoleic acid (trans-
C16:1(n-7)) is another trans fatty acid which can be found in dairy products[18]. Ruminantly 
derived products also contain conjugated linoleic acids (CLA) of which more than 90% is rumenic 
acid (cis-9, trans-11 CLA) [14,17,19-21]. In the rumen, CLA can be formed as an intermediate 
during the biohydrogenation of C18:2 into C18:0[22,23]. Additionally, Vaccenic acid, another 
intermediate of rumen biohydrogenation of C18:2 and C18:3, can be desaturated into rumenic 




Commonly used methods to measure dairy fat intake include validated food frequency 
questionnaire (FFQ), food diary and 24h recall; they are frequently used in many published 
studies before. The use of an FFQ remains popular to date, as is evidenced by two recent large 
prospective cohort studies from 2014 and 2016, both reporting on prospective associations of 
dairy consumption with the risk of developing type 2 diabetes[25,26]. Although these methods 
provide specific information about dairy products, data are subjective and often biased. The 
methods are observational and based on self-reporting, which can lead to misclassification, 
underreporting and/or overreporting of intake[27]. Alternative or complementary methods for 
measuring dairy intake are therefore needed.
Researchers have shown an increased interest in biomarkers of dairy intake, since biological 
markers are considered a more objective parameter of this intake. As previously mentioned, dairy 
fat consists of several fatty acids, of which some are (to a large extent) unique for dairy fat. These 
fatty acids are present in quantitatively measurable amounts, even in the human circulation 
and body tissues making them interesting biomarkers of dairy fat intake. Biomarkers for dairy 
fat intake are most commonly measured in plasma/serum (cholesterol esters (CE), triglycerides 
(TG), phospholipids (PL), free fatty acids (FFA), or a combination of the four), erythrocytes and 
adipose tissue (AT)[28-31]. Adipose tissue can be investigated to determine long-term dairy fat 
intake, while plasma and serum are used to estimate short-term intake; for instance, triglycerides 
reflect intake over the past few hours, and cholesterol esters and phospholipids reflect intake 
of the past few days[31,32]. A convenient and efficient tool to measure the fatty acids is a 
gas chromatograph (GC) equipped with a flame ionization detector (FID) and a capillary polar 
column[33]. Polar columns are typically used for the analyses of complex fatty acids (i.e. trans 
fatty acids), since the polar columns can reach a higher selectivity and separation compared 
to apolar columns[34]. After analyzing, fatty acid samples remain stable for at least four years 
when stored at -80°C[35].
A common belief is that dairy fats are potentially unhealthy due to the presence of saturated 
and trans fatty acids. For trans fatty acids, a distinction can be made between industrially and 
ruminantly produced trans fatty acids[16]. Trans fats from industrial origin (e.g. Elaidic acid (trans-
C18:1(n-9))) have been shown to be associated with increased risk of coronary heart disease, 
insulin resistance, inflammation, breast cancer, prostate cancer and colorectal cancer[36,37]. 
There is growing body of evidence indicating that adverse health effects associated with 
industrially produced trans fatty acids intakes may not necessarily apply for trans fatty acids 
found in dairy products (e.g. trans-C18:1(n-7))[38,39]. In contrast to what has been reported 
for industrialized trans fatty acids, there does not seem to be an association between ruminant 
trans fatty acid intake and risk for coronary heart disease[16,19,40]. In addition, positive effects 
on immune function, cardiovascular health and cancer risk have been ascribed to dairy fatty 
acids such as rumenic acid (cis-9, trans-11 CLA)[39].
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 Recently, studies indicate that the fatty acids C14:0, C15:0, C17:0, trans-C16:1, trans-
C18:1(n-7) and CLA might be useful biomarkers of dairy fat intake[29,41,42]. However, a clear 
overview of fatty acids that can be used as biological markers of dairy and dairy fat intake is 
lacking. To examine which circulating fatty acids are suitable as biomarkers of dairy and dairy 
fat intake in the general population, we reviewed observational studies that assessed the 
correlation between circulating dairy fatty acids and total dairy (fat) intake as measured by 
dietary questionnaires. The research question also includes the current laboratory techniques 
that are used to measure the biomarkers of interest (fraction, column and equipment).
METHODS
For the main objective, we followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines[43] (Appendix 1). Inclusion criteria and methods of analysis 
were specified in advance in a review protocol (Appendix 2).
Data sources and searches
A systematic search for relevant literature has been carried out to identify fatty acids as 
biomarkers of dairy and dairy fat intake in the general population. We searched MEDLINE, 
EMBASE and Web of Knowledge till June 2017. We developed a search string for each database 
consisting of the search terms biomarker, dairy fat intake, fatty acids and synonyms. We excluded 
animal studies. Searches were limited to papers that were published in English. Duplicates 
were removed before analyses. All included studies were screened for potential references 
that were not included in the main search. An overview of the search strategies can be found 
in Supplemental Table 1.
Study selection and data extraction
The PICOS criteria used to perform the systematic review are listed in Table 1. All observational 
studies were considered for inclusion. Intervention studies, letters to the editor and reviews were 
not included. Articles were included when researchers were analyzing circulating fatty acids as 
biomarkers of dairy (fat) intake. Fatty acids had to be measured in plasma/serum, erythrocytes 
or adipose tissue, while dairy (fat) intake had to be measured by FFQ, food records and/or 24-
hour recalls. We required potentially relevant articles to report on the correlation of biomarkers 
with total dairy intake or intake of total dairy fat. We limited our search to studies with an 
epidemiological perspective, focusing on investigation of correlations of biomarkers with dairy 
(fat) intake. Studies in which dairy fat intake was regulated by supplements or a controlled diet 
were not included in the review. Title and abstract were screened by two independent reviewers 
(I.G.P and M.L.J). Studies which were in agreement with the eligibility criteria were retrieved 




for exclusion and percentage of agreement, as Cohen’s kappa, between the assessors were 
documented. In addition, the two independent reviewers extracted data and assessed the risk 
of bias for each study. From the included studies, the following data were extracted: name first 
author, publication year, potential dairy fatty acids measured in plasma/serum, erythrocytes 
and adipose tissue, dairy intake by dietary questionnaires, correlation between dairy intake and 
circulating fatty acids. Selected papers were also screened for used laboratory techniques with 
focus on fraction, column and equipment.
Table 1. The PICOS criteria which were used to perform the systematic review
PICOS
Population The general population. This includes all age, sex , race and ethnicity 
groups.
Intervention (exposure) Dairy (fat) intake measured by dietary assessment tools (Food 
Frequency Questionnaires, food record, 24-h recalls
Comparator (control group) There is no comparison against a control group.
Outcome Potential dairy fatty acid biomarkers (circulating fatty acids) measured 
in plasma/serum (cholesterol esters, triglycerides, phospholipids, 
free fatty acids or a combination of all four), erythrocytes or adipose 
tissue.
Study Design All observational studies (cross-sectional and prospective studies) 
were considered for inclusion. Intervention studies, letter to the 
editor and reviews were not included. Studies in which intake of 
dairy fat was regulated by supplements or a controlled diet were 
not included in the review. Relevant articles had to report on the 
correlation of circulating dairy fatty acids with total dairy intake or 
total dairy fat intake (as measured by questionnaires).
Quality assessment
Only observational studies were included in this review. Previous studies have emphasized the 
need for a uniform methodological assessment tool for observational studies[44,45]. The STROBE 
recommendations are thereby frequently used in an inappropriate way, i.e. as a methodological 
guideline (to assess the methodological quality of observational epidemiological studies, or to 
conduct or design observational studies), rather than as a reporting guideline to ensure a clear 
and complete report of study design, conduct and findings[46]. The Cochrane Non-Randomized 
Studies Methods Working Group recommends the Newcastle-Ottawa Scale (NOS) for assessing 
the quality of non-randomized studies in meta-analyses[47]. We therefore used the NOS and 
adapted it so it is in line with the current review (Appendix S3). The adapted NOS makes it 
possible to judge studies that focus specifically on the correlation between dairy (fat) intake 
and potential circulating dairy fat biomarkers. The ‘start’ system has developed in which a study 
is judged on three domains: (1) the selection (representativeness of the sample population, 
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appropriate sample size, ascertainment of the exposure, i.e. validated tool to measure dairy 
fat intake); (2) the comparability (appropriate control of confounding factors); and (3) the 
outcome (appropriate assessment of the outcome (validated tool to measure circulating dairy 
fat biomarkers), appropriate description of statistical test). The item ‘respondents comparability 
and response rate’ was excluded from the original quality tool since it is not applicable to the 
current review. Instead, we added the item ‘Sample Size’ whereby a sample size of n ≥ 100 was 
justified and satisfactory[48-50]. The maximum attainable quality score was 6. A minimum of 
two-thirds of the quality score was chosen as cut-off to represent reasonable quality studies (> 4).
Data synthesis and analysis
We first conducted an overview of available biomarker studies. Characteristics of the included 
studies were systematically listed to generate a clear overview of the current literature on 
potential dairy fat biomarkers in the general population. Papers were classified by type of 
fraction. For those biomarkers with ≥ two studies available, we did quantitative syntheses on 
aggregated data. When articles investigated dairy intake both by FFQ and food record, only the 
result of the FFQ was included in the analysis since the FFQ is the most common type of dietary 
questionnaire and seen as the most reliable method to measure long term intake. When dairy 
intake was investigated by both food record and 24h-recall, only the result of the food record 
was included in the analysis. Dairy intake and dairy fat intake were analyzed separately. In 
addition, separate meta-analyses were carried out for different lipid fractions. In the separate 
analyses for the different fractions, plasma/serum PL and CE were preferred over plasma TG 
[51,52]. In addition, fatty acids were measured in plasma FFA only once and therefore not 
incorporated in the meta-analysis. For the syntheses, data was pooled with the random effects 
model of meta-analysis, using MedCalc for Windows, version 17.6 (MedCalc Software, Ostend, 
Belgium). To allow pooling across studies, we used the Fisher Z transformation of the correlation 
coefficients. Subsequently, the Fisher Z for each study was weighted by their inverse variance 
and the corresponding 95%CI were calculated. The variance of the Fisher Z transformation 
was calculated with the formula z’ = 0.5x[ln(1+r) – ln(1-r)]. Then, the summary values were 
converted back to correlations for presentation. The existence of heterogeneity among studies 
was assessed by Q-tests, and the degree of the heterogeneity was quantified by calculating the 
I-squared (I2) value. Publication bias was inspected visually by a funnel plot. Sensitivity analyses 
were performed including studies with more than two-thirds of the quality score (> 4 quality 
points), if more than two studies with a sufficient quality score were available. Findings were 





Results of the systematic review and meta-analysis are presented in a flow diagram (Figure 1). 
Cohen’s kappa for the abstract selection was 0.97, indicating high agreement between the two 
researchers. Out of the 19 studies included for full text review, 18 were used for the qualitative 
synthesis and meta-analysis.
Figure 1: Flow Diagram of the literature search process
Study inclusion
Characteristics of the included studies can be found in Table 2[28-30,42,53-66]. The summary 
shows that C14:0, C15:0, C17:0 and trans-C16:1(n-7) were investigated as potential biomarkers of 
dairy (fat) intake. trans-C18:1(n-7) and CLA were also mentioned as potential biomarkers, but the 
correlation of trans-C18:1(n-7) and CLA with total dairy intake has only been investigated once 
and for reasons of conciseness we did not incorporate reporting on these fatty acids in Table 2.
The circulating fatty acids were derived from plasma/serum (CE, TG, PL, FFA or a 
combination of the four), erythrocytes or adipose tissue. Circulating fatty acids were detected 
with a gas (liquid) chromatography (G(L)C)-(Flame ionization detector (FID)) using polar columns 
with a length ranging from 25 till 100m long.
As described in the method section, we only included studies that measured dairy intake as 
total dairy fat or total dairy intake. Total dairy (fat) intake was measured with an FFQ, 24h-recall 
or food record of which the FFQ was the most common methodology.
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The results of the quality assessment (NOS) can be found in Table 3[28-30,42,53-66]. The NOS 
revealed good study quality in 11 out of 18 studies (n > 4 quality points). Representativeness 
of the general population was not always found in the studies (n = 7/18). The majority of the 
studies had an appropriate sample size (n ≥ 100) (n = 16/18) and validated measurement tools 
to measure the exposure (Dairy intake) (n = 18/18). Around half of the studies adjusted their 
analyses for any potential confounder (n = 10/18). All 18 studies reported a correlation, including 
the probability level (p-value). One study failed to report on how they measured the outcome 
(circulating fatty acids) exactly. The study was included in the main analyses, but excluded in 
the sensitivity analyses.









Aslibekyan et al. (2012)[64] ** * ** 5
Baylin et al. (2002)[65] *** * ** 6
Biong et al. (2006)[30] ** * ** 5
Brevik et al.(2005)[56] *** ** 5
Giovanneli et al. (2014)[53] *** * 4
Golley et al. (2014)[57] ** ** 4
Lund-Blix et al. (2016)[60] ** ** 4
Oliveira et al. (2013)[42] *** * ** 6
Rosell et al. (2005)[62] ** ** 4
Santaren et al. (2014)[28] *** ** 5
Smedman et al. (1999)[58] * * ** 4
Sun et al. (2007)[29] *** * ** 6
Thiebaut et al. (2009)[63] ** * ** 5
Warensjo et al. (2015)[61] *** * ** 6
Wolk et al. (1998)[66] ** ** 4
Wolk et al. (2001)[59] ** ** 4
Yakoob et al. (2014)[54] ** * ** 5
Yakoob et al. (2016)[55] ** * ** 5
According to the adapted Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomized 
studies in meta-analyses (Appendix B). The maximum attainable quality score is 6. A minimum of two-
thirds of the quality score represent a reasonable quality study (> 4).
Systematic review
 From the papers included in the qualitative analyses, the majority of the studies measured 
the fatty acids in plasma/serum (n = 15/18), of which C15:0 was the most commonly measured 
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dairy fat biomarker, followed by C17:0 and C14:0. Eight papers reported on measurement 
of dairy fatty acid biomarkers in more than one fraction (plasma/serum (CE, TG, PL, FFA, or 
a combination of the four), erythrocytes and adipose tissue), which allow for evaluation of 
differences in correlations of the biomarkers assessed in different fractions with dairy (fat) intake 
(Supplemental Table 2)[29,30,54-56,58,59,62].
Results of the studies investigating C14:0, C15:0, C17:0 and trans-C16:1(n-7) which were not 
included in the meta-analyses can be found in Table 4[29,30,53,56,59,66]. One study investigated 
the correlation of dairy fat intake measured by FFQ with circulating dairy fatty acids in serum 
TG and FFA[30]. In both serum TG and FFA, C14:0 had a correlation of 0.18 with dairy fat intake. 
C15:0 measured in serum TG had a correlation of 0.45 with dairy fat intake, while C15:0 measured 
in FFA was not correlated with dairy fat intake. The single study reporting on trans-C18:1(n-7) in 
plasma and erythrocytes was not correlated with dairy fat intake [29]. The single study reporting 
on CLA in adipose tissue and total dairy fat intake found a correlation of 0.24 (p<0.001)[64]. 
There were no papers that reported on a correlation of trans-C16:1(n-7) in adipose tissue with 
dairy (fat) intake.
Meta-analysis
C14:0, C15:0, C17:0 and trans-C16:1(n-7) in plasma/serum and erythrocytes, and C14:0, C15:0 and 
C17:0 in adipose tissue were reported in more than two studies and were therefore investigated 
using meta-analysis. Overall, fatty acids in plasma/serum were positively correlated with dairy 
(C14:0 (r [95%CI] = 0.15 [0.11 – 0.18]), C15:0 (0.20 [0.13 – 0.27]), C17:0 (0.10 [0.03 – 0.16]) 
and trans-C16:1(n-7) (0.08 [-0.01 – 0.16])) and dairy fat intake (C14:0 (0.16 [0.10 – 0.22], C15:0 
(0.33 [0.27 – 0.39]), C17:0 (0.19 [0.14 – 0.25]) and trans-C16:1(n-7) (0.21 [0.14 – 0.29])) (Figure 
2)[28-30,42,53-66]. Separate analyses for fatty acids in plasma/serum showed that the total 
correlations of fatty acids measured in plasma/serum CE with dairy fat intake were higher 
compared to the total correlations of fatty acids measured in total plasma/serum and plasma/
serum PL with dairy fat intake. The dairy fatty acid biomarkers assessed in erythrocytes were 
also correlated with dairy fat intake (C14:0 (0.08 [-0.002 – 0.16]), C15:0 (0.16 [0.03 – 0.28]), C17:0 
(0.07 [-0.04 – 0.18]) and trans-C16:1(n-7) (0.20 [0.09 – 0.30])). A correlation with dairy intake 
was not investigated. The dairy fatty acid biomarkers assessed in adipose tissue were positively 
correlated with dairy (C15:0 (0.34 [0.31 – 0.36]) and C17:0 (0.23 [0.08 - 0.37])) and dairy fat intake 
(C14:0 (0.53 [0.43 – 0.62]), C15:0 (0.51 [0.37 – 0.63]) and C17:0(0.22 [0.12 – 0.32])).
Analysis revealed substantial to considerable heterogeneity for plasma/serum C14:0 
(I2 = 66.9%, P = 0.004 for the analysis with dairy fat intake), C15:0 (I2 = 80.9% and 71.2%, P ≤ 0.001, 
respectively for the analysis with dairy intake and dairy fat intake), C17:0 (I2 =49.7% and 55.8%, 
P ≤ 0.03) and trans-C16:1(n-7) (I2 = 82.5% and 71.7%, P ≤ 0.02). Substantial heterogeneity was 
also found for the erythrocytes and adipose tissue fatty acids. Funnel plots of the meta-analysis 
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Some of the funnel plots are asymmetric, which is suggestive of publication bias for these 
analyses.
Sensitivity analyses were performed including studies with more than half the maximum 
study quality score ( > 4 quality points), if more than two studies with a sufficient quality score 
were available (Supplemental Figure 2 and 3)[28-30,42,54-56,61,63-65]. Meta-analyses were not 
repeated in the sensitivity analyses when the included studies for the sensitivity analyses were the 
same as for the main analyses. Therefore, these analyses are not incorporated in Supplemental 
Figure 2 and 3. Correlations between the circulating fatty acids and dairy (fat) intake did not 
materially differ compared to the regular analyses. However, a decreased heterogeneity for 
C14:0 and C15:0 in plasma/serum was observed. Interestingly, the heterogeneity for the analyses 
of C17:0 and dairy intake in plasma/serum decreased from an I2 of 49.7% with P = 0.01 to an 
I2 of 0.0% with P = 0.82, while the heterogeneity for the analyses of C17:0 and dairy fat intake 
in plasma/serum increased from an I2 of 55.8% with P = 0.03 to an I2 of 65.2% with P = 0.02. 
The heterogeneity for fatty acids in adipose tissue did not materially differ from the main 
analyses, except for the analyses in which the association between C17:0 and dairy fat intake 
was investigated. The heterogeneity increased from an I2 of 47.5% with P = 0.11 to an I2 of 81.1% 
with P = 0.02.
Figure 2: Forest plots of studies investigating potential circulating dairy fatty acid biomarkers. A: Meta-anal-
ysis C14:0 and dairy intake , B: Meta-analysis C14:0 and dairy fat intake, C: Meta-analysis C15:0 and dairy 
intake, D: Meta-analysis C15:0 and dairy fat intake, E: Meta-analysis C17:0 and dairy intake, F: Meta-analysis 
C17:0 and dairy fat intake, G: Meta-analysis trans-C16:1(n-7) and dairy intake, H: Meta-analysis trans-


























To date, there is no clear overview of biomarkers that can be used as marker of dairy fat intake. 
This paper systematically reviewed current literature to identify and summarize the fatty acids 
that can potentially be used as biomarkers of dairy and dairy fat intake in the general population. 
Meta-analysis revealed that C14:0, C15:0, C17:0 and trans-C16:1(n-7) in plasma/serum can be 
used as biomarkers for dairy and dairy fat intake. Correlations were even higher in adipose tissue.
The current study has several strengths. Although the subject of biomarkers for dairy and 
dairy fat intake has been reviewed before[67], this is to our knowledge the first systematic review 
and meta-analysis investigating the correlation between dairy (fat) intake and circulating dairy 
fatty acids in the general population. Another strong point of the study is that the vast majority 
of the studies were of good quality. Results from the overall analyses and sensitivity analyses 
(studies > 4 quality points) did not materially differ from each other.
We must acknowledge that this study also has its limitations. Studies included in this 
systematic review and meta-analysis are all observational studies. In general, observational 
studies have a lower validity than randomized controlled trials and they are more susceptible 
to bias (e.g. selection and information bias) and confounding factors. Analyses were adjusted 
for confounding factors in about half of the studies. The results of the current study may 
be affected by the methodological weaknesses of observational studies. Other study types 
(e.g. randomized controlled trials, intervention studies) may show a different strength of 
the correlation. Another limitation is the fact that we found indicators for the presence of 
substantial to considerable heterogeneity and publication bias. Although we used random effect 
models to account for the observed heterogeneity, it cannot be excluded that the presence of 
heterogeneity adversely influenced the validity of the effect estimates of the meta-analysis 
that we performed. Publication bias might affect the validity of meta-analysis also. Publication 
bias was inspected visually by funnel plots. Asymmetric funnel plots, as visible for some of the 
analyses, is suggestive of selective reporting. For instance, for the correlation between C14:0 and 
dairy intake (Supplemental Figure 1A), studies reporting relatively low correlation coefficients 
at a high standard error may be missing. Lack of such studies may have led to overestimation 
of the meta-analysis derived correlation between C14:0 and dairy intake . A third limitation is 
the lack of data on fatty acids measured in liver tissue. The liver is the main metabolizing organ 
after dietary intake and it would therefore have been interesting if it would have been possible 
to incorporate data on the liver as well.
The review showed that the correlations of dairy fatty acid biomarkers in plasma/serum 
with total dairy (fat) intake did not materially differ from the correlations found in erythrocytes. 
Correlations of dairy fatty acid biomarkers in adipose tissue with dairy (fat) intake were higher 
compared to plasma/serum and erythrocytes. Although the strength of the correlation of dairy 
fatty acid biomarkers with dairy (fat) intake varies between the papers, all show a similar trend. 
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Biong et al (2006) investigated the correlation of potential dairy fatty acid biomarkers in plasma/
serum, erythrocytes and adipose tissue with dairy (fat) intake. The strongest correlations for 
the dairy fatty acid biomarkers with dairy (fat) intake were found when the biomarkers were 
measured in adipose tissue[30]. Additionally, a study from 1999 showed that the correlation 
of the dairy fatty acid biomarker CLA in adipose tissue with milk fat was stronger than the 
correlation of the dairy fatty acid biomarker CLA in serum with milk fat[41]. The paper also 
showed that the concentration of the biomarker in adipose tissue was twice as high as the 
concentration of the biomarker in serum [41]. That adipose tissue dairy fatty acid biomarkers 
relate better with dairy and dairy fat intake than circulating fatty acid biomarkers, might be a 
consequence of the fact circulating fatty acids are more influenced by short-term changes in diet, 
while data of food frequency questionnaires, to which they are compared usually reflect long-
term intake. Because turnover of adipose tissue is much slower, fatty acid biomarkers measured 
in adipose tissue might more strongly relate to data of food frequency questionnaires, which also 
reflect long-term intake[31]. Furthermore, fatty acids from dairy are incorporated into serum 
lipid fractions differently than in adipose tissue[30]. This could be due to different turnover rates 
of the fatty acids in various fractions, or due to selective mobilization and incorporation[30]. 
These differences may also influence the strength of correlations.
The meta-analysis revealed the strongest correlations of circulating dairy fatty acid 
biomarkers with total dairy (fat) intake for C15:0 and C17:0. The correlations of the dairy fatty 
acid biomarkers C15:0 and C17:0 with dairy (fat) intake show the same overall trend, however 
the correlations of C15:0 with dairy (fat) intake are slightly higher than the correlations of C17:0 
with dairy (fat) intake. Recently, a review about the odd-chain fatty acids C15:0 and C17:0 was 
published which described that the ratio of C15:0 and C17:0 is approximately 2:1 within ruminant 
milk fat, while it is approximately 1:2 across all lipid classes in humans[10]. It was suggested 
that the 2:1 ratio in ruminants can be explained in part by the fact that C15:0 and C17:0 can be 
produced from respectively C16:0 and C18:0 via an alternative route, the α-oxidation[10]. During 
the de novo lipogenesis more C16:0 will be produced compared to C18:0. Thus, the process of 
α-oxidation is expected to result in a higher conversion of C16:0 to C15:0 compared to conversion 
of C18:0 to C17:0. Furthermore, it is known that the apparent oxidation of individual fatty acids 
decreases with increase in carbon chain length. This will further favor the availability of C16:0 
for conversion to C15:0. These effects would together result in the approximate 2:1 ratio[68]. 
The contrasting C15:0 to C17:0 ratio across all lipid classes in humans may point to a higher 
endogenous synthesis of C17:0, a more efficient oxidation of C15:0, or both[10]. The fact that 
C15:0 has a stronger correlation with total dairy and total dairy fat intake compared to C17:0 
suggests that C15:0 is more specific to ingestion of dairy products.
The dairy fatty acid biomarker C14:0 was positively correlated with dairy intake. An 




erythrocytes with total dairy intake was weaker compared to the correlation of C15:0 and C17:0 
in plasma/serum and erythrocytes with total dairy intake. The weaker correlation of C14:0 in 
plasma/serum and erythrocytes with dairy intake may be caused by the presence of C14:0 in 
other products such as meat, coconut oil and palm kernel oil[69,70]. Therefore, C14:0 is not 
considered to be a good specific marker for dairy intake.
Total dairy (fat) intake has predominantly been measured with validated FFQs, 24-h recalls 
and food records. As expected, the FFQ was the most common type of methodology, but did 
not show better results when compared to the 24-h recall and food record[56,59,66]. In the 
current review, only those studies measuring total dairy (fat) intake were taken into account 
to overcome the problem of having a widespread variation in reporting dairy intake. Despite 
this narrowing down of included studies, we still saw variation between studies regarding the 
strength of the correlation of circulating fatty acids with dairy intake. This variation could have 
been due to differences in defining total dairy (fat) intake. A study of Santaren et al (2014) defined 
dairy intake as sum of whole milk, 2% milk, skim milk, 1% buttermilk, buttermilk, cottage and 
ricotta cheese, cheese, flavored yoghurt, low-fat flavored yoghurt, ice cream, frozen yoghurt, 
ice milk, milk in coffee or tea, and cream or half-and-half in coffee or tea[28]. Another study 
defined the dairy intake as a sum of milk, sour milk, yoghurt, cheese, ice cream and butter[30]. 
Unfortunately, several studies did not define dairy (fat) intake at all. Discrepancy between results 
also occurred due to differences in reporting dairy intake. Dairy intake was described in terms 
of ‘% of total fat’, ‘servings per week’, or ‘grams per day’. Such differences in reporting may 
cause variability between study outcomes making comparison between studies difficult, and 
may also confound conclusions. Furthermore, questionnaires are observational and based on 
self-report; this may reduce the accuracy and precision of measuring dietary intake, and also 
lead to systematic errors[27,71,72].
We included studies on the ruminant trans fatty acids trans-C18:1(n-7) and CLA as dairy 
fatty acid biomarkers in our review. So far, studies in which these ruminant trans fatty acids have 
been used as dairy fatty acid biomarkers are limited. Trans-C18:1(n-7) and cis-9, trans-11 CLA are 
naturally occurring fatty acids which are synthesized via bacterial metabolism of unsaturated 
fatty acids in ruminant animals and found in ruminant-derived foods[16]. Trans-C18:1(n-7) is the 
most common trans fatty acid found in dairy fat, and is therefore an interesting target for further 
research[73]. However, the current equipment and column possibilities may be inadequate to 
measure the specific dairy fatty acids such as trans-C18:1(n-7). Most studies investigating these 
two fatty acids use polar columns up till 100 m long, however such a column may not have 
the separation efficiency to prevent coeëluting of trans-C18:1(n-7) acid with other trans fatty 
acids, making quantification difficult. Furthermore, both trans-C18:1(n-7) and CLA have a low 
measurement intensity when FID is used, potentially leading to the introduction of larger error 
margin. It is therefore more common to identify a cluster of trans-C18:1 isomers instead of trans-
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C18:1(n-7) only. A disadvantage of this method is that a cluster of trans-C18:1 isomers contains 
both trans fatty acid isomers of ruminant as well as of industrial origin, and is therefore not a 
pure measurement of dairy fat intake. Several studies investigated the correlation between total 
trans-C18:1 and dairy intake[41,74,75] and/ or the association of total trans-C18:1 as a marker 
of dairy intake with health outcomes[74-80].
Overall, this review showed that several dairy fatty acid biomarkers correlate with dairy 
(fat) intake. Nevertheless, the association between dairy (fat) intake and circulating C15:0, C17:0 
and trans-C16:1(n-7) has been called into question in some studies. For instance, trans-C16:1(n-7) 
raised questions in some studies, since it is a fatty acids that cannot only be found in the diet, 
but has recently been found to be produced by β-oxidation of trans-C18:1(n-7) as well[81]. 
In addition, a study from 2017 found that the intake of dietary fibers may influence the odd-
chain fatty acids C15:0 and C17:0 [82]. The researchers showed that supplementation with inulin 
(fermentable dietary fiber) and propionate (major product of intestinal bacteria fermentation of 
dietary fibers) for a week increased both plasma C15:0 and C17:0, while this was not seen after 
supplementation with cellulose (control). Furthermore, a study from 2015 demonstrated that 
adipocytes can convert the branched chain amino acids, valine and isoleucine into propionyl-
CoA, which can subsequently act as precursor for the synthesis of odd-chain fatty acid[83]. 
Thus, catabolism of branched chain amino acids derived from dietary proteins, including dairy 
proteins, can theoretically also contribute to circulating concentrations of C15:0 and C17:0. 
Moreover, besides dairy products, C15:0 and C17:0 can also be found in marine water fish and 
have recently found to be related to DHA, a common fatty acid found in fatty fish[84,85]. C15:0 
and C17:0 might therefore be an invalid biomarker of dairy intake in a population with a high fish 
consumption. However, in countries such as the Netherlands, where consumption of dairy is high 
(a median of 321 g/day according to the Dutch Food Consumption Survey)[86] and fish intake 
low (70 g/week)[87], use of C15:0 and C17:0 as dairy fat biomarkers should give no concerns. 
For example, in salmon, the most common eaten fatty fish in the Netherlands, the amount of 
C15:0 and C17:0 is around 40mg respectively 20mg per 100g[88], while the intake of C15:0 and 
C17:0 via dairy products is around 1.10 and 0.56 g per 100g[9,10].
CONCLUSION
In the systematic review, C14:0, C15:0, C17:0 trans-C16:1(n-7), trans-C18 :1(n-7) and CLA in 
plasma/serum (cholesterol esters, triglycerides, phospholipids, free fatty acids or a combination 
of the four), erythrocytes, and adipose tissue were validated as potential dairy fatty acid 
biomarkers. The meta-analysis confirmed C14:0, C15:0, C17:0 and trans-C16:1(n-7) as biomarkers 
of dairy and dairy fat intake, with weaker correlations for dairy intake than for dairy fat intake. 
For example, for C17:0 the correlation coefficient with dairy intake was 0.10 (95%CI 0.03-0.16), 




reported dairy intake, while the correlation coefficient with dairy fat intake was 0.19 (95%CI 
0.14-0.25), which suggest that a higher, but still limited amount of about 3.6% of the variance 
of serum/plasma can be explained by self-reported dairy fat intake. Unfortunately, until now, 
research has mainly focused on use of single markers, and little is known about the performance 
of prediction models for self-reported dairy and dairy fat intake based on inclusion of two or 
more biomarkers at the same time. Given the low explained variance of single biomarkers by 
self-reported dairy and dairy fat intake, it would be interesting if future cross-sectional and 
prospective studies in the field would provide such information. , Among different fractions, 
we found fatty acid biomarkers measured in adipose tissue to be most strongly associated with 
dairy and dairy fat intake. Adipose tissue is, however, not always available in studies. In most 
fractions, including adipose tissue, C15:0 was found to be the strongest fatty acid biomarker 
among the set of biomarkers investigated in this review. Thus, future prospective studies in the 
field would preferably include C15:0 as a biomarker, either alone or in combination with other 
fatty acid biomarkers. Caution has to be taken with C14:0 as dairy fat biomarker, since this 
marker is also present in dietary products other than dairy. Trans-C18:1(n-7) and CLA still need 
further investigation, because of problems with separation between trans-C18:1(n-7) and other 
trans fatty acids in commonly applied measurement techniques and a small number of studies.
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Appendix S1: PRISMA checklist
Section/topic # Checklist item Reported on 
page #
TITLE




Structured summary 2 Provide a structured summary including, as applicable: 
background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal 
and synthesis methods; results; limitations; conclusions 




Rationale 3 Describe the rationale for the review in the context of 
what is already known.
3-6
Objectives 4 Provide an explicit statement of questions being 
addressed with reference to participants, interventions, 






5 Indicate if a review protocol exists, if and where it can be 
accessed (e.g., Web address), and, if available, provide 
registration information including registration number.
7,
Appendix A
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-
up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, 
giving rationale.
7,8
Information sources 7 Describe all information sources (e.g., databases with 
dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.
7
Search 8 Present full electronic search strategy for at least one 
database, including any limits used, such that it could be 
repeated.
Table S1
Study selection 9 State the process for selecting studies (i.e., screening, 
eligibility, included in systematic review, and, if applicable, 




10 Describe method of data extraction from reports 
(e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from 
investigators.
7,8
Data items 11 List and define all variables for which data were sought 
(e.g., PICOS, funding sources) and any assumptions and 
simplifications made.
7,8
Risk of bias in 
individual studies
12 Describe methods used for assessing risk of bias of 
individual studies (including specification of whether this 
was done at the study or outcome level), and how this 
information is to be used in any data synthesis.
8,9, 
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page #
Synthesis of results 14 Describe the methods of handling data and combining 
results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.
9, 10
Risk of bias across 
studies
15 Specify any assessment of risk of bias that may affect 
the cumulative evidence (e.g., publication bias, selective 
reporting within studies).
10
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity 




Study selection 17 Give numbers of studies screened, assessed for eligibility, 
and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.
10, Figure 1
Study characteristics 18 For each study, present characteristics for which data 
were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.
Table 2, 11
Risk of bias within 
studies
19 Present data on risk of bias of each study and, if available, 
any outcome level assessment (see item 12).
Table 3, 11, 
12
Results of individual 
studies
20 For all outcomes considered (benefits or harms), present, 
for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.
Figure 2 
A-H, Table 4, 
12-14
Synthesis of results 21 Present results of each meta-analysis done, including 
confidence intervals and measures of consistency.
Figure 2 
A-H, 13,14
Risk of bias across 
studies
22 Present results of any assessment of risk of bias across 
studies (see Item 15).
Figure S1 
A-H, 14
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity 







24 Summarize the main findings including the strength of 
evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy 
makers).
14-22
Limitations 25 Discuss limitations at study and outcome level (e.g., risk 
of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).
15,16
Conclusions 26 Provide a general interpretation of the results in the 




Funding 27 Describe sources of funding for the systematic review and 
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Appendix S2: Research protocol
Title
Fatty acids as Biomarkers of Dairy and Dairy fat intake: A systematic review and Meta-analysis.
Authors
Ilse Pranger1, Monica Joustra2, Eva Corpeleijn3, Frits Muskiet4, Ido Kema4, Stefanie Oude Elferink5, 
Cecile Singh-Povel5, Stephan Bakker1
1 Department of Internal Medicine, University Medical Center Groningen and University of 
Groningen, Groningen, The Netherlands
2 Interdisciplinary Center Psychopathology and Emotion regulation, University Medical Center 
Groningen and University of Groningen, Groningen, The Netherlands
3 Department of Epidemiology, University Medical Center Groningen and University of Groningen, 
Groningen, The Netherlands
4 Department of Laboratory Medicine, University Medical Center Groningen and University of 
Groningen, Groningen, The Netherlands
5 FrieslandCampina Amersfoort, The Netherlands
Review Question
Which circulating fatty acids can be used as potential biomarkers of dairy fat intake in the 
general population?
Sub question:
What is the association between circulating fatty acids and dairy fat intake measured by dietary 
questionnaires in the general population?
Searches
The databases MEDLINE, EMBASE and Web of Knowledge will be systematically searched for 
eligible studies. Duplicates will be removed and animal studies will be excluded. Searches will 
be limited to papers which are written in English.
Types of study to be included
All observational studies will be considered for inclusion. Intervention studies whereby intake 
of dairy fat was regulated by supplements or a controlled diet, (systematic) reviews, letters to 
the editor, and other study designs will be excluded.
Condition or domain being studied
A frequently used method to measure dairy fat intake is a validated food frequency questionnaire 
(FFQ)[S1-S3]. Although these methods provide specific information about dairy products, data 
are subjective and often biased [S4]. Alternative or complementary methods for measuring dairy 
intake are therefore needed. Researchers have shown an increased interest in biomarkers of 
dairy intake, since biological markers are considered to be a more objective parameter of this 
intake. Dairy fat consist of several fatty acids, of which some are (to a large extend) unique for 




them interesting as biomarkers for dairy fat intake. Studies recently showed that the fatty acids 
C14:0, C15:0, C17:0, Trans-C16:1, Trans-C18:1(n-7) and CLA might be useful biomarkers of dairy 
fat intake [S6-S8]. However, a clear overview of fatty acids that can be used as biological markers 
of dairy fat intake is lacking.
Participants/population
The population that will be studied is the general population, with no restriction for age and 
sex. Animal studies will be excluded.
Exposure
Dairy fat intake should be assessed by a dietary questionnaire (FFQ, Food record or 24h recall) 
and reported in the article. Studies whereby dairy intake was regulated by supplements or a 
controlled diet will be excluded. Measurements of dairy intake will be restricted to ‘Total dairy 
intake’ or ‘Total dairy fat intake’ to overcome the problem of having a widespread variation in 
reporting on dairy intake.
Outcome
Circulating fatty acids are preferably measured by a GC (Gas Chromatograph). Fatty acids should 
be measured in plasma/serum, erythrocytes or adipose tissue. Furthermore, articles should 
report on the correlation between exposure (dairy fat intake) and outcome (circulating fatty 
acids), including the probability level (p-value).
Data selection and extraction
Title and abstract will be screened by two independent reviewers (I.G.P and M.L.J). Articles will 
be rated separately. Disagreements between the two researchers will be resolved by consensus. 
Studies which are in agreement with the eligibility criteria will be retrieved as full text. Reasons 
for exclusion and percentage of agreement, as Cohen’s kappa, between the assessors will be 
documented. When data of interest are unclear, authors of the corresponding article will be 
contacted for more information.
Two independent reviewers will be extracting data and assess the risk of bias for each study. From 
the included studies, the following data will be extracted: name first author, publication year, 
study design, mean status of potential dairy fatty acids measured in plasma/serum, erythrocytes 
and adipose tissue, mean dairy intake by dietary questionnaires, correlation between dairy intake 
and circulating fatty acids. Selected papers will be screened for used laboratory techniques as 
well (fatty acid analysis, fraction, column and equipment).
Risk of bias (quality assessment)
Only observational studies will be included in this review. Previous studies have emphasized 
the need for a uniform methodological assessment tool for observational studies [S9,S10]. 
The STROBE recommendations are thereby frequently used in an inappropriate way to assess 
the methodological quality of observational epidemiological studies [S11]. The Cochrane Non-
Randomized Studies Methods Working Group recommends the Newcastle-Ottawa Scale (NOS) 
for assessing the quality of non-randomized studies in meta-analyses [S12]. We therefore 
designed a methodological study quality tool that assesses the quality of studies that focuses 
specifically on the correlation between dairy (fat) intake and potential circulating dairy fat 
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biomarkers. A study will be judged on three domains: the selection (representativeness of the 
sample population, appropriate sample size, ascertainment of the exposure (validated tool to 
measure dairy fat intake)), the comparability (appropriate control of confounding factors), and 
the outcome (appropriate assessment of the outcome (validated tool to measure circulating dairy 
fat biomarkers), appropriate description of statistical test). The item ‘respondents comparability 
and response rate’ was excluded from the original quality tool since it is not applicable in the 
current review. Instead, we added the item ‘Sample Size’ whereby a sample size of n ≥ 100 is 
justified and satisfactory. The maximum attainable quality score is 6.
Strategy for data synthesis
We will first perform a narrative overview of available biomarker studies. Articles will be classified 
by type of fraction (plasma/serum, erythrocytes, adipose tissue). For those biomarkers with more 
than four studies available, we plan quantitative synthesis on aggregate data.
For the quantitative synthesis, data will be pooled with the random effects model of meta-
analysis using MedCalc. The existence of heterogeneity among studies will be assessed by 
Q-tests, and the degree of the heterogeneity will be quantified by calculating the I-squared value.
Analysis of subgroups or subsets
Subgroup analyses will be performed including studies with more than two-thirds of the quality 
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Appendix S3
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE
(adapted for cross-sectional studies)
Selection: (Maximum 3 stars)
1) Representativeness of the sample:
a) Truly representative of the average in the general population. * (all subjects or random 
sampling)
b) Somewhat representative of the average in the general population. * (non-random sampling)
c) Selected group of users.
d) No description of the sampling strategy.
2) Sample size:
 a) Justified and satisfactory (namely n ≥ 100 ). *
 b) Not justified.
3) Ascertainment of the exposure (risk factor; dairy (fat) intake):
 a) Validated measurement tool (FFQ, food record, 24h recall). *
 b) Non-validated measurement tool, but the tool is available or described.
 c) No description of the measurement tool.
Comparability: (Maximum 1 stars)
1) The subjects in different outcome groups are comparable, based on the study design or 
analysis. Confounding factors are controlled.
 a) The study controls for the most important factor (age, sex, BMI). *
 b) The study controls for any additional factor. *
 c) The study did not control for any additional factors.
Outcome: (Maximum 2 stars)
1) Assessment of the outcome (circulating fatty acids):
 a) Validated measurement tool (Quantitative determination of fatty acids, G(l)C-FID, capillary 
(a)polar column). *
 b) Non-validated measurement tool, but the tool is available or described *
 c) No description of the measurement tool
2) Statistical test:
a) The statistical test used to analyze the data is clearly described and appropriate, and the 
measurement of the correlation is presented, including the probability level (p value). *
b) The statistical test is not appropriate, not described or incomplete.
This scale has been adapted from the Newcastle-Ottawa Quality Assessment Scale for cohort 
and case-control studies to perform a quality assessment of cross-sectional studies for the 
systematic review, “Fatty acids as Biomarkers of Total Dairy and Dairy Fat Intake: A Systematic 
Review and Meta-analysis”. This scale was a modified version of the NOS scale, as also used by 
several other studies that have felt the need to adapt the NOS scale so as to appropriately assess 
the quality of cross-sectional studies.
A maximum obtainable quality score of the modified version of the NOS is 6. A minimum of two-




Industrial versus ruminant trans fatty 










Background: Trans-C18:1 fatty acids in the diet derive from two distinct sources: industrially 
produced trans-C18:1 (i-TFA) and ruminant trans-C18:1, which is mainly from dairy (r-TFA). 
I-TFA has shown to be associated with increased cardiovascular risk, whereas r-TFA has been 
suggested to have a protective effect. We investigated whether the association between r-TFA 
and cardiovascular risk factors is different compared to the association between i-TFA and 
cardiovascular risk factors.
Materials and Methods: Data were obtained from the Lifelines Cohort (n=769). Intakes of dairy 
were determined by food frequency questionnaire. R-TFA and i-TFA were analyzed in fasting 
plasma triglycerides (TG) and phospholipids (PL) and measured with an GC-FID equipped with 
an 200 m polar column.
Results: Mean±SD age of included subjects was 53±16 years. Median(25th-75th) intakes of dairy 
and dairy fat were 322(209–447) and 12.3(8.4–17.4) g/d respectively. Dairy fat was associated 
with r-TFA (TG std.β=0.249; PL std.β=0.264), and remained associated after adjustment for 
I-TFA. Plasma TG r-TFA was positively associated with total TG (std.β=0.127) and cholesterol (std.
β=0.128). Plasma PL r-TFA was inversely associated with cardiovascular risk factors such as weight 
(std.β=-0.114), waist circumference (std.β=-0.102), BMI (std.β=-0.107), hs-CRP (std.β = -0.147) 
and uric acid (std.β=-0.243). R-TFA remained associated with cardiovascular risk factors after 
adjustments for age, sex, total TG and cholesterol. These associations were not found for i-TFA.
Conclusion: r-TFA, which can be seen as a predictor for the intake of dairy, was inversely 
associated with cardiovascular risk factors, this in contrast to i-TFA.
79
I-TFA and R-TFA and their association with dairy and CVD
INTRODUCTION
In the general population, cardiovascular disease (CVD) has become the number one cause of 
death worldwide[1]. The total number of CVD deaths has increased globally from 14.1 million in 
1990 till 17.7 million in 2015[1,2]. In Europe, more than 85 million people had CVD in 2015, and 
around 11.3 million new cases were detected[3]. Recognized risk factors for the development of 
CVD are an increased BMI, elevated levels of total cholesterol and triglycerides, hypertension, 
insulin resistance and diabetes[4-10]. Other reported predictors of CVD are the inflammatory 
marker high-sensitive C-reactive protein (Hs-CRP), and the kidney marker uric acid[11-15]. The 
diet plays an important role in the prevention of CVD and its risk factors[16,17]. However, the 
optimal dietary composition for CVD prevention is still debated. One of the dietary factors on 
which more research is needed is dairy fat. Fat from dairy products may have beneficial effects 
on cardiovascular risk factors such as BMI, fasting glucose and insulin sensitivity[18-21]. However, 
due to presence of saturated and trans fatty acids such as trans-C18:1, there is skepticism 
regarding the potential protective effects and even the notion that dairy fat is unhealthy[22,23].
Evidence on the effects of trans-C18:1 fatty acids in cardiovascular disease risk is 
contradictive. Data from the Cardiovascular Health Study, a prospective study on cardiovascular 
disease risk factors among older men and women from the USA, showed that high levels of 
plasma phospholipid trans-C18:1 are inversely associated with overall cardiovascular risk and 
sudden cardiac death[24]. In another study it was found that high levels of trans-C18:1 fatty acids 
in adipose tissue were related to an increased risk of myocardial infarction[25]. Importantly, 
these studies investigated the trans-C18:1 fatty acid cluster as a whole rather than its individual 
components. It should be realized that the individual components derive from two distinct 
sources, i.e. industrially produced trans-C18:1 (i-TFA) and ruminant trans-C18:1, mainly from 
dairy origin (r-TFA)[26]. I-TFA (e.g. elaidic acid or trans-C18:1(n-9)) has been associated with 
increased cardiovascular risk, while it has been suggested that this is not the case for r-TFA 
(e.g. vaccenic acid or trans-C18:1(n-7))[27,28]. It was therefore suggested that the effects of 
i-TFA and r-TFA should be investigated separately. Few studies have indeed done so[29-31], 
however these studies found the same result for i-TFA and r-TFA or found no significant result. 
Therefore, most studies still report the TFA as a cluster of trans-C18:1. Furthermore, in the 
studies analyzing separate effects, the employed method for separating plasma TFA may have 
been suboptimal[32,33]. The commonly used method to measure trans fatty acids is a GC-FID[34], 
equipped with a polar column up till 100 m long (e.g. CP-Sil 88)[32,35-37]. However, this method 
may potentially overestimate the status of i-TFA and r-TFA due to poor separation. Since 2014, 
polar columns with lengths up till 200 m (i.e. CP Select for FAME) became available that are 
specifically developed to allow better separation between trans-C18:1 fatty acids[38].
The first aim of the current study was to investigate whether r-TFA was associated with 




measured the plasma trans fatty acids on a 200 m polar column. Secondly, we examined the 
associations of i-TFA and r-TFA with cardiovascular risk factors. A subset of the data from the 
population based Lifelines Biobank and Cohort study was used to explore these questions.
MATERIALS AND METHODS
Study design and population
The LifeLines Cohort Study is a large observational population-based cohort study and Biobank 
that examines the health and health-related behaviors of more than 167,000 persons[39]. The 
participants were recruited from the three Northern provinces of the Netherlands between 
2006 and 2013. A more detailed description of the Lifelines Cohort study can be found 
elsewhere[40,41]. In short, the first group of 25-50 years old participants was recruited via 
general practitioners. Participants could indicate whether family members were interested as 
well. In addition, individuals who were interested in the study had the possibility to register via 
an online self-registration. Individuals with insufficient knowledge of the Dutch language, with 
severe psychiatric or physical illness, and those with limited life expectancy (< 5 years) were 
excluded from the study. Participants (> 18 years old) completed several questionnaires, including 
topics such as occurrence of diseases, general health, medication use, diet, physical activity 
and personality. Participants were invited to the Lifelines Research sites for a comprehensive 
health assessment. All participants provided written consent. The current study used a randomly 
selected subset from the cross-sectional data set (n = 864). The Lifelines Cohort Study was 
conducted according to the principles of the Declaration of Helsinki and approved by the Medical 
ethical committee of the University Medical Center Groningen, The Netherlands.
Dietary intake
To asses dietary intake in the Lifelines Cohort, a 110-item semi-quantitative baseline food 
frequency questionnaire (FFQ) assessing food items over the previous month was developed 
and validated by the Wageningen University using the Dutch FFQTOOLTM, in which food items 
were selected based on the Dutch national Food Consumption Survey of 1997/1998[42]. Seven 
answer categories were used to assess consumption frequency, ranging from ‘not this month’ 
to ‘6-7 days a week’. Portion size was estimated by fixed portion sizes (e.g. slices of bread, pieces 
of fruit) and commonly used household measures (e.g. cups, spoons). Energy and macronutrient 
intake, including dairy consumption, was estimated from the FFQ data by using the Dutch food 
composition database of 2011 (NEVO)[43]. For this study, ‘total dairy intake’ and ‘total dairy fat 
intake’ (consisting of cheese, milk, buttermilk, yoghurt, sweetened yoghurt drinks, custard, curd 
cheese, ice cream, whipped cream and porridge) were calculated.
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Cardiovascular risk factors
A standardized protocol was used to obtain blood pressure, height, weight and waist 
circumference. Systolic and diastolic blood pressures were measured 10 times during a period 
of 10 min, using an automated Dinamap Monitor (GE Healthcare, Freiburg, Germany). The 
average of the final three readings was used for each blood pressure parameter. Anthropometric 
measurements were done without shoes, for body weight to the nearest 0.1 kg and height and 
waist circumference to the nearest 0.5 cm. Height was measured with a stadiometer and waist 
circumference was measured in standing position with a tape measure all around the body, at 
the level midway between the lower rib margin and the iliac crest. BMI was calculated by dividing 
weight in kilograms by the squared height in meters (kg/m2).
For analysis of lipids, glucose, uric acid, creatinine and the inflammation marker high 
sensitivity C-reactive protein (hs-CRP), blood samples were drawn in the morning between 8:00 
and 10:00 am after a period of overnight fasting. Serum levels of total cholesterol and high-
density lipoprotein (HDL) cholesterol were measured with an enzymatic colorimetric method, 
low-density lipoprotein (LDL) cholesterol with an enzymatic method and total triglycerides with a 
colorimetric UV method, all on a Roche Modular P chemistry analyzer (Roche, Basel, Switserland). 
Fasting blood glucose was measured using a hexokinase method. HbA1c was determined in whole 
blood (EDTA-anticoagulated) by means of turbid metric inhibition immunoassay on a Cobas 
Integra 800 CTS analyzer (Roche Diagnostics Netherland BV, Almere, The Netherlands). Insulin 
resistance was estimated by calculating the ratio total triglycerides/HDL cholesterol[44]. Serum 
uric acid and creatinine were measured on a Roche Modular P chemistry analyzer (Roche, Basel, 
Switzerland). The Hs-CRP was determined by nephelometry (BN II system Siemens, Marburg, 
Germany).
Data on education and smoking habits
Information about education, smoking and general health was collected from the self-
administered questionnaire. Educational level was categorized in four groups (1. never been to 
school or elementary school only, 2. lower vocational or secondary schooling, 3. intermediate 
vocational schooling or intermediate/higher secondary schooling or 4. higher vocational 
schooling or university). Subjects were also classified as non-smokers, former smokers or current 
smokers.
Sample preparation and analyses
Fatty acid analyses
EDTA-plasma samples were collected at baseline and stored at -80⁰C until use for assessment 
of fatty acid profiles. Analyses of fatty acids were performed at the Department of Laboratory 




as described by Hoving et al [45]. In short, total lipids were extracted by the method of Folch et 
al., using 6 ml of chloroform-methanol (2:1) and 200 µl EDTA-plasma sample[46]. In addition, a 
shortened version of the method of Kaluzny et al. was used to isolate plasma cholesterol esters 
(CE), triglycerides (TG) and phospholipids (PL), using aminopropyl SPE columns for the separation 
(Isolute, Biotage)[47]. Fatty acids were transmethylated with methanolic-HCL into fatty acid 
methyl esters (FAME). The samples were extracted with hexane and eventually redissolved into 
100 µl hexane. 100 µl of an internal standard for the quantification of fatty acids in CE (17:0) 
(50.1 mg/100 ml chloroform-methanol, 2:1 v/v), and 100 µl of an internal standard for the 
quantification of fatty acids in TG (19:0) (19.9 mg/100 ml chloroform-methanol, 2:1 v/v), both 
obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands), were added before isolation of lipid 
classes. For the quantification of fatty acids in PL, 100 µl of free fatty acid 19:0 (50.0 mg/100 ml 
methanol), obtained from Larodan (Solna, Sweden), was added after isolation of lipid classes. 
100 µl Butylated Hydroxytoluene (1 g/100 ml methanol) from Sigma-Aldrich (Zwijndrecht, The 
Netherlands) was added to prevent fatty acid oxidation. An overview of the sample preparation 
and analyses can be found in Figure 1.
Conditions of the Gas Chromatography and Flame ionization Detector
Aliquots of 2 µl were injected into an Agilent model 6890 gas chromatography (GC) equipped with 
a 200 m x 0.25 mm polar column (CP Select for FAME) and detected with an Agilent 7683 series 
flame ionization detector (FID). The carrier gas was helium, there was a constant pressure of 550 
kPa and a split ratio of 1:20. The injector temperature was 260⁰C and the detector temperature 
was 300⁰C. The temperature program started with a temperature of 150⁰C and increased with 
a rate of 1⁰C/min till a temperature of 250⁰C. The temperature was subsequently increased 
with 20⁰C/min till a final temperature of 270⁰C for 15 min. The conditions of the GC-FID can be 
found in Table A of the supporting information ‘Methods and Validation’. Chromatograms of 
the trans-C18:1 fatty acids in plasma TG and PL are shown in Supplemental Figures A and B.
Identification, quantification and quality control
FAME were identified by comparing retention times with those of known standards (Supelco 
37 component FAME mix (Sigma-Aldrich)). Peak areas were calculated using Atlas 8.2.3. 
Chromatography Data System (Thermo Fisher Scientific Inc.) and Atlas Report Manager (Blaise 
software Series Inc.). Data on fatty acids were calculated into mol%. Variation coefficients (CV) 
of the fatty acids were determined using quality-control samples (pooled plasma samples). CVs 
were obtained from 10 replicates measured in a single series. CV% of I-TFA and r-TFA in both 
plasma TG and PL were ≤ 10% (Supporting information ‘Methods and Validation’ Table B). All 
heights of the identified peaks in plasma TG and PL exceeded 100 times the average background 
noise.
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Figure 1: Sample preparation and analyses of fatty acids in plasma cholesterol esters (CE), 





Prior to the current analyses, fasting EDTA plasma samples of the selected Lifelines participants 
had been frozen at -80⁰C. They were transported to the Central Laboratory of the University 
Medical Center Groningen. We first performed a pilot study for which we measured trans-C18:1 
fatty acids in plasma CE, TG and PL of 96 participants. In this pilot, we found that trans-C18:1 
fatty acids were not detectable in plasma CE, while they were well above the detection limit in 
TG and PL. Subsequently, we decided to move forward with measurements only in plasma TG 
and PL. In total, 864 samples were analyzed.
Statistical analyses
All analyses were performed using IBM SPSS Statistics, version 22.0 for Windows software (IBM 
Armonk, NY, USA) and GraphPad Prism, version 5.03 for Windows software (Graphpad Software, 
La Jolla, CA, USA). In total, circulating fatty acids were measured in 864 participants, whereof 
776 had completed the FFQ. Cases with missing data on either dietary intake or circulating fatty 
acids were removed before analyses leaving 769 participants in the lifelines cohort with complete 
data. Characteristics of the Lifelines population are reported as mean ± SD for continuous data 
with a normal distribution and as median (25th-75th percentile) for continuous data with a skewed 
distribution. Categorical data are presented as number (%). Dairy and dairy fat intake were 
measured as absolute and relative intakes, of which relative intakes were stratified for sex and 
adjusted for total energy intake using the residual method[48]. Multivariate linear regression 
analyses were used to investigate the association of absolute and relative dairy and dairy fat 
intake with I-TFA, R-TFA and I-TFA+R-TFA in plasma TG and PL. Non-normal data were transformed 
(square root) before analyses. Models were adjusted for I-TFA or R-TFA, age, education and 
smoking habits, and total carbohydrates and total fat intake. Multivariate linear regression 
analyses were also used to examine the cross-sectional association of trans-C18:1 fatty acids 
measured in plasma TG and PL with cardiovascular risk factors. Associations were adjusted 
for age and sex, and education and smoking habits. Associations with plasma TG were further 
adjusted for total triglycerides, while associations with plasma PL were further adjusted for total 
triglycerides and total cholesterol. Associations between dairy fat intake (relative intake) and 
cardiovascular risk factors were investigated as an extra analyses. The analyses were adjusted for 
age, education, smoking habits, total carbohydrate and total fat intake. All reported probability 
values are two-tailed, and P ≤ 0.05 was considered statistically significant.
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RESULTS
Study population
In the present study, 769 subjects with complete data on dietary intake and circulating trans 
fatty acids were included. Characteristics of the study population are shown in Table 1. Age of 
the included subjects was 53.0 ± 15.5 years and 404 subjects were male (52.5%). The subjects 
were slightly overweight with a BMI of 26.0 ± 4.0 kg/m2 and blood pressure was within normal 
boundaries (127/74 mmHg). Total TG/HDL-c ratio (mol/mol) was 0.72 (0.45 - 1.17), whereas 
glucose and HbA1c were 5.1 ± 0.7 and 5.6 ± 0.4% mmol/L, respectively. The study population had 
a serum Hs-Crp of 1.0 (0.5 – 2.2) mg/L and a serum uric acid level of 0.31 ± 0.1 mmol/L. Energy 
intake of the population was 1975 ± 624 kcal/d (8274 ± 2613 KJ/d). Of the total intake, 46 En% 
was derived from carbohydrates, 15 En% from proteins, and 35 En% from fats. Absolute intakes 
of dairy and dairy fat intake were 322 (209 – 447) g/d and 12.3 (8.4 – 17.4) g/d respectively. 
Total dairy intake consisted for 12.8% of cheese, for 35.1% of milk and for 10.0% of yoghurt. Of 
the products, 25% were skimmed dairy products, 23% semi-skimmed dairy products and 24% 
full-fat dairy products. Status of i-TFA was 0.12 (0.09 – 0.15) mol% in plasma TG and 0.05 (0.04 
– 0.06) mol% in plasma PL. Status of r-TFA was 0.10 (0.07 – 0.13) mol% in plasma TG and 0.09 
(0.07 – 0.11) mol% in plasma PL.
Table 1: Characteristics of the Lifelines Population (n = 769)
 Baseline Characteristics Mean/Median/Amount SD/25th-75th percentile/%
General
Age visit 1, years 53.0 15.5
Male sex (%) 404 52.5%
Weight, kg 79.3 14.2
BMI, kg/m2 26.0 4.0
Smoking, yes (%) 115 15.0%
SBP, mmHg 126.5 17.0
DBP, mmHg 73.7 9.7
Laboratory measurements
Total Cholesterol, mmol/L 5.2 1.0
HDL-c, mmol/L 1.5 0.4
LDL-c, mmol/L 3.3 0.9
Total TG, mmol/L 1.0 0.8 - 1.5
TG/HDL-c ratio, mol/mol 0.72 0.45 – 1.17
Glucose, mmol/L 5.1 0.7





 Baseline Characteristics Mean/Median/Amount SD/25th-75th percentile/%
Creatinine, umol/L 76.0 13.6
C-reative protein (hs-CRP), mg/L1 1.0 0.5 – 2.2
Uric acid, mmol/L1 0.31 0.1
Dietary intake (FFQ)
Energy intake, Kcal/d 1971 624
Total carbohydrates, g/d 228.8 76.7
Total protein, g/d 74.8 20.9
Total fat, g/d 77.2 30.0
Dairy intake (FFQ)
Total Dairy intake (absolute intake), g/d 322 209 – 447
Total Dairy fat intake (absolute intake), g/d 12.3 8.4 – 17.4
Total Dairy intake (relative intake), g/d 331 217 – 443
Total Dairy fat intake (relative intake), g/d 12.7 9.2 – 16.4
Trans-fatty acid status in Plasma TG
I-TFA, mol% 0.12 0.09 – 0.15
R-TFA, mol% 0.10 0.07 – 0.13
I-TFA + R-TFA, mol% 0.22 0.17 – 0.29
Trans-fatty acid status in Plasma PL
I-TFA, mol% 0.05 0.04 – 0.06
R-TFA, mol% 0.09 0.07 – 0.11
I-TFA + R-TFA, mol% 0.14 0.11 – 0.17
Data are presented as mean ± SD, median (25th-75th percentile) or number (%). Abbreviations: SD, 
standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; TG, Triglycerides; 
TG/HDL-c ratio, Total Triglycerides/HDL cholesterol ratio; HbA1C, Hemoglobin A1C; FFQ, Food Frequency 
Questionnaire; Kcal, Kilocalories; PL, Phospholipids; I-TFA, industrial trans fatty acid (Elaidic acid; trans-
C18:1(n-9)); r-TFA, ruminant trans fatty acid (Vaccenic acid; trans-C18:a(n-7)). 1. Hs-CRP was available in 
n = 412, uric acid was available in n = 348
Dairy intake and trans-C18:1 fatty acids
The associations of i-TFA and r-TFA with dairy and dairy fat intakes (absolute and relative) are 
shown in Table 2. In plasma TG, i-TFA and r-TFA were associated with absolute intakes of dairy 
(std.β = 0.078 and std.β = 0.101, p ≤ 0.03) and with dairy fat (std.β = 0.181 and std.β = 0.261, 
both P < 0.001) (Model 1). I-TFA and r-TFA were also associated with relative intakes of dairy 
(std.β = 0.087, p = 0.01 and std.β = 0.105, p = 0.003) and dairy fat (std.β = 0.217, std.β = 0.292, 
both p < 0.001). The associations were also found for i-TFA and r-TFA measured in plasma 
PL, and the combination of i-TFA and r-TFA in plasma TG and PL. The associations of i-TFA, 
measured in both plasma TG and PL, with absolute and relative dairy and dairy fat intakes did 
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not remain after adjustment for r-TFA (Model 2). In contrast, the associations of r-TFA with 
absolute and relative dairy and dairy fat intakes remained after adjustment for i-TFA, for which 
the associations between r-TFA and relative dairy fat intakes were strongest in both plasma TG 
and PL (std.β = 0.249 and std.β = 0.264, p < 0.001, respectively) (Model 2). The association of 
trans-C18:1 with dairy and dairy fat intakes was further explored by adjusting the model for age, 
education and smoking habits (Supplemental Table 1, Model S1), and total carbohydrates and 
total fat intakes (Supplemental Table 1, Model S2). R-TFA and i-TFA + r-TFA remained related to 
absolute and relative dairy and dairy fat intakes.
Trans-C18:1 in plasma TG and cardiovascular risk factors
The associations of industrial and ruminant TFA measured in plasma TG with cardiovascular 
risk factors are shown in Table 3. I-TFA, r-TFA and i-TFA + r-TFA were positively associated with 
age (std.β = 0.120, std.β = 0.088 and std.β = 0.122, respectively, all P ≤ 0.01). Additionally, r-TFA 
and i-TFA + r-TFA were positively associated with total cholesterol (std.β = 0.128 for r-TFA and 
std.β = 0.131 for i-TFA + r-TFA, P < 0.001), LDL cholesterol (std.β = 0.119 for r-TFA and std.β = 0.106 
for i-TFA + r-TFA, P ≤ 0.003) and total TG (std.β = 0.127 for r-TFA and std.β = 0.133 for i-TFA + 
r-TFA, P < 0.001). The associations remained after adjustment for age and sex (Figure 2). I-TFA was 
associated with glucose (std.β = 0.119, p = 0.001) and HbA1c% (std.β = 0.114, p = 0.001), however 
only the association with glucose remained after adjustment for age and sex (std.β = 0.085, 
p = 0.01) and there was no association with the insulin sensitivity marker TG/HDL-c ratio. The 
association of i-TFA + r-TFA with glucose and HbA1c% showed the same trends. The inflammatory 
marker Hs-CRP was not associated with the trans fatty acids measured in plasma TG. Uric acid 
was inversely associated with r-TFA after adjustment for age and sex (std.β = -0.108, p = 0.03).
In further analyses, the associations were also adjusted for education, smoking and total 
triglycerides (Supplemental Table 2). The association between r-TFA and BMI became inverse 
(std.β = -0.067, P = 0.05). The association of r-TFA with total cholesterol and LDL cholesterol 
became weaker and disappeared respectively, while the inverse association with uric acid 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Age and sex adjusted associations between ruminant TFA measured in plasma triglycerides and 
cardiovascular risk factors. * = P < 0.05
Abbreviations: WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; Total C, Total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, 
low density lipoprotein cholesterol; Total TG, Total triglycerides; HbA1c, hemoglobin A1c; Hs-CRP, High-
sensitive C-reactive protein.
Trans-C18:1 fatty acids in plasma PL and cardiovascular risk factors
The associations of industrial and ruminant TFA measured in plasma PL with cardiovascular 
risk factors are shown in Table 4. I-TFA, r-TFA and i-TFA + r-TFA were positively associated 
with age (std.β = 0.104, std.β = 0.071 and std.β = 0.093, all p ≤ 0.03, respectively) and sex 
(std.β = 0.124, std.β = 0.102 and std.β = 0.130, all p ≤ 0.01, respectively). R-TFA was inversely 
associated with weight (std.β = -0.114, P = 0.002), waist circumference (std.β = -0.102, p = 0.01), 
BMI (std.β = -0.107, p = 0.003), and systolic (std.β = -0.081, p = 0.02) and diastolic blood pressure 
(std.β = -0.072, P = 0.05), while this was not the case for i-TFA. R-TFA was also inversely associated 
with total TG (std.β = -0.098, p = 0.01), the TG/HDL-c ratio (std.β = -0.108, p = 0.003) and glucose 
(std.β = -0.077, p = 0.03), while this was again not the case for i-TFA. Both r-TFA and i-TFA 
+ r-TFA were inversely associated with the inflammatory marker Hs-CRP (std.β = -0.147 and 
std.β = -0.131, respectively, all p ≤ 0.01), and with the kidney marker uric acid (std.β = -0.243 and 
std.β = -0.222, respectively, all p < 0.001). All associations remained significant after adjustment 
for age and sex (Figure 3).
In additional analyses, associations were additionally adjusted for education, smoking, 
total triglycerides and total cholesterol (Supplemental Table 3). Although weaker compared to 
model 1 and 2, significant inverse associations of r-TFA with waist circumference, BMI, systolic 
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blood pressure, glucose, Hs-CRP and uric acid remained after adjustment for age, sex, total 
triglycerides and total cholesterol.
Dairy (fat) intake and cardiovascular risk factors
As an extra analysis, relative intakes of dairy and dairy fat intake were associated with 
cardiovascular risk factors (Supplemental Table 4). Dairy and dairy fat intake were associated 
with several cardiovascular risk factors such as waist circumference, blood pressure, cholesterol, 
glucose, HbA1c% and uric acid. However, these associations disappeared after adjustment for 
age, education, smoking, and total carbohydrates and total fat intake.
Figure 3: Age and sex adjusted associations between ruminant TFA measured in plasma phospholipids and 
cardiovascular risk factors. * = P < 0.05
Abbreviations: WC, waist circumference; BMI, body mass index; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; Total C, Total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, 
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DISCUSSION AND CONCLUSION
In a population-based study of 769 participants, we demonstrated that r-TFA was significantly 
associated with absolute and relative intakes of dairy and dairy fat. Furthermore, we showed that 
r-TFA, but not i-TFA were inversely associated with cardiovascular risk factors. To the best of our 
knowledge, we are the first to have performed such an analysis with r-TFA and i-TFA measured 
by a 200 m polar column, a technique which is superior in separating r-TFA’s from i-TFA’s.
Previous studies on the association between TFA and dairy (fat) intake have mainly used a 
total cluster of trans-C18:1 fatty acids, not separating the industrial and ruminant variant. Earlier 
cross-sectional studies on the trans-C18:1 cluster showed contradicting results. Two studies from 
2014 showed that a cluster of trans-C18:1 fatty acids measured in erythrocytes was positively 
correlated with dairy intake[49,50]. In contrast, a cluster of trans-C18:1 fatty acids measured in 
adipose tissue was not associated with dairy intake[51]. In our cohort, in line with the studies of 
2014, the combinations of industrial and ruminant trans fatty acids, in both plasma TG and PL, 
were significantly correlated with dairy intake in the general population.
In our cohort, the associations between dairy (fat) intake and trans-C18:1 fatty acids were 
stronger for the relative intakes compared to absolute intakes. This is in line with the current 
literature. Results from the Nurses’ Health Study gathered between 1989-1990 showed that the 
correlation between trans fatty acids measured in plasma and trans fatty acid intake measured by 
an FFQ changed from an β of 0.17 for the unadjusted correlation (absolute intake) to an β of 0.30 
when adjusted for energy intake (relative intake). The same was seen when the trans fatty acids 
were measured in erythrocytes (unadjusted: β = 0.25 and adjusted: β = 0.37)[52]. The authors 
explained the differences between absolute and relative intakes by the fact that energy intake 
can operate as a confounding variable and that failure to adjust for total energy intake can lead 
to attenuation of the associations[48,52]. In the current study, there was a high inter-correlation 
between energy intake and dairy (fat) intake measured with the FFQ (std.β = 0.34; std.β = 0.48, 
both P < 0.001, respectively dairy intake and dairy fat intake), which indicates that energy intake 
might be a confounding factor in our dataset as well. It was therefore to be expected that the 
energy-adjusted models (relative intakes) had a higher significant correlation with dairy and 
dairy fat intake compared to the unadjusted models (absolute intakes).
In the current study both the industrial and ruminant trans fatty acids correlated with 
absolute and relative intakes of dairy (fat), with a slightly stronger association between dairy and 
r-TFA. The correlation between r-TFA and dairy (fat) intake remained after adjustment for the 
i-TFA, while the correlation between i-TFA and dairy (fat) intake disappeared after adjustment for 
the r-TFA. A combination of i-TFA and r-TFA was associated with dairy as well. That i-TFA and r-TFA 
were both associated with dairy (fat) intake can be explained by the fact that both trans fatty 
acids can be found in ruminant derived products, such as dairy. Ruminant and industrial food 




in ruminant food items (> 40 wt% of total trans-C18:1 in ruminant products vs <15 wt% of total 
trans-C18:1 in industrial products), while elaidic acid is the major trans-C18:1 in industrial food 
items (< 10 wt% of total trans-C18:1 in ruminant products vs >20wt% of total C18:1 in industrial 
products)[53,54]. In theory, r-TFA and i-TFA+r-TFA may both act as biomarker for dairy and 
dairy fat intake. It is, however, important to note that the content of i-TFA in apparently similar 
foods may vary considerably in the same country and from time to time[26]. Concentration 
of r-TFA in ruminant fat may vary as well, particularly via the feed of the animal and therefore 
with season[55]. The variation is however much lower compared to the variation observed for 
i-TFA[26]. It is therefore preferable to use r-TFA as marker of dairy (fat) intake only.
Dairy intake and fats from dairy products may have a favorable effect on cardiovascular risk 
factors such as body weight, blood pressure, abnormal glucose homeostasis, insulin resistance 
and dyslipidemia [18,29,56-59]. Since r-TFA is associated with dairy (fat) intake, an inverse 
association between r-TFA and cardiovascular risk factors was therefore expected in this cohort. 
R-TFA measured in plasma PL was inversely associated with several cardiovascular risk factors, 
such as weight, waist circumference, BMI, systolic and diastolic blood pressure, total TG, TG/
HDL-c ratio. All associations remained after adjustment for age and sex. In line with our results, 
a Canadian study with 100 obese and 100 non-obese participants showed that the ones with 
a higher percentage of r-TFA in plasma PL had a lower systolic (124.4 vs 118.4 mmHg, p < 0.01) 
and diastolic blood pressure (80.3 vs 75.6 mmHg, p = 0.04) compared to the ones with a lower 
percentage of r-TFA in plasma PL[60]. Furthermore, a study in which the intake of r-TFA was 
measured by FFQs also suggested a favorable effect on cardiovascular health as results from 
this cohort showed an inverse association between intake of r-TFA and changes in weight[61].
In our cohort, plasma PL r-TFA showed to be inversely associated with glucose and 
HbA1c%. Literature reports on the associations of r-TFA with the markers glucose and HbA1c% 
are contradictive to those results. In a randomized controlled trial with 42 healthy young men, 
glucose levels did not change after taken an r-TFA enriched butter for 5 weeks[62]. Additionally, 
fasting plasma glucose levels were also not affected by dietary r-TFA in obese and insulin 
resistant rats[63]. In contrast, literature does report on inverse associations between the 
dairy fat biomarkers C15:0, C17:0 and trans-C16:1(n-7) and diabetes related outcomes. In a 
cross-sectional study with 17 men and women without nonalcoholic fatty liver disease, it was 
found that serum PL C15:0, C17:0 and trans-C16:1(n-7) were inversely associated with fasting 
glucose[21]. Furthermore, a higher PL trans-C16:1(n-7) status was found to be associated with 
lower insulin resistance and lower incidence of diabetes[19]. In the Lifelines cohort , the dairy 
fat biomarkers C15:0, C17:0 and trans-C16:1(n-7) correlated well with r-TFA. PL r-TFA exhibited 
correlation coefficients of 0.38 with PL C15:0, of 0.53 with PL C17:0 and of 0.56 with PL trans-
C16:1(n-7). The inverse association of r-TFA with glucose and HbA1c% in our cohort may therefore 
not be surprising.
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An inverse association was found with the inflammatory marker Hs-CRP in plasma PL. 
Yet, the association between plasma r-TFA and Hs-CRP in humans has not been investigated 
in detail. There is an intervention study that investigated the effect of a butter enriched r-TFA 
on Hs-CRP[62]. However, the authors of the paper did not find a significant decrease in the 
inflammatory marker. On the other hand, an experimental study on the effect of r-TFA and 
dairy proteins in human endothelial cells found a reduction in inflammatory responses[64]. 
Although the researchers focused on different outcomes, such as prostaglandin excretion and 
inflammatory gene expression, it showed that r-TFA may have an impact on human inflammation.
The strongest association in our study was found between uric acid and r-TFA in both 
plasma TG and PL. Additionally, an inverse association between uric acid and dairy fat intake 
was found. This inverse association between uric acid levels and dairy intake has been 
observed before[65]. An increased uric acid level may increase the risk for the development of 
cardiovascular diseases[13,66]. It can be hypothesized that the opposite may actually reduce the 
risk for the development of cardiovascular diseases. It therefore seems like r-TFA, in this cohort, 
may have a beneficial effect on cardiovascular health by reducing uric acid levels.
Until now we discussed the results of the phospholipids fraction. In the TG fraction, i-TFA+r-
TFA was positively associated with total cholesterol, LDL cholesterol, total triglycerides and TG/
HDL cholesterol ratio. The associations with cholesterol were driven by the ruminant variant. 
The industrial variant in triglycerides adversely associated with glucose and waist circumference. 
This study is the first to find those associations with r-TFA or i-TFA measured in TG. Interestingly, 
the beneficial associations in the PL fraction between trans fatty acids and cardiovascular risk 
factors were neutral or even adverse in the TG fraction and some neutral association in the PL 
were adverse in the TG. This might be due to the fact that the association between plasma TG 
trans fatty acids and cardiovascular risk factors can be influenced by recent dietary intakes and 
de novo lipogenesis, whereas this is less important for plasma PL[67]. The latter is confirmed 
by the fact that fatty acids from de novo lipogenesis (i.e. C14:0, C16:0, C16:1(n-7)) measured in 
plasma TG) were significantly associated with total triglycerides (data not shown), which might 
explain the discrepant findings.
Some strengths and limitations of the study have to be addressed. A main strength of 
the study was the separation between the industrial and ruminant trans fatty acids in plasma 
TG and PL, what made it possible to investigate the association of the rumen derived C18:1 
trans fat and cardiovascular risk factors, independently of the industrial derived C18:1 trans 
fat. This separation was made by using a 200 m polar column, which is a superior method for 
the separation of industrial and ruminant derived fatty acids. A second strong point is that 
we measured the fatty acids in two different compartments, i.e. plasma TG and PL, providing 
the opportunity to investigate whether the association of i-TFA and r-TFA with cardiovascular 




lives. Another strong point is the relatively large number of participants included in this study. 
Furthermore, Lifelines is building a biobank and database. For this purpose, Lifelines has collected 
and is still collecting information via questionnaires, physical examinations and biological 
samples, including information on several cardiovascular risk factors. This huge collection of 
data and samples allowed us to investigate the association of trans fatty acids with multiple 
cardiovascular risk factors.
This study also has its limitations. Firstly, we utilized cross-sectional data from which we 
cannot infer causality. It is therefore not possible to rule out reverse causality between the trans 
fatty acids and cardiovascular risk factors. Secondly, the Lifelines cohort study uses an FFQ to 
measure dietary intake of the participants which is a method based on self-report, and therefore 
subject to recall bias. It is possible that the intakes of absolute and relative dairy and dairy fat 
are over- or underreported. On the other side, the current FFQ is specifically developed for 
the Dutch population and consists therefore of a relatively large number of dairy items, which 
makes it a reliable measurement for this paper. Furthermore, since there is no gold standard for 
measuring dietary intakes so far, FFQs are still seen as one of the best methods since they are 
able to capture usual, individual, long-term dietary intakes[68,69].
In summary, we found that the ruminant trans-C18:1 fatty acid, that was found to be a 
predictor for the intake of dairy and dairy fat intake in our population, was inversely associated 
with cardiovascular risk factors, including Hs-CRP and uric acid. This in contrast to the industrial 
trans-C18:1 fatty acid, which were not associated with cardiovascular risk factors. Research in 
intervention and longitudinal studies is warranted to further unravel the association between 
r-TFA and cardiovascular risk factors.
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SUPPORTING INFORMATION: METHODS AND VALIDATION
Supplemental Table A: Conditions of the GC-FID
Overall
Technique GC model 6890
Injection technique Split, 1:20
Analytical column Agilent CP select CB for FAME
Detection technique FID 7683 series
Parameters
Column 0.25 mm x 200 m
Carrier gas Helium









Make up gas N
2




Final temperature and time 250⁰C for 0 min
Rate 2 20⁰C/min
Final temperature and time 270⁰C for 15 min





Supplemental Table B: Variation coefficients of quality-control samples (10 pooled samples)
Plasma TG Plasma PL
Fatty acid Mean ± SD CV % Mean ± SD CV %
SFA
C14:0 2.62 ± 0.05 2.0 0.56 ± 0.03 5.5
C15:0 0.28 ± 0.01 4.1 0.24 ± 0.02 8.6
C16:0 30.0 ± 0.25 0.8 33.52 ± 0.23 0.7
C17:0 0.43 ± 0.01 2.2 0.39 ± 0.01 2.4
C18:0 5.58 ± 0.11 2.0 13.66 ± 0.06 0.4
MUFA (cis)
C16:1(n-7) 3.41 ± 0.11 3.2 0.46 ± 0.02 5.0
C18:1(n-9) 31.94 ± 0.30 1.0 9.65 ± 0.08 0.8
C18:1(n-7) 1.80 ± 0.07 3.7 1.15 ± 0.02 1.3
TFA
Trans-C18:1(n-9) 0.15 ± 0.01 7.6 0.05 ± 0.001 7.8
Trans-C18:1(n-7) 0.11 ± 0.01 8.5 0.06 ± 0.01 8.7
Abbreviations: TG, Triglycerides; PL, Phospholipids; SFA, saturated fatty acids; MUFA, mono-unsaturated 
fatty acids; TFA, Trans-fatty acids
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Supplemental Figure A: Chromatogram of the cluster of C18:1 in plasma Triglycerides measured on a 200m 
polar column (Agilent CP select CB for FAME)
Supplemental Figure B: Chromatogram of the cluster of C18:1 in plasma Phospholipids measured on a 200m 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Circulating fatty acids as biomarkers of 
dairy fat intake: Data from the Lifelines 











Background: C14:0, C15:0, C17:0 and trans-C16:1(n-7) are often used as biomarkers for dairy fat 
intake. Trans-C18:1(n-7) and CLA, two fatty acids which are also present in dairy, have hardly been 
explored. We investigated whether trans-C18:1(n-7) and CLA can enrich the existing biomarker 
portfolio.
Methods: Data were obtained from Lifelines (n=769). Dairy fat intake was determined by FFQ. 
Fatty acids were measured in fasting plasma triglycerides (TG), phospholipids (PL) and cholesterol 
esters (CE).
Results: Median (25th-75th percentile) intakes of dairy and dairy fat were 322(209-447) and 
12.3(8.4-17.4) g/d respectively. A pilot study showed that trans-C18:1(n-7) and CLA were only 
detectable in TG and PL. Of the established markers, TG C15:0 was most strongly associated 
with dairy fat intake (standardized β (std.β)=0.286, R2=0.111). Of the less established markers, 
TG trans-C18:1(n-7) was most strongly associated with dairy fat intake (Std.β=0.292, R2=0.115), 
followed by PL CLA (Std.β=0.272, R2=0.103) and PL trans-C18:1(n-7) (Std.β=0.269, R2=0.099). In 
TG, a combination of C15:0 and trans-C18:1(n-7) performed best (R2=0.128). In PL, a combination 
of C14:0, C15:0, trans-C18:1(n-7) and CLA performed best (R2=0.143).
Conclusion: Trans-C18:1(n-7) and CLA can be used as biomarkers of dairy fat intake. Additionally, 
combining established with less established markers allowed even stronger predictions for dairy 
fat intake.
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INTRODUCTION
Dairy consumption is part of the food culture in many countries. Worldwide intake of dairy 
products is high, particularly in developed countries such as Canada, North America and 
parts of the European Union. For instance, in the European Union and in the USA, the average 
per capita milk consumption is 1.01 and 0.91 servings per day respectively [1]. While dietary 
recommendations tend to set an upper limit to certain types of dairy products as a result of the 
high saturated fat or sodium content, dairy intake is generally considered healthy, particularly 
because of the numerous essential nutrients it contains, including calcium, proteins, phosphorus, 
magnesium, and several vitamins and minerals [2]. It has been observed that high dairy intake 
is associated with a reduced risk for hypertension [3]. Furthermore, dairy has been suggested 
to have a positive influence on bone health by increasing bone mineral density [4,5]. There 
is also increasing evidence that fat from dairy products (as reflected by circulating dairy fat 
biomarkers) has a positive effect on various cardiovascular risk factors such as BMI, fasting 
glucose and insulin sensitivity [6-8]. Moreover, prospective studies have reported lower risk of 
stroke and coronary heart disease with higher levels of circulating dairy fat biomarkers [9,10]. 
Additionally, high circulating concentrations of dairy fat biomarkers were found to be associated 
with reduced risk of development of type 2 diabetes as was evidenced in several longitudinal 
observational studies [11-14].
Dairy fat consists of more than 400 different fatty acids [15]. The fatty acids in dairy fat 
derive either directly from the animal’s diet, or indirectly from ruminal fermentation. The fatty 
acid composition of plasma, serum, erythrocytes and adipose tissue are known to partially 
reflect the fatty acid composition of the diet. Several fatty acids are to a large extent unique 
for dairy fat intake. They are present in measurable amounts in the circulation and tissue of 
humans [6]. Myristic acid (C14:0), pentadecanoic acid (C15:0), heptadecanoic acid (C17:0) and 
trans-palmitoleic acid (Trans-C16:1(n-7)) are commonly used dairy fat biomarkers [13,16-22]. 
Particularly the odd-chain fatty acids C15:0 and C17:0 [13,16,17,20-23], and the natural ruminant 
trans fat trans-C16:1(n-7) are often considered as fatty acids that mainly originate from dairy 
fat [13,20,21], because these fatty acids are synthesized by the bacterial flora in the rumen of 
the animal and cannot be synthesized in the human body [24]. Correlations of C15:0, C17:0 
and trans-C16:1(n-7) with dairy fat intake are variable. Papers that reported on the correlation 
between circulating dairy fat biomarkers in plasma and dairy fat intake showed correlations of 
0.10 - 0.53 with C15:0 [6,13,16,18-22], of 0.16 - 0.36 with C17:0 [13,16,18-21], and of 0.13 - 0.30 
with Trans-C16:1(n-7) [13,20,21]. Despite the specific origin of these fatty acids, the correlations 
are relatively low and interest in other potential dairy fat biomarkers is therefore growing.
Trans fatty acids which are also thought to mainly originate from rumen derived products 
are vaccenic acid (trans-C18:1(n-7)) and rumenic acid, a conjugated linoleic acid with the lipid 




microbial fermentation of C18 unsaturated fatty acid in the rumen of the animal [25,26]. They 
can be found in several ruminant derived foods [9,13,20,21,27-30]. Despite their occurrence 
in dairy products, vaccenic acid and CLA are hardly explored as potential dairy fat biomarkers. 
Current studies on the association of trans fats with dairy intake use a cluster of trans-C18:1, 
which is actually a combination of mainly rumen-derived trans-C18:1(n-7) and industrially (trans-
C18:1(n-9) produced trans fats, possibly leading to biased associations [31,32]. It is therefore 
of interest to determine the association of dairy fat intake and the genuine rumen derived 
Trans-C18:1(n-7).
The main objective of this study was to investigate the fatty acids trans-C18:1(n-7) and 
CLA as potential biomarkers of dairy fat intake and to compare them with more commonly used 
dairy fat biomarkers. Secondly, we investigated whether a combination of biomarkers provides 
a better predictor for dairy fat intake compared to single biomarkers. For this we developed 
and validated a model for the prediction of dairy fat intake in the general population. We used 
data from the LifeLines Biobank and Cohort Study, a large observational cohort study of initially 
healthy participants living in the Northern part of the Netherlands.
Clinical significance
· Despite their occurrence in dairy products, trans-C18:1(n-7) and CLA are hardly explored as 
potential dairy fat biomarkers in the general population.
· The present study confirmed the commonly used biomarkers C14:0, C15:0, C17:0 and 
trans-C16:1(n-7). and identified the biomarkers trans-C18:1(n-7) and CLA as additional dairy 
fat biomarkers. A combination of the commonly used biomarkers with less established 
biomarkers allowed even stronger predictions for dairy fat intake.
MATERIALS AND METHODS
Study Design and Subjects
The LifeLines Cohort Study is a large observational population-based cohort study and Biobank 
that examines the health and health-related behaviors of more than 167,000 persons [33]. The 
participants were recruited from the three Northern provinces of the Netherlands between 
2006 and 2013. The first group of 25-50 years old participants was recruited via general 
practitioners. Participants could indicate whether family members were interested as well. In 
addition, individuals who were interested in the study had the possibility to register via an online 
self-registration. Individuals with insufficient knowledge of the Dutch language, with severe 
psychiatric or physical illness, and those with limited life expectancy (< 5 years) were excluded 
from the study. Participants (> 18 years old) completed several questionnaires, including 
topics such as occurrence of diseases, general health, medication use, diet, physical activity 
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and personality. Participants were invited to the Lifelines Research sites for a comprehensive 
health assessment. A more detailed description of the Lifelines Cohort study can be found 
elsewhere [34,35]. For the present study, we used a subset of the cross-sectional data. 864 
participants were randomly selected from the Lifelines biobank. Additionally, 776 of the 864 
participants had filled in a food frequency questionnaire (FFQ). Cases with missing data on 
either FFQ or circulating fatty acids were removed before analysis leaving 769 participants in 
the lifelines cohort with complete data (Figure 1). All participants provided written consent. The 
Lifelines Cohort Study was conducted according to the principles of the Declaration of Helsinki 
and approved by the Medical ethical committee of the University Medical Center Groningen, 
The Netherlands.
Dietary assessment
To asses dietary intake in the Lifelines Cohort, a 110-item semi-quantitative baseline food 
frequency questionnaire (FFQ) assessing food items over the previous month was developed 
and validated by the Wageningen University using the Dutch FFQTOOLTM, in which food items 
were selected based on the Dutch national Food Consumption Survey of 1997/1998 [36]. Seven 
answers categories were used to assess consumption frequency, ranging from ‘not this month’ 
to ‘6-7 days a week’. Portion size was estimated by fixed portion sizes (e.g. slices of bread, pieces 
of fruit) and commonly used household measures (e.g. cups, spoons). Energy and macronutrient 
intake, including dairy consumption, was estimated from the FFQ data by using the Dutch food 
composition database of 2011 (NEVO) [37]. For this study, ‘total dairy intake’ and ‘total dairy 
fat intake’ (cheese, milk, buttermilk, yoghurt, sweetened yoghurt drinks, custard, curd cheese, 
ice cream, whipped cream and porridge) were calculated. Butter was not included in the ‘total 
dairy intake’ and ‘total dairy fat intake’ calculation.
Clinical measurements
Anthropometric measurements (weight, height, and waist circumference) and blood pressure 
were measured by well-trained staff. The anthropometric measurements were measured without 
shoes. Body weight was measured to the nearest 0.1 kg. Height was measured to the nearest 
0.5 cm with a stadiometer placing their heels against the rod and the head in Frankfort Plane 
position. Waist circumference was measured to the nearest 0.5 cm in standing position with a 
tape measure all around the body, at the level midway between the lower rib margin and the 
iliac crest. BMI was calculated as weight (kg) divided by height squared (m2). Systolic and diastolic 
blood pressures were measured 10 times during a period of 10 minutes, using an automated 
Dinamap Monitor (GE Healthcare, Freiburg, Germany). The average of the final three readings 




Figure 1: Flow diagram of the participants in the study
115
Circulating fatty acids as biomarkers of dairy fat
Data on smoking and general health
Information about smoking and general health was collected from the self-administered 
questionnaire. Subjects were classified as non-smokers, former smokers or current smokers. 
Information on history and prevalence of hypertension, hypercholesterolemia and diabetes 
type 2 were collected in the same questionnaire.
Biochemical measurements
Blood samples were collected in the fasting state, between 8.00 and 10.00 a.m. and transported 
on ice to the Central Lifelines Laboratory in the University Medical Center Groningen. Serum 
levels of total and HDL cholesterol were measured using an enzymatic colorimetric method, 
triglycerides using a colorimetric UV method, and LDL cholesterol using an enzymatic method, 
all on a Roche Modular P chemistry analyzer (Roche, Basel, Switzerland). Fasting blood glucose 
was measured using a hexokinase method. HbA1c was determined in whole blood (EDTA-
anticoagulated) by means of turbid metric inhibition immunoassay on a Cobas Integra 800 
CTS analyzer (Roche Diagnostics Netherland BV, Almere, The Netherlands). The hs-CRP was 
determined by nephelometry (BN II system Siemens, Marburg, Germany). Serum creatinine was 
measured on a Roche Modular P chemistry analyzer (Roche, Basel, Switzerland).
Fatty acid analyses
EDTA-plasma samples were collected at baseline and stored frozen at -80⁰C until use for 
assessment of fatty acid profiles. Analyses of fatty acids were performed in the Department 
of Laboratory Medicine of the University Medical Center Groningen, The Netherlands using 
the methodology as described by Hoving et al. [38]. In short, total lipids were extracted by the 
method of Folch et al., using 6 ml of chloroform-methanol (2:1) and a 200 µl EDTA-plasma sample 
[39]. After that, a shortened version of the method of Kaluzny et al. was used to isolate plasma 
cholesterol esters (CE), triglycerides (TG) and phoshpolipids (PL), using aminopropyl SPE columns 
(Isolute, Biotage) [40]. Fatty acids were transmethylated with methanolic-HCL into fatty acid 
methyl esters (FAME). The samples were extracted with hexane and eventually redissolved into 
100 µl hexane. Internal standards for the quantification of fatty acids in CE (100 µl of a solution 
of 50.1 mg C17:0/100 ml chloroform-methanol, 2:1 v/v) and TG (100 µl of a solution of 19.9 mg 
of C19:0/100 ml chloroform-methanol, 2:1 v/v), both obtained from Sigma-Aldrich (Zwijndrecht, 
The Netherlands), were added before isolation of lipid classes. An internal standard for the 
quantification of fatty acids in PL (100 µl of a solution of 50.0 mg free fatty acid 19:0/100 ml 
methanol), obtained from Larodan (Solna, Sweden), was added after isolation of lipid classes. 
100 µl Butylated Hydroxytoluene (1 g/100 ml methanol) from Sigma-Aldrich (Zwijndrecht, The 
Netherlands) was added to prevent fatty acid oxidation.
Aliquots of 2 µl were injected into an Agilent model 6890 gas chromatography equipped with 




flame ionization detector. The 200 m polar column is specifically developed to allow for better 
separation between trans C18:1 fatty acids [41]. FAME were identified by comparing retention 
times with those of known standards (Supelco 37 component FAME mix (Sigma-Aldrich)). Fatty 
acid compositions were expressed into mol%. Firstly, circulating fatty acid compositions were 
analyzed in 96 samples to investigate whether the potential dairy fat biomarkers, and especially 
trans-C18:1(n-7) and CLA, could be detected in the three fractions (plasma CE, TG and PL). 
Subsequently, we proceeded with analyses in those fractions in which all potential dairy fat 
biomarkers could be detected. The precision of the potential dairy fat biomarkers was calculated 
by measuring 10 quality-control samples. Potential dairy fat biomarkers had an average variation 
coefficient of ≤ 10%. In TG, the CVs for the potential new biomarkers Trans-C18:1(n-7) and CLA 
were 8.5% and 7.9% respectively, and in PL, the CVs for Trans-C18:1(n-7) and CLA were 9.3% 
and 9.6% respectively.
Statistical analyses
All analyses were performed using IBM SPSS Statistics, version 22.0 for Windows software 
(IBM, Armonk, NY, USA) and STATA/MP version 13.1 for Windows software (Statacorp, College 
Station, Texas, USA). In total, circulating fatty acids in plasma TG and PL were measured in 864 
participants, whereof 776 participants had also completed an FFQ. Cases with missing data on 
either FFQ or circulating fatty acids were removed before analysis leaving 769 participants in 
the lifelines cohort with complete data. Baseline data are presented for the total population and 
separately for males and females to check for potential differences between males and females. 
Data are presented as N (%), mean ± SD or as in case of non-normally distributed data as median 
(25th-75th percentile). Differences in baseline data between males and females were tested with 
an independent t-test (continuous data), Mann-Whitney U test (non-normally distributed data) 
or Chi-square test (categorical data). For the main analyses, we used energy-adjusted total 
dairy fat intake. Energy-adjusted intakes were generated by adjustment for total energy intake 
using the residual method [42]. Because men usually have a higher energy and macronutrient 
intake compared to women, adjustment for energy intake was performed for men and women 
separately. Energy-adjusted intakes are expressed in grams/day. Linear regression models were 
used to examine the association between circulating fatty acids and total dairy fat intake. We 
also examined the association of circulating fatty acids with (semi-) skimmed dairy products, 
full fat dairy products, fermented dairy products, milk and cheese. As sensitivity analyses, we 
tested whether removal of outliers for energy intake (participants with energy intakes lower or 
higher than 3 SDs from the mean value of energy intake) influenced the associations between 
dairy fat biomarkers and energy-adjusted dairy fat intake. We also tested for potential effect 
modification of the associations of circulating fatty acid biomarkers with total dairy fat intake by 
sex. Furthermore, in subsidiary analyses, the associations were adjusted for age, sex, BMI, total 
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meat intake, and the industrialized trans fatty acid trans-C18:1(n-9) (Elaidic acid). Skewed data 
were transformed before analyses (square root or log-transformed). Multivariate backwards 
regression analyses were carried out with all potential dairy fat biomarkers in TG, PL and a 
combination of both to identify the best combination of markers to predict energy-adjusted dairy 
fat intake in our population (cutoff for removal p < 0.10). We compared the performance of the 
models against each other by comparing the explained variance (R2). Bland-Altman plots were 
created to indicate the agreement of observed (FFQ-derived data) compared to the estimated 
models (based on circulating fatty acids). The mean of the observed and estimated models 
were plotted against the difference between the observed and estimated models. To be able 
to compare both models with each other the observed measurement as well as the estimated 
measurement were standardized before analyses. Validity of the models was evaluated by 
ranking ability (cross-classification between the observed (FFQ-derived) intake data and the 
estimated intake data (based on circulating fatty acids)) [43]. For the ranking ability, both 
observed (FFQ-derived) intake data and estimated intake data (based on circulating fatty acids) 
were ranked into quintiles. To validate the models, we repeated the multivariate backwards 
regression analyses in STATA, by implementing the swboot command which created a table with 
the number of times each variable is selected after 1000 bootstrap samples [44]. Variables were 
included in the bootstrap models when these were present in the majority of the bootstrap 
attempts (>50%). In secondary analyses, variables were included in the bootstrap models when 
these were present in >70% of the bootstrap attempts. As additional analyses, we repeated the 
multivariate backwards regression analyses for unadjusted dairy fat intake (rather than energy-
adjusted dairy fat intake which was used for the primary analyses), and also assessed predictive 
capacity for energy-adjusted dairy intake. All reported probability values are two-tailed, and P 
≤ 0.05 was considered statistically significant.
RESULTS
The baseline characteristics of the 769 participants overall and for males and females separately 
are shown in Table 1. The total population had a mean age of 53.0 ± 15.5 years and a BMI of 26.0 
± 4.0 kg/m2. Blood pressure was slightly higher in males (130/77 mmHg) compared to females 
(123/71 mmHg). Total and HDL cholesterol were higher in females, whereas total triglycerides 
was higher in males. Energy intake of the population was 1975 ± 624 kcal/d (8274 ± 2613 KJ/d). 
Of the total intake, 46 En% was derived from carbohydrates, 15 En% from proteins, and 35 En% 
from fats. The Lifelines dataset confirms that males overall have a higher dietary intake compared 
to females. Total meat intake of the population was 73.5 g/d, which contributed for 13% to the 
daily fat intake. Median dairy intake of the population was 322 (209 – 447) g/d and consisted 
for 12.8% of cheese, for 35.1% of milk, for 10.0% of yoghurt, and for 42.1% of other milk (based) 




intake of the population was 12.3 (8.4 – 17.4) g/d. Skimmed dairy products contributed for 2% 
to total dairy fat intake, while semi-skimmed and full-fat products contributed for 20% and 78% 
respectively. Median dairy fat intake, rather than median dairy intake overall, was significantly 
higher in males compared to females (median intakes males: 13.5 (9.0 – 18.3) g/d vs females: 
11.3 (8.0 – 15.6) g/d; p < 0.001). Males consumed more semi-skimmed and full-fat dairy products, 
while females consumed more skimmed dairy products.
Table 1: Baseline Characteristics of the Lifelines Population






Age visit 1, years 53.0 ± 15.5 53.3 ± 15.2 52.7 ± 16.0 0.60
BMI, kg/m2 26.0 ± 4.0 26.3 ± 3.4 25.8 ± 4.6 0.08
Smoking, yes (%) 115 (15.0%) 68 (16.8%) 47 (12.9%) 0.13
SBP, mmHg 126.5 ± 17.0 129.5 ± 15.1 123.1 ± 18.2 < 0.001
DBP, mmHg 73.7 ± 9.7 76.6 ± 9.8 70.5 ± 8.4 < 0.001
Laboratory measurements
Total Cholesterol, mmol/L 5.2 ± 1.0 5.1 ± 1.0 5.3 ± 1.1 0.03
HDL cholesterol, mmol/L 1.5 ± 0.4 1.3 ± 0.3 1.7 ± 0.4 < 0.001
LDL cholesterol, mmol/L 3.3 ± 0.9 3.3 ± 0.9 3.3 ± 1.0 0.27
Total Triglycerides, mmol/L 1.0 (0.8 - 1.5) 1.2 (0.9 – 1.6) 1.0 (0.7 – 1.3) < 0.001
Glucose, mmol/L 5.1 ± 0.7 5.2 ± 0.6 5.0 ± 0.7 0.003
HbA1c, % 5.6 ± 0.4 5.6 ± 0.4 5.6 ± 0.4 0.99
Creatinin, umol/L 76.0 ± 13.6 83.6 ± 12.3 67.6 ± 9.3 < 0.001
C-reative protein (hs-CRP), mg/L 1.0 (0.5 – 2.2) 0.9 (0.4 - 1.9) 1.1 (0.5 – 2.9) 0.05
General health
Diabetes Type 2, yes (%) 22 (2.9%) 12 (3.0%) 10 (2.8%) 0.86
Hypertension, yes (%) 200 (26.0%) 96 (23.8%) 104 (28.6%) 0.21
High cholesterol, yes (%) 165 (21.5%) 95 (23.5%) 70 (19.3%) 0.35
Dietary intake (FFQ)
Energy intake, Kcal/day 1971 ± 624 2206 ± 665 1711 ± 449 < 0.001
Total carbohydrates, g/d (En%) 228.8 ± 76.7 (46%) 254.4 ± 80.7 (46%) 200.4 ± 60.6 (47%) < 0.001
Total protein, g/d (En%) 74.8 ± 20.9 (15%) 81.5 ± 22.6 (15%) 67.3 ± 15.8 (16%) < 0.001
Total fat, g/d (En%) 77.2 ± 30.0 (35%) 87.1 ± 32.7 (36%) 66.2 ± 22.0 (35%) < 0.001
Total Meat, g/d 73.5 ± 37.5 83.8 ± 40.1 62.0 ± 30.7 < 0.001
Total Meat fat, g/d 10.2 ± 5.8 11.9 ± 6.3 8.3 ± 4.5 < 0.001
Dairy intake (FFQ)
Total Dairy intake, g/d 322 (209 – 447) 315 (202 – 444) 324 (216 – 447) 0.99
Total Dairy fat intake, g/d 12.3 (8.4 – 17.4) 13.5 (9.0 – 18.3) 11.3 (8.0 – 15.6) < 0.001
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Table 1: Continued





Circulating fatty acids in plasma TG
C14:0, mol% 1.87 (1.40 – 2.48) 1.98 (1.49 – 2.68) 1.74 (1.35 – 2.35) < 0.001
C15:0, mol% 0.30 (0.25 – 0.35) 0.29 (0.24 – 0.35) 0.30 (0.25 – 0.35) 0.27
C17:0, mol% 0.49 (0.41 – 0.59) 0.48 (0.39 – 0.58) 0.52 (0.44 – 0.62) < 0.001
T-C16:1(n-7), mol% 0.026 (0.018 – 0.036) 0.025 (0.017 – 0.036) 0.026 (0.019 – 0.037) 0.05
T-C18:1(n-7), mol% 0.098 (0.064 – 0.141) 0.099 (0.067 – 0.147) 0.096 (0.070 – 0.138) 0.30
CLA, mol% 0.077 (0.050 – 0.095) 0.068 (0.049 – 0.094) 0.071 (0.050 – 0.097) 0.24
Circulating fatty acids in plasma PL
C14:0, mol% 0.49 (0.41 – 0.57) 0.47 (0.40 – 0.55) 0.50 (0.43 – 0.58) < 0.001
C15:0, mol% 0.28 (0.24 – 0.33) 0.28 (0.24 – 0.33) 0.29 (0.25 – 0.33) 0.09
C17:0, mol% 0.40 (0.36 – 0.44) 0.39 (0.35 – 0.44) 0.40 (0.36 – 0.45) 0.08
T-C16:1(n-7), mol% 0.020 (0.014 – 0.025) 0.019 (0.013 – 0.024) 0.020 (0.015 – 0.025) 0.002
T-C18:1(n-7), mol% 0.091 (0.068 – 0.115) 0.086 (0.063 – 0.111) 0.094 (0.072 – 0.119) 0.002
CLA, mol% 0.033 (0.022 – 0.043) 0.030 (0.020 – 0.041) 0.032 (0.017 – 0.044) 0.01
Data are presented as mean ± SD, median (25th – 75th percentile) or number (%). Differences between sex 
were tested by independent t-test, Mann-Whitney U test or Chi-square test.
Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, 
high density lipoprotein; LDL, low density lipoprotein; HbA1C, Hemoglobin A1C; FFQ, Food Frequency 
Questionnaire; Kcal, Kilocalories, TG, Triglycerides; PL, Phospholipids, C14:0, Margaric acid; C15:0, 
Pentadecanoic acid; C17:0, Heptadecanoic acid; Trans-C16:1(n-7), T-Palmitoleic acid; T-C18:1(n-7), 
Vaccenic acid; CLA, Cis-9, Trans-11 Conjugated linoleic acid.
Circulating fatty acids were measured in the first 96 samples (Supplemental Table 1). Trans-
C18:1(n-7) appeared not detectable in plasma CE, since it was below the detection limit. All 
potential dairy fat biomarkers, including trans-C18:1(n-7) and CLA, were detectable in plasma 
TG and PL. Since we were especially interested in the potentially less established biomarkers, 
we decided to further only analyze plasma TG and PL. Data on potential circulating dairy fat 
biomarkers in plasma TG and PL of all 769 participants are shown in Table 1. Dairy fatty acids 
in plasma TG were higher compared to plasma PL. The quantitatively most abundant dairy fat 
marker was C14:0 (Total TG: 1.87 mol%, PL: 0.49 mol%), followed by C17:0 and C15:0 in both 
fractions. Trans-C18:1(n-7) was the highest trans fat in both fractions (TG: 0.10 mol%, PL: 0.09 
mol%).
Energy-adjusted dairy fat intake
In the univariate main analyses, all potential dairy fat biomarkers in plasma TG, except C17:0, were 
associated with energy-adjusted dairy fat intake (Table 2, Model 1). The highest associations 
were found for the commonly used biomarker C15:0 (standardized β (std β) = 0.286, P < 0.001)) 




fat biomarkers in plasma PL were also moderately associated with energy-adjusted dairy fat 
intake (Table 2, Model 1). Slightly higher, but still moderate associations were found with the 
less established biomarkers trans-C18:1(n-7) (std β = 0.269, P < 0.001) and CLA (std β = 0.272, 
P < 0.001) compared to the commonly used biomarkers. The highest associations with more 
commonly used biomarkers were found for C14:0 (std β = 0.214, P < 0.001) and C15:0 (std 
β = 0.215, P < 0.001), but these were still moderate. In sensitivity analyses, removal of outliers for 
energy intake did not materially change the association between dairy fat biomarkers and energy-
adjusted dairy fat intake. In multivariate regression analyses, associations between fatty acids 
in plasma TG and PL with energy-adjusted dairy fat intake remained after adjustments for age, 
sex, BMI, total meat intake, and the industrial trans fatty acid Trans-C18:1(n-9) (Supplemental 
Table 2A). The association between the biomarkers and energy-adjusted dairy fat intake did 
not differ between males and females, except for PL C14:0 (P=0.03 for interaction, association 
in males: std β = 0.264, P < 0.001, association in females: std β = 0.173, P < 0.001 (Supplemental 
Table 2B, Model 1).
In plasma TG, multivariate backwards regression analyses identified a combination of C15:0 
and trans-C18:1(n-7) as the best combination to predict energy-adjusted dairy fat intake (Table 
2, Model 3). The explained variance of this combination was 0.128, which was higher than 
the explained variance of the single markers (TG model: R2 = 0.128 vs C15:0: R2 = 0.111 and 
trans-C18:1(n-7): R2 = 0.115). In plasma PL, the fatty acids C14:0, C15:0, trans-C18:1(n-7) and 
CLA were identified as the best combination to predict energy-adjusted dairy fat intake in the 
general population. This model had an explained variance of 0.143, which is again higher than 
the explained variance of the single markers (PL model: R2= 0.143 vs C14:0: R2 = 0.074, C15:0: 
R2 =0.075, trans-C18:1(n-7): R2 = 0.099 and CLA: R2 = 0.103). A combination of fatty acids from TG 
(C15:0, trans-C18:1(n-7), CLA) and PL (C15:0, trans-C16:1(n-7), trans-C18:1(n-7), CLA) explained 
energy-adjusted dairy fat intake in the general population with an R2 of 0.154. Based on these 
data, a combination of biomarkers can be seen as a better predictor for energy-adjusted dairy 
fat intake compared to single biomarkers.
Total dairy intake, total dairy fat intake and dairy product groups
For all, but one, circulating potential dairy fatty acid biomarkers in TG and PL, associations with 
total dairy fat intake were present and strongest compared to associations with total dairy intake 
and dairy product groups (Supplemental Table 3). C17:0 is a single exception, with absence of 
an association with total dairy fat intake for TG and a stronger association with total dairy intake 
than with total dairy fat intake for PL. All fatty acid biomarkers, except C17:0 in TG and PL and 
Trans-C16:1(n-7) in PL were relatively strongly associated with intake of cheese and full fat dairy.
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Table 2: Univariate regression analyses and multivariate models to predict dairy fat with circulating fatty 
acids in plasma TG, plasma PL and a combination of the two in the Lifelines Cohort
Model 1 Model 2 Model 3
Plasma TG Std β R2 P-value Std β P-value Std β P-value
TG C14:0 0.204 0.071 < 0.001 0.049 0.27
TG C15:0 0.286 0.111 < 0.001 0.133 0.01 0.162 0.001
TG C17:0 0.049 0.032 0.19 0.016 0.67
TG T-C16:1(n-7) 0.233 0.072 < 0.001 0.031 0.54
TG T-C18:1(n-7) 0.292 0.115 < 0.001 0.162 0.002 0.181 < 0.001
TG CLA 0.215 0.076 < 0.001 -0.004 0.94
R2= 0.130 R2= 0.128
Plasma PL Std β R2 P-value Std β P-value Std β P-value
PL C14:0 0.214 0.074 < 0.001 0.073 0.07 0.074 0.06
PL C15:0 0.215 0.075 < 0.001 0.104 0.02 0.085 0.03
PL C17:0 0.132 0.047 < 0.001 -0.017 0.70
PL T-C16:1(n-7) 0.130 0.046 < 0.001 -0.062 0.13
PL T-C18:1(n-7) 0.269 0.099 < 0.001 0.181 < 0.001 0.148 < 0.001
PL CLA 0.272 0.103 < 0.001 0.154 < 0.001 0.151 < 0.001
R2= 0.146 R2= 0.143
Plasma TG+PL Std β P-value Std β P-value
TG C14:0 0.033 0.57
TG C15:0 0.088 0.15 0.111 0.04
TG C17:0 0.005 0.90
TG T-C16:1(n-7) 0.023 0.66
TG T-C18:1(n-7) 0.095 0.10 0.113 0.04
TG CLA -0.092 0.07 -0.088 0.08
PL C14:0 0.023 0.64
PL C15:0 0.087 0.06 0.081 0.05
PL C17:0 -0.024 0.62
PL T-C16:1(n-7) -0.071 0.11 -0.077 0.06
PL T-C18:1(n-7) 0.131 0.01 0.113 0.02
PL CLA 0.151 0.001 0.169 < 0.001
R2= 0.160 R2= 0.158
Model 1: Univariate linear regression analysis of the fatty acid with dairy fat intake; Model 2: 
Multivariate model with all fatty acids from our population in one model; Model 3: Multivariate model 
with the best combination of fatty acids in our population (backwards regression).
C14:0, C17:0, Trans-C16.1(n-7), Trans-C18.1(n-7) and CLA in plasma TG and Trans-C16.1(n-7), Trans-
C18.1(n-7) and CLA in plasma PL were transformed before analyses. Dairy fat intake was transformed and 
adjusted for energy intake according to the residual method. β’s are standardized beta’s.
Abbreviations: TG, Triglycerides; PL, Phospholipids, C14:0, Margaric acid; C15:0, Pentadecanoic acid; 
C17:0, Heptadecanoic acid; Trans-C16:1(n-7), T-Palmitoleic acid; T-C18:1(n-7), Vaccenic acid; CLA, Cis-9, 




Agreement and ranking ability
To indicate the agreement between the observed intake (FFQ-derived) and estimated intake 
(based on circulating fatty acids) Bland-Altman plots were made. Plots were made for the best 
single markers (from a set of markers) which were found by backward regression analyses 
(Figures 2 and 3). In addition, validity of the models was evaluated by ranking ability (cross-
classification between the observed intake data (FFQ-derived) and the estimated intake data 
(TG, PL and TG+PL model based on circulating fatty acids)). Both the observed and estimated 
intake data were ranked into quintiles and compared. For all three estimated models, ≈67% of 
the participants were classified in the same or adjacent quintile of the observed model, whereas 
2-3% of the participants were classified in extreme quintiles. Overall, both methods showed 
acceptable agreement between the observed and estimated models.
  A)              B)
Figure 2: Bland-Altman plots for the agreement between the observed intake (FFQ-derived) and the 
estimated intake (based on the best circulating fatty acids in plasma TG) for the measurement of dairy 
fat intake in the general population. Plots of the differences between the observed intake (FFQ-derived) 
and the estimated intake (based on the best circulating fatty acids in plasma TG) vs the mean of the 
observed intake (FFQ-derived) and the estimated intake (based on the best circulating fatty acids in 
plasma TG) method, with (a) representing C15:0 and (b) Trans-C18:1(n-7) as the estimated intake. The red 
line displays the mean of the difference. The black dotted lines represents the limits of agreement (lower 
limit: mean - SD*1.96; upper limit: mean + SD*1.96). Abbreviation: C15:0, Pentadecanoic acid; FFQ, food 
frequency questionnaire; SD, standard deviation; TG, triglycerides; Trans-C18:1(n-7), Trans-Vaccenic acid
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           A)           B)
           C)           D)
Figure 3: Bland-Altman plots for the agreement between the observed intake (FFQ-derived) and the es-
timated intake (based on the best circulating fatty acids in plasma PL) for the measurement of dairy fat 
intake in the general population. Plots of the differences between the observed intake (FFQ-derived) and 
the estimated intake (based on the best circulating fatty acids in plasma PL) vs the mean of the observed 
intake (FFQ-derived) and the estimated intake (based on the best circulating fatty acids in plasma PL), with 
(a) representing C14:0, (b) C15:0, (c) Trans-C18:1(n-7) and (d) CLA as the estimated intake. The red line 
displays the mean of the difference. The black dotted lines represents the limits of agreement (lower limit: 
mean - SD*1.96; upper limit: mean + SD*1.96). Abbreviation: C14:0, Myristic acid; C15:0, Pentadecanoic 
acid; CLA; Conjugated Linolenic acid; FFQ, food frequency questionnaire; PL; phospholipids; SD, standard 
deviation; Trans-C18:1(n-7), Trans-Vaccenic acid
Internal consistency of the models
To judge the internal consistency of the models, we performed backwards multivariate analyses 
using a bootstrap selection method (Supplemental Table 4). In the TG model, C15:0 and trans-
C18:1(n-7) were present in more than half of the bootstrap attempts, whereas in the PL model 
this was the case for C14:0, C15:0, trans-C18:1(n-7) and CLA. When fatty acids from TG and PL 
were combined, C15:0, trans-C18:1(n-7) and CLA from both plasma TG and PL were found in 




prediction model. Complete bootstrap models of TG, PL and a combination of the two can be 
found in Table 3. Overall, the internal consistency for the fatty acids in plasma TG and PL was 
good, with exception for trans-C16:1(n-7) measured in plasma PL.
Table 3: Multivariate models to predict dairy fat with circulating fatty acids in plasma TG, plasma PL and a 
combination of the two in the Lifelines Cohort based on 1000 bootstraps
Variable Beta ± SE Std (beta) P-value 95%CI
Plasma TG
TG C15:0 1.752 ± 0.55 0.162 0.001 0.74 ; 2.86
TG T-C18:1(n-7) 1.798 ± 0.48 0.181 0.001 0.85 ; 2.71
Plasma PL
PL C14:0 0.538 ± 0.27 0.074 0.04 0.02 ; 1.07
PL C15:0 1.102 ± 0.47 0.085 0.02 0.19 ; 2.02
PL T-C18:1(n-7) 2.032 ± 0.52 0.148 0.001 0.94 ; 3.05
PL CLA 2.844 ± 0.74 0.151 0.001 1.41 ; 4.31
Plasma TG+PL
TG C15:0 1.083 ± 0.63 0.100 0.08 -0.20 ; 2.31
TG T-C18:1(n-7) 1.144 ± 0.59 0.115 0.05 -0.10 ; 2.56
TG CLA -1.131 ± 0.67 -0.091 0.09 -2.53 ; 0.15
PL C15:0 0.912 ± 0.52 0.070 0.08 -0.11 ; 1.96
PL T-C18:1(n-7) 1.155 ± 0.59 0.084 0.04 0.04 ; 2.28
PL CLA 3.112 ± 0.78 0.166 0.001 1.56 ; 4.63
Fatty acids are included in the multivariate model when the circulating fatty acids were present in more 
than 50% of the models during the bootstrap process based on the backwards stepwise algorithm.
C14:0, C17:0, Trans-C16.1(n-7), Trans-C18.1(n-7) and CLA in plasma TG and Trans-C16.1(n-7), Trans-
C18.1(n-7) and CLA in plasma PL were transformed before analyses. Dairy fat intake was transformed and 
adjusted for energy intake according to the residual method. β’s are standardized beta’s.
Abbreviations: TG, Triglycerides; PL, Phospholipids, C14:0, Margaric acid; C15:0, Pentadecanoic acid; 
C17:0, Heptadecanoic acid; T-C16:1(n-7), T-Palmitoleic acid; T-C18:1(n-7), Vaccenic acid; Trans-C18:1(n-9), 
Eilaidic acid; CLA, Cis-9, Trans-11 Conjugated linoleic acid
In secondary analyses, the bootstrap selection method was repeated with selection of fatty acids 
that were present in more than 70% of the 1000 bootstrap attempts. In the TG model, C15:0 
and trans-C18:1(n-7) were again present, whereas the PL model included C15:0, trans-C18:1(n-7) 
and CLA, but not C14:0. The stricter selection criteria slightly worsened the internal consistency 
of the PL model. Fatty acids from TG and PL were also combined for this analyses. Interestingly, 
only the fatty acids trans-C18:1(n-7) and CLA from plasma PL remained in the model.
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Additional analyses
As additional analyses, we repeated the multivariate backwards regression analyses for 
unadjusted dairy fat intake (rather than energy-adjusted dairy fat intake), and also assessed 
predictive capacity for energy-adjusted total dairy intake (Supplemental Table 5 and 6). The 
associations of the fatty acids with unadjusted dairy fat intake were weaker compared to the 
associations of the fatty acids with energy-adjusted dairy fat intake. However, C15:0 and trans-
C18:1(n-7) remained the best predictive fatty acids in plasma TG, whereas trans-C18:1(n-7) and 
CLA remained the best predictive fatty acids in plasma PL.
DISCUSSION
The main objective of the current study was to investigate whether the circulating fatty acids 
trans-C18:1(n-7) and CLA are an addition to the already existing dairy fat biomarkers in the 
general population. First of all, we found that the less established biomarkers for dairy fat intake 
were best quantifiable in plasma TG and PL. Additionally, we showed that trans-C18:1(n-7) and 
CLA, in both plasma TG and PL, were moderately associated with dairy fat intake. In plasma PL, 
these biomarkers were slightly higher compared to the commonly used biomarkers. Lastly, we 
developed and validated a model to predict dairy fat intake in the general population. Compared 
to the single markers, we found that a combination of less established and commonly used 
biomarkers, including the C15:0, trans-C18:1(n-7) and CLA, showed a slightly higher association 
with dairy fat intake in the general population.
Significant associations of C15:0 and C17:0 with dairy fat intake were reported in the 
literature before [13,16,17,19-23,45-48]. In the Lifelines Cohort, C15:0 was also associated with 
dairy fat intake, while there was no consistent independent association of C17:0 with dairy 
fat intake. Plasma TG C17:0 was not associated with total dairy fat intake. Plasma PL C17:0 
was associated with total dairy fat intake, however in backwards regression analyses taking all 
potential dairy fat biomarkers from plasma PL into account, plasma PL C17:0 did not remain in 
the PL model. Additionally, the bootstrapping with stepwise backwards algorithm showed that 
C17:0 remained in the minority of the 1000 bootstrap attempts (TG: 91x, PL: 149x) (Supplemental 
Table 4). A Norwegian study with 110 healthy men (age 21-55 years), published in 2005, also 
found that C15:0 from serum and adipose tissue were significantly correlated with dairy fat intake 
(both r = 0.28), while this was not the case for C17:0 (serum: r = -0.10, adipose tissue: r = 0.03) 
[23]. Overall, C17:0 might not be such a useful marker for dairy fat intake. Instead, in the Lifelines 
cohort other biomarkers were found to be better predictors of dairy fat intake.
C15:0 and trans-C18:1(n-7) in plasma TG and PL, emerged as the best biomarkers from the 
set of investigated biomarkers for the prediction of dairy fat intake. Every prediction model in 
the lifelines cohort included C15:0 as an important marker of dairy fat intake with standardized 




results are in line with the current literature. For instance, in a study with more than 3000 
subjects, published in 2016, the correlation for total plasma C15:0 with dairy fat intake was 0.29 
[13]. In addition, in a study with 279 subjects, published in 2015, the correlation of plasma PL 
C15:0 with dairy fat intake was 0.32 [16].
This is one of the first studies investigating the association between trans-C18:1(n-7), 
measured in plasma TG and PL, and dairy fat intake. A single study measured trans-C18:1(n-7) 
in total plasma and erythrocytes, but did not find a significant correlation (r = 0.06 and r = -0.01 
respectively) [21]. Most other studies investigated a cluster of trans-C18:1 fatty acids, which is 
a combination of the rumen (trans-C18:1(n-7)) and industrial derived (trans-C18:1(n-9)) trans 
fatty acids, rather than trans-C18:1(n-7) alone [31,32]. One of these studies is a Chinese study 
of 2091 adult participants aged 50-70 years, published in 2014, which found an association of 
0.37 between the cluster of trans-C18:1 fatty acids assessed in erythrocytes and total dairy 
consumption [31]. The current study showed a lower, but significant association between the 
ruminant derived trans fatty acid trans-C18:1(n-7) and dairy fat intake with a standardized beta 
of 0.29 for TG and of 0.27 for PL.
CLA in plasma PL was also found to be associated with dairy fat intake in the Lifelines 
population, both as a single marker and in combination with C14:0, C15:0 and trans-C18:1(n-7), 
while CLA in plasma TG was less strongly associated with dairy fat intake. CLA in plasma TG as 
a single marker was significantly associated with dairy fat intake (std.β = 0.22), however the 
association of CLA with dairy fat intake did not remain in the backwards regression model 
when only plasma TG fatty acids were included. Current papers report mainly on the correlation 
between dairy fat intake and CLA in adipose tissue. For example, in a study of 3630 Costa-
Rican adults, published in 2012, the correlation of CLA with dairy fat intake was 0.24 [29]. The 
correlation in adipose tissue is in line with the correlation found with CLA in plasma PL.
In the current cohort, we found that a combination of biomarkers is a slightly better 
predictor for dairy fat intake in the general population when compared to single markers. C15:0 
and trans-C18:1(n-7) were found in all three models and in the bootstrap models. Therefore, a 
combination of dairy fat biomarkers, particularly models including these two, may be the best 
combination to predict the dairy fat intake in the general population.
The combined fatty acids assessed in PL provided a slightly better prediction of dairy fat 
intake than the combined fatty acids in TG (R2 PL: 0.143 vs R2 TG: 0.128). Consistent with this, 
when the selection criterium for inclusion in the model was set at present in > 70% of the models, 
it was found that only plasma PL trans-C18:1(n-7) and plasma PL CLA remained in the model, 
if both TG and PL fatty acids were combined. This suggests that fatty acids in PL are stronger 
predictors than fatty acids in TG. This might be due to the fact that plasma TG is influenced 
by recent dietary intake (intake in the last few hours), whereas this is less so for plasma PL 
[49]. Recent meals, including large amounts of carbohydrates, can for instance turn on de novo 
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lipogenesis which changes the fatty acid balance in plasma triglycerides and may therefore 
change the association with dairy fat intake. Researchers of the FORCE consortium therefore 
recommend to measure biomarkers of dietary intake in plasma CE and PL over plasma TG [50-
52]. Indeed, most of the biomarker studies are carried out in plasma PL [6,16,17,19,22,45], while 
only one study reported on biomarkers in serum TG [17]. Importantly, however, one of the most 
promising markers, i.e. ruminant trans-C18:1(n-7), was only detectable in PL and TG, and not 
in CE. Furthermore, by measuring the fatty acids in both plasma TG and PL, it was possible to 
identify differences between both fractions.
Prediction of energy-adjusted dairy fat intake was the primary outcome for this paper. In 
additional analyses, we repeated the analyses for unadjusted dairy fat intake, and also assessed 
predictive capacity for energy-adjusted dairy intake. Both C15:0 and trans-C18:1(n-7) in plasma 
TG and both trans-C18:1(n-7) and CLA in plasma PL were associated with unadjusted dairy fat 
intake, albeit with slightly lower effect sizes than with energy-adjusted dairy fat intake. The 
associations between dairy biomarkers and energy-adjusted dairy intake were weaker than for 
energy-adjusted dairy fat intake. Obviously, dairy fatty acid biomarkers serve best to predict 
dairy fat intake.
This study has several strong points. Firstly, we are one of the first studies to identify trans-
C18:1(n-7) and CLA in both plasma TG and PL as biomarkers of dairy fat intake. Another strength 
of the present study is its large population size. In total, complete data of 769 participants were 
used for analyses. Additionally, we were able to measure a large amount of dairy fat biomarkers 
in both plasma TG and PL in one cohort.
We must acknowledge that the current study has some limitations. First of all, the R-squares 
of the models for prediction of dairy fat intake were relatively low. This means that the dairy fatty 
acid biomarkers are not strongly related to the dairy fat intake from the FFQ. However, it cannot 
be discerned whether the weak associations are intrinsic to the dairy fatty acid biomarkers, or 
that the FFQ as a reference is not optimal. Concerning the dairy fatty acid biomarkers, it has 
been shown that some of the fatty acids in plasma are not only influenced by dairy fat intake, 
but can also be affected by metabolic processes (e.g. trans-C16:1(n-7) can be influenced by 
β-oxidation of trans-C18:1(n-7)), or by the intake of dietary fibers (e.g. C17:0 can be influenced 
by inulin), meat and coconut oil (e.g. C14:0) [53-56]. A limitation of this study is that we have no 
specific data on types of oils and types of meat, which precluded adjustment of these potential 
confounders. However, we had data on total meat intake. In our cohort adjustment for total meat 
intake did not alter the association between fatty acid biomarkers and energy-adjusted dairy fat 
intake (Supplemental Table 2A). Another limitation is that circulating fatty acids as biomarkers 
for dietary intake were expressed as proportions rather than as absolute concentrations, which 
makes them relative and therefore dependent on the presence of other major circulating fatty 




literature and make results comparable. It should also be noted that the fatty acid composition 
of dairy fat can vary depending on factors such as cow genetics, forage content, production 
level, time of lactation, physiological status of the animal and seasonal variation (German et al. 
2006; Jensen 2002, Mansson 2008, Hanus et al. 2018). Nevertheless, fatty acid biomarkers can 
provide an objective estimation of dairy fat intake, while this is intrinsically not the case with 
FFQ, which may be subject to under- and over reporting by participants [43,57]. Overall, there 
is no gold standard for measuring dietary intakes and the FFQ can therefore be seen as the best 
method so far.
This study is the first observational study investigating commonly used biomarkers in 
combination with less investigated trans fatty acid biomarkers. A first step towards validation 
would be performance of similar studies in other populations. Furthermore, as the applied 
assessment method is labor intensive, the results of this study should first be replicated in other 
studies to show that incorporation is worthwhile. Concluding, this paper showed associations 
between circulating dairy fatty acids and dairy fat intake in the general population, which can 
be seen as a first step towards better measurement techniques for dairy fat intake.
CONCLUSION
In this study, models were developed and validated for the prediction of dairy fat intake in the 
general population. The study confirmed the utility of commonly used biomarkers and identified 
the biomarkers trans-C18:1(n-7) and CLA as potential dairy fat biomarkers, which are one of the 
best biomarkers to predict dairy fat intake in the Lifelines population. Moreover, a combination 
of the biomarkers may be even a stronger predictor for dairy fat intake. A first step towards 
validation would be performance of similar studies in other populations.
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Supplementary Table 1: Potential dairy fat biomarkers in plasma cholesterol esters (CE), triglycerides (TG) 
and phospholipids (PL) measured in the pilot study of the Lifelines cohort (n = 96)
Fatty Acid Plasma CE (mol%) Plasma TG (mol%) Plasma PL (mol%)
C14:0 0.78 (0.66 – 0.95) 1.62 (1.25 – 2.24) 0.46 (0.40 – 0.56)
C15:0 0.20 (0.17 – 0.23) 0.30 (0.26 – 0.37) 0.29 (0.25 – 0.33)
C17:0 IS 0.49 (0.42 – 0.58) 0.39 (0.35 – 0.42)
T-C16:1(n-7) 0.025 (0.017 – 0.036) 0.026 (0.022 – 0.036) 0.023 (0.017 – 0.027)
T-C18:1(n-7) BDL 0.10 (0.07 – 0.15) 0.11 (0.08 – 0.13)
CLA 0.052 (0.037 – 0.065) 0.069 (0.042 – 0.091) 0.037 (0.028 – 0.046)
Data are raw data (mol%) presented as Median (25th – 75th percentile).
Abbreviations: CE, cholesterol esters; TG, Triglycerides; PL, Phospholipids, C14:0, Margaric acid; C15:0, 
Pentadecanoic acid; C17:0, Heptadecanoic acid; T-C16:1(n-7), Trans-Palmitoleic acid; T-C18:1(n-7), 
Vaccenic acid; CLA, Cis-9, Trans-11 Conjugated linoleic acid; IS, Internal standard; BDL, below detection 
limit.
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Supplementary Table 2B: Univariate regression analyses and multivariate models for the association 
between PL C14:0 and energy-adjusted dairy fat intake (g/d) stratified for males (n = 403) and females 
(n = 364)
Males Females
Std β p-value Std β p-value
Plasma PL
Model 1 0.264 <0.001 0.173 <0.001
Model 2 0.248 <0.001 0.147 0.003
Model 3 0.250 <0.001 0.148 0.003
Model 4 0.250 <0.001 0.141 0.004
Model 5 0.232 <0.001 0.147 0.003
Model 1: Crude analyses; Model 2: Adjusted for Model 1 + age; Model 3: Adjusted for Model 2 + BMI; 
Model 4: Adjusted for Model 3 + Total Meat Intake; Model 5: Adjusted for Model 3 + Trans-C18.1(n-9). 
Trans-C18.1(n-9) in plasma PL was transformed before analyses. Dairy fat intake was transformed and 
adjusted for energy intake according to the residual method. β’s are standardized beta’s. Abbreviations: 
C14:0, Myristic acid; PL, Phospholipids; BMI, Body Mass Index; Trans-C18:1(n-9), Elaidic acid.
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Supplementary Table 4: Number of times each variable is selected after 1000 bootstrap attempts in the 
lifelines cohort
(n = 769)




























C14:0, C17:0, Trans-C16.1(n-7), Trans-C18.1(n-7) and CLA in plasma TG and Trans-C16.1(n-7), Trans-
C18.1(n-7) and CLA in plasma PL were transformed (sqrt) before analyses. Dairy fat intake was 
transformed and adjusted for energy intake according to the residual method.
Abbreviations: TG, Triglycerides; PL, Phospholipids; C14:0, Myristic acid; C15:0, Pentadecanoic acid; 
C17:0, Heptadecanoic acid; T-C16:1(n-7), Trans-Palmitoleic acid; T-C18:1(n-7), Vaccenic acid; CLA, 
Conjugated Linolenic acid
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Supplementary Table 5: Univariate regression analyses and multivariate models to predict total dairy fat 
intake (g/d) with circulating fatty acids in plasma TG, plasma PL and a combination of the two in the Lifelines 
cohort (n = 769)
Model 1 Model 2 Model 3
Plasma TG Std β R2 P-value Std β P-value Std β P-value
TG C14:0 0.222 0.066 < 0.001 0.096 0.02 0.091 0.03
TG C15:0 0.257 0.084 < 0.001 0.125 0.02 0.117 0.02
TG C17:0 0.030 0.019 0.43 - -
TG T-C16:1(n-7) 0.188 0.045 < 0.001 0.013 0.80
TG T-C18:1(n-7) 0.261 0.086 < 0.001 0.151 0.01 0.135 0.01
TG CLA 0.171 0.047 < 0.001 -0.047 0.32
R2= 0.104 R2= 0.103
Plasma PL Std β R2 P-value Std β P-value Std β P-value
PL C14:0 0.198 0.057 < 0.001 0.083 0.04 0.083 0.04
PL C15:0 0.192 0.054 < 0.001 0.090 0.04 0.095 0.02
PL C17:0 0.127 0.034 0.001 0.010 0.82
PL T-C16:1(n-7) 0.085 0.025 0.02 -0.096 0.02 -0.096 0.02
PL T-C18:1(n-7) 0.232 0.070 < 0.001 0.167 0.001 0.167 < 0.001
PL CLA 0.228 0.070 < 0.001 0.123 0.003 0.123 0.003
R2= 0.110 R2= 0.110
Plasma TG+PL Std β P-value Std β P-value
TG C14:0 0.120 0.04 0.129 0.003
TG C15:0 0.059 0.35
TG C17:0 - -
TG T-C16:1(n-7) 0.013 0.80
TG T-C18:1(n-7) 0.083 0.16 0.102 0.07
TG CLA -0.122 0.02 -0.111 0.03
PL C14:0 -0.008 0.87
PL C15:0 0.086 0.06 0.111 0.004
PL C17:0 0.024 0.62
PL T-C16:1(n-7) -0.087 0.05 -0.074 0.08
PL T-C18:1(n-7) 0.125 0.02 0.140 0.01
PL CLA 0.132 0.01 0.124 0.01
R2= 0.130 R2= 0.128
Model 1: Univariate linear regression analysis of the fatty acid with total dairy fat intake; Model 2: 
Multivariate model with all fatty acids from our population in one model; Model 3: Multivariate model 
with the best combination of fatty acids in our population (backwards regression). C14:0, C17:0, Trans-
C16.1(n-7), Trans-C18.1(n-7) and CLA in plasma TG and Trans-C16.1(n-7), Trans-C18.1(n-7) and CLA in 
plasma PL were transformed before analyses. Dairy fat intake was transformed. β’s are standardized 
beta’s.
Abbreviations: TG, Triglycerides; PL, Phospholipids, C14:0, Margaric acid; C15:0, Pentadecanoic acid; 
C17:0, Heptadecanoic acid; Trans-C16:1(n-7), T-Palmitoleic acid; T-C18:1(n-7), Vaccenic acid; CLA, Cis-9, 




Supplementary Table 6: Univariate regression analyses and multivariate models to predict energy-adjusted 
dairy intake (g/d) with circulating fatty acids in plasma TG, plasma PL and a combination of the two in the 
Lifelines Cohort (n = 769)
Model 1 Model 2 Model 3
Plasma TG Std β R2 P-value Std β P-value Std β P-value
TG C14:0 0.073 0.045 0.04 0.013 0.77
TG C15:0 0.141 0.059 < 0.001 0.144 0.01 0.141 < 0.001
TG C17:0 0.066 0.043 0.08 0.051 0.21
TG T-C16:1(n-7) 0.069 0.043 0.09 -0.039 0.45
TG T-C18:1(n-7) 0.105 0.050 0.003 0.052 0.35
TG CLA 0.053 0.042 0.14 -0.058 0.23
R2= 0.064 R2= 0.059
Plasma PL Std β R2 P-value Std β P-value Std β P-value
PL C14:0 0.080 0.046 0.02 0.020 0.62
PL C15:0 0.143 0.060 < 0.001 0.057 0.20 0.075 0.07
PL C17:0 0.170 0.068 < 0.001 0.140 0.002 0.131 0.002
PL T-C16:1(n-7) 0.071 0.044 0.05 -0.033 0.45
PL T-C18:1(n-7) 0.111 0.051 0.002 0.008 0.86
PL CLA 0.082 0.046 0.02 0.047 0.27
R2= 0.075 R2= 0.072
Plasma TG+PL Std β P-value Std β P-value
TG C14:0 0.085 0.17 0.087 0.01
TG C15:0 0.039 0.54
TG C17:0 0.011 0.79
TG T-C16:1(n-7) -0.038 0.48
TG T-C18:1(n-7) 0.024 0.69
TG CLA -0.097 0.07
PL C14:0 -0.034 0.51
PL C15:0 0.062 0.19
PL C17:0 0.147 0.004 0.177 < 0.001
PL T-C16:1(n-7) -0.012 0.80
PL T-C18:1(n-7) 0.006 0.91
PL CLA 0.075 0.13
R2= 0.083 R2= 0.075
Model 1: Univariate linear regression analysis of the fatty acid with energy-adjusted dairy intake; Model 
2: Multivariate model with all fatty acids from our population in one model; Model 3: Multivariate 
model with the best combination of fatty acids in our population (backwards regression). C14:0, C17:0, 
Trans-C16.1(n-7), Trans-C18.1(n-7) and CLA in plasma TG and Trans-C16.1(n-7), Trans-C18.1(n-7) and CLA 
in plasma PL were transformed before analyses. Dairy intake was transformed and adjusted for energy 
intake according to the residual method. β’s are standardized beta’s.
Abbreviations: TG, Triglycerides; PL, Phospholipids, C14:0, Margaric acid; C15:0, Pentadecanoic acid; 
C17:0, Heptadecanoic acid; Trans-C16:1(n-7), T-Palmitoleic acid; T-C18:1(n-7), Vaccenic acid; CLA, Cis-9, 
Trans-11 Conjugated linoleic acid
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Potential biomarkers for fat from 
dairy and fish and their association 
with cardiovascular risk factors: Cross-
sectional data from the Lifelines 










Dairy fat intake, reflected by the biomarkers C14:0, C15:0, C17:0, trans-C16:1 (n-7), trans-C18:1 
(n-7) and CLA, may have beneficial effects on cardiovascular health. It has, however, been 
questioned whether this association is genuine, since C15:0 and C17:0 are also biomarkers from 
fish. We investigated whether the above biomarkers are reliable markers for dairy fat intake 
in 864 healthy subjects. Subsequently, we explored the association between these biomarkers 
and cardiovascular risk factors. Intakes of dairy and fish were determined by Food Frequency 
Questionnaires (FFQs). Fatty acids were analyzed in plasma triglycerides (TG) and phospholipids 
(PL). Median intakes of dairy and fish fat were 12.3 (8.4–17.4) g/day and 1.14 (0.53–1.75) g/day. 
All fatty acids, except TG C17:0, were associated with dairy fat (std.β range TG: 0.12 for C14:0 till 
0.25 for C15:0 and Trans-C18:1 (n-7); and std.β range PL: 0.12 for C17:0 and Trans-C16:1 (n-7) till 
0.24 for Trans-C18:1 (n-7) and CLA; P <0.001). TG C17:0 was associated with fish fat (std.β = 0.08; 
P = 0.03), whereas PL C17:0 was not. Associations remained after adjustment for fish/dairy fat 
intake. Strongest inverse associations with biological variables were found with PL C17:0 and 
Trans-C18:1 (n-7) (Std.βs: waist circumference: −0.18, P <0.001 and −0.10, P <0.05; BMI: −0.17, 
P <0.001, −0.11, P <0.01; glucose: −0.10, P <0.01 and −0.08, P <0.05; high sensitive C-reactive 
protein (hs-CRP): −0.22, P <0.001 and −0.16, P <0.01; uric acid: −0.27, P <0.001 and −0.24, P 
<0.001). In conclusion, fatty acid biomarkers, except plasma TG C17:0, were associated with 
dairy fat intake, independent of fish fat intake. PL C17:0 and trans-C18:1 (n-7) were inversely 
associated with adiposity, diabetes, inflammation and uric acid.
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INTRODUCTION
Cardiovascular diseases have become the number one cause of death worldwide [1]. Dietary 
and nutritional components are relevant players in the development and progression of 
cardiovascular diseases. Fatty acids are one of the nutritional components that may have 
influence on cardiovascular diseases. Whether this impact is positive or negative can for instance 
depend on the dietary source of the fatty acid. Earlier research has already shown that this was 
the case for the associations between saturated fatty acids and incident cardiovascular diseases 
[2,3]. For example, saturated fatty acids from meat were found to increase cardiovascular risk, 
while saturated fatty acids from dairy were inversely associated with cardiovascular risk [3–7]. 
Additionally, researchers have reported that trans fatty acids from processed foods, margarines, 
frying fast foods and commercial baked goods may increase risk for cardiovascular disease [8–11]. 
In contrast, trans fatty acids from dairy may actually be inversely related to cardiovascular risk 
factors [5]. Saturated and trans fatty acids from dairy products therefore seem to have a positive 
effect on cardiovascular health.
The saturated fatty acids pentadecanoic acid (C15:0), heptadecanoic acid (C17:0), and to 
a lesser extent myristic acid (C14:0), and the trans fatty acids trans-palmitoleic acid (trans-
C16:1(n-7), vaccenic acid (trans-C18:1(n-7) and the major conjugated linoleic acid (CLA) (cis-9, 
trans-11 CLA) were identified as dairy fat biomarkers. Additionally, dairy fat intake, measured with 
the dairy fat biomarkers, was found to be inversely associated with cardiovascular risk factors 
[4–6,12–16]. Despite the evidence, researchers raised concerns on the association between 
dairy fat intake, measured by dairy fat biomarkers, and cardiovascular health, since dairy fat 
biomarkers may not be explicit enough for the prediction of dairy fat intake [17]. For instance, 
C15:0 and C17:0 were also identified as possible biomarkers for fish fat intake [18,19]. Both fish 
intake and fish fat intake have already been found to be inversely related to the development 
of cardiovascular diseases [20]. In a meta-analysis of 19 observational studies, it was found that 
fish consumption was associated with a risk reduction of 17% for fatal coronary heart disease 
[21]. Additionally, a meta-analysis with 14 randomized controlled trials demonstrated that an 
intervention group who consumed omega-3 fatty acid supplements (eicosapentaenoic acid (EPA) 
+ docosahexaenoic acid (DHA), two fatty acids that are well-known biomarkers of fish intake) 
had an 8% reduction for cardiac death compared to the control group [22]. Because of the 
potential association of C15:0 and C17:0 with fish intake, researchers are concerned that the 
current circulating fatty acids that have been identified as dairy fat biomarkers, are not explicit 
enough for the prediction of dairy fat intake [19]. Therefore, inverse associations of the fatty 
acids with cardiovascular health may potentially not be ascribed to dairy fat intake, but fish fat 
intake instead.
One of the main purposes of this paper was therefore to find out whether the dairy fat 




investigated the association of the saturated fatty acids C15:0 and C17:0 with dairy fat intake, 
and additionally for fish fat intake. We repeated these measurements for the other dairy fat 
biomarkers (C14:0, trans-C16:1 (n-7), trans-C18:1 (n-7) and CLA). Secondly, we wanted to explore 
whether these circulating fatty acids were associated with cardiovascular risk factors, and so 
whether the association with cardiovascular risk factors could be ascribed to dairy fat intake, fish 
fat intake or both. To answer these questions, a subset from the Lifelines Biobank and Cohort 
study was used, a large observational cross-sectional study with initially healthy participants 
living in the northern part of the Netherlands.
MATERIALS AND METHODS
Study Design and Population
The Lifelines Cohort Study is a large observational population-based cohort study and Biobank 
which examines the health and health-related behaviors of more than 167,000 persons 
[23]. The participants were recruited from the three Northern provinces of the Netherlands 
between 2006 and 2013. A more detailed description of the Lifelines Cohort study can be found 
elsewhere [24,25]. In short, the first group of participants were recruited via local general 
practices. Participants could indicate whether family members were interested as well. In 
addition, individuals who were interested in the study had the possibility to register via an 
online self-registration. Individuals with insufficient knowledge of the Dutch language, with 
severe psychiatric or physical illness, and those with limited life expectancy (<5 years) were 
excluded from the study. Participants (>18 years old) completed several questionnaires, including 
topics such as occurrence of diseases, general health, medication use, diet, physical activity and 
personality. Participants were invited to the Lifelines Research sites for a comprehensive health 
assessment. A randomly selected amount of 864 participants from the baseline cross-sectional 
database were included in the current study. All participants provided written consent. The 
Lifelines Cohort Study was conducted according to the principles of the Declaration of Helsinki 
and approved by the Medical ethical committee of the University Medical Center Groningen, 
The Netherlands.
Dietary Intake
To asses dietary intake in the Lifelines Cohort, a 110-item semi-quantitative baseline food 
frequency questionnaire (FFQ) assessing food items over the previous month was developed 
and validated by Wageningen University using the Dutch FFQTOOLTM, in which food items were 
selected based on the Dutch national Food Consumption Survey of 1997/1998 [26]. Seven 
answers categories were used to assess consumption frequency, ranging from ‘not this month’ 
to ‘6–7 days a week’. Portion size was estimated by fixed portion sizes (e.g., slices of bread, pieces 
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of fruit) and commonly used household measures (e.g., cups, spoons). Energy and macronutrient 
intake was estimated from the FFQ data by using the Dutch food composition database of 2011 
(NEVO). This study specifically looked at total dairy fat intake and total fish fat intake. Total dairy 
fat intake consisted of fat from cheese, milk, buttermilk, yoghurt, sweetened yoghurt drinks, 
custard, curd cheese, ice cream, whipped cream and porridge. Total fish fat intake consisted of 
fat from lean and fatty fish, including types such as salmon, herring and codfish.
Data on Education, Smoking Habits and General Health
Information about education, smoking and general health was collected from the self-
administered questionnaire. Educational level was categorized in four groups (1. Never been to 
school or elementary school only, 2. Lower vocational or secondary schooling, 3. Intermediate 
vocational schooling or intermediate/higher secondary schooling or 4. Higher vocational 
schooling or university). Additionally, subjects were classified according to their smoking habits 
(non-smokers, former smokers or current smokers).
Clinical Measurements
Anthropometric measurements (weight, height, and waist circumference) and blood pressure 
were measured by well-trained staff. The anthropometric measurements were measured without 
shoes. Body weight was measured to the nearest 0.1 kg. Height and waist circumferences were 
measured to the nearest 0.5 cm. Height was measured with a stadiometer placing their heels 
against the rod and the head in Frankfort Plane position. Waist circumference was measured 
in standing position with a tape measure all around the body, at the level midway between 
the lower rib margin and the iliac crest. BMI was calculated as weight (kg) divided by height 
squared (m2). Systolic and diastolic blood pressures were measured 10 times during a period 
of 10 minutes, using an automated Dinamap Monitor (GE Healthcare, Freiburg, Germany). The 
average of the final three readings was used for each blood pressure parameter.
Biochemical Measurements
For analysis of lipids, glucose, uric acid, creatinine and the inflammation marker high sensitivity 
C-reactive protein (hs-CRP), blood samples were drawn in the morning between 8:00 and 
10:00 am after a period of overnight fasting. Serum levels of total cholesterol and high-density 
lipoprotein (HDL) cholesterol were measured with an enzymatic colorimetric method, low-
density lipoprotein (LDL) cholesterol with an enzymatic method and total triglycerides with a 
colorimetric UV method, all on a Roche Modular P chemistry analyzer (Roche, Basel, Switzerland). 
Fasting blood glucose was measured using a hexokinase method. HbA1c was determined in whole 
blood (EDTA-anticoagulated) by means of turbid metric inhibition immunoassay on a Cobas 
Integra 800 CTS analyzer (Roche Diagnostics Netherland BV, Almere, The Netherlands). Insulin 




uric acid and creatinine were measured on a Roche Modular P chemistry analyzer (Roche, Basel, 
Switzerland). The hs-CRP was determined by nephelometry (BN II system Siemens, Marburg, 
Germany).
Fatty Acid Analyses
EDTA-plasma samples were collected at baseline and stored at −80°C until analyses of fatty 
acids were carried out. Analyses of fatty acids were performed at the Department of Laboratory 
Medicine of the University Medical Center Groningen, The Netherlands using the methodology 
as described by Hoving et al. [28]. In short, total lipids were extracted by the method of Folch et 
al., using 6 mL of chloroform-methanol (2:1) and a 200 µL EDTA-plasma sample [29]. Additionally, 
a shortened version of the method of Kaluzny et al. was used to isolate plasma cholesterol esters 
(CE), triglycerides (TG) and phospholipids (PL), using aminopropyl SPE columns for the separation 
(Isolute, Biotage) [30]. Fatty acids were transmethylated with methanolic-HCL into fatty acid 
methyl esters (FAME). The samples were extracted with hexane and eventually redissolved into 
100 µL hexane. 100 µL of an internal standard for the quantification of fatty acids in CE (17:0) 
(50.1 mg/100 mL chloroform-methanol, 2:1 v/v), and 100 µL of an internal standard for the 
quantification of fatty acids in TG (19:0) (19.9 mg/100 mL chloroform-methanol, 2:1 v/v), both 
obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands), were added before isolation of 
classes. For the quantification of fatty acids in PL, 100 µL of free fatty acid 19:0 (50.0 mg/100 
mL methanol), obtained from Larodan (Solna, Sweden), was added after isolation of classes. 
100 µL Butylated Hydroxytoluene (1 g/100 mL methanol) from Sigma-Aldrich (Zwijndrecht, The 
Netherlands) was added to prevent fatty acid oxidation.
Aliquots of 2 µL were injected into an Agilent model 6890 gas chromatography equipped 
with a 200 m x 0.25 mm polar column (CP Select for FAME) and detected with an Agilent 7683 
series flame ionization detector. FAME were identified by comparing retention times with 
those of known standards (Supelco 37 component FAME mix (Sigma-Aldrich)). Fatty acids were 
calculated into mol%. Firstly, fatty acids were measured in a pilot of 96 samples to investigate 
whether the fatty acids of interest were detectable in plasma CE, TG and PL. Compared to plasma 
TG and PL, potentially interesting fatty acids were less detectable in plasma CE. Subsequently, 
we decided to only move forward with plasma TG and PL. The precision of the measurements 
was tested by calculating the variation coefficient from 10 replicate samples using quality-
control samples (pooled plasma samples). The circulating fatty acids reported in this paper had 
a variation coefficient ≤15%.
Statistical Analyses
All analyses were performed using IBM SPSS Statistics, version 22.0 for Windows software (IBM, 
Armonk, NY, USA) and GraphPad Prism, version 5.03 for Windows software (Graphpad Software, 
La Jolla, CA, USA). At the start of the study, plasma circulating fatty acids were measured in 864 
149
Biomarkers for dairy or fish and their association with CVD
lifelines participants, whereof 776 had complete FFQ data. Cases with missing data either on 
circulating fatty acids or dietary intake were removed before analysis leaving 769 participants 
in the lifelines cohort with complete data. For illustrative purposes, baseline data are presented 
for the total population, and separately for males and females. Baseline data are presented as 
mean ± SD (normally distributed data), median (25th–75th percentile) (non-normally distributed 
data) or as number (%) (categorical data). Differences in baseline data between males and 
females were tested with an independent t-test (continuous data), Mann-Whitney U test (non-
normally distributed data) or Chi-square test (categorical data). Multivariate linear regression 
analyses were carried out to investigate the association of circulating fatty acids in plasma TG 
and PL with dairy fat intake. Non-normal data were transformed before analyses. Models were 
adjusted for total energy intake (model 2), followed by further adjustments for age, education, 
smoking habits, BMI, total carbohydrates and total fat intake, fish fat intake, and total serum 
triglycerides and serum cholesterol (model 3–7). The same analyses were carried out to examine 
the association between circulating fatty acids and fish fat intake, except that the additional 
adjustments now included dairy fat intake instead of fish fat intake. As a sensitivity analysis, 
we also examined the association of EPA and DHA in plasma TG and PL with fish fat intake. To 
investigate our second purpose, multivariate linear regression analyses were used to examine 
the cross-sectional association of circulating fatty acids in plasma TG and PL with cardiovascular 
risk factors. Associations were adjusted for age and sex (model 2). In secondary analyses, models 
were additionally adjusted for education and smoking habits, total serum triglycerides, total 
serum cholesterol (only plasma PL), and fatty acids from de novo lipogenesis (C14:0 + C16:0 + 
C16:1 (n-7) from plasma TG). Lastly, the association between dairy fat intake and cardiovascular 
risk factors, and the association between fish fat intake and cardiovascular risk factors was 
investigated. Models were adjusted for total energy intake, age, sex, education, smoking habits, 
BMI, total carbohydrates and total fat intake, total fish fat intake/total dairy fat intake, and total 
serum triglycerides and serum cholesterol. All reported probability values are two-tailed, and 
a P ≤0.05 was considered statistically significant.
RESULTS
The Lifelines Population
The characteristics of the lifelines population (total population and separately for males (n = 404) 
and females (n = 365)) can be found in Table 1. The total population had a mean age of 53.0 ± 
15.5 years and a BMI of 26.0 ± 4.0 kg/m2. Differences in dietary intake were observed between 
males and females, i.e., the total energy intake, and the carbohydrate, protein and fat intake 
were significantly higher in males compared to females. However, after correction for individual 




males compared to females (Table 1). Concerning intake of dairy fat and fish fat, if corrected for 
individual energy intake, dairy fat intake did not differ between males and females, while fish 
fat intake was higher in females compared to males (Table 1).
The circulating fatty acids C14:0, C15:0, C17:0, trans-C16:1 (n-7), trans-C18:1 (n-7) and CLA were 
measured in plasma TG and PL. Overall, the circulating fatty acids in plasma TG were higher 
compared to plasma PL. The quantitatively most abundant investigated marker was C14:0 (Total 
TG: 1.87 mol%, PL: 0.49 mol%), followed by C17:0 and C15:0 in both fractions.
Table 1: Characteristics of the total Lifelines Population, separate for males and females.







Age visit 1, years 53.0 ± 15.5 53.3 ± 15.2 52.7 ± 16.0 0.60
Weight, kg 79.3 ± 14.2 85.7 ± 11.9 72.3 ± 13.2 <0.001
BMI, kg/m2 26.0 ± 4.0 26.3 ± 3.4 25.8 ± 4.6 0.08
Smoking, yes (%) 115 (15.0%) 68 (16.8%) 47 (12.9%) 0.13
SBP, mmHg 126.5 ± 17.0 129.5 ± 15.1 123.1 ± 18.2 <0.001
DBP, mmHg 73.7 ± 9.7 76.6 ± 9.8 70.5 ± 8.4 <0.001
Laboratory measurements
Total Cholesterol, mmol/L 5.2 ± 1.0 5.1 ± 1.0 5.3 ± 1.1 0.03
HDL cholesterol, mmol/L 1.5 ± 0.4 1.3 ± 0.3 1.7 ± 0.4 <0.001
LDL cholesterol, mmol/L 3.3 ± 0.9 3.3 ± 0.9 3.3 ± 1.0 0.27
Total Triglycerides, mmol/L 1.0 (0.8–1.5) 1.2 (0.9–1.6) 1.0 (0.7–1.3) <0.001
Total TG/HDL-c ratio 0.72 (0.45–1.17) 0.92 (0.60–1.43) 0.56 (0.38–0.88) <0.001
Glucose, mmol/L 5.1 ± 0.7 5.2 ± 0.6 5.0 ± 0.7 0.003
HbA1c, % 5.6 ± 0.4 5.6 ± 0.4 5.6 ± 0.4 0.99
Creatinine, umol/L 76.0 ± 13.6 83.6 ± 12.3 67.6 ± 9.3 <0.001
Hs-CRP, mg/L1 1.0 (0.5–2.2) 0.9 (0.4–1.9) 1.1 (0.5–2.9) 0.05
Uric acid, mmol/L1 0.31 ± 0.1 0.34 ± 0.1 0.28 ± 0.1 <0.001
Dietary intake (FFQ)
Energy intake, Kcal/day 1971 ± 624 2206 ± 665 1711 ± 449 <0.001
Total carbohydrates, g/day 228.8 ± 76.7 254.4 ± 80.7 200.4 ± 60.6 <0.001
Total carbohydrates, En% 46.4 ± 6.0 46.2 ± 5.7 46.7 ± 6.2 0.08
Total protein, g/day 74.8 ± 20.9 81.5 ± 22.6 67.3 ± 15.8 <0.001
Total protein, En% 15.5 ± 2.4 15.0 ± 2.1 16.0 ± 2.6 0.05
Total fat, g/day 77.2 ± 30.0 87.1 ± 32.7 66.2 ± 22.0 <0.001
Total fat, En% 34.9 ± 5.1 35.1 ± 5.0 34.6 ± 5.1 0.82
Total Dairy intake, g/day 322 (209–447) 315 (202–444) 324 (216–447) 0.99
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Total Dairy fat intake, g/day 12.3 (8.4–17.4) 13.5 (9.0–18.3) 11.3 (8.0–15.6) <0.001
Total Dairy fat intake (En%) 6.0 (4.3–7.8) 5.7 (3.4–7.4) 6.2 (4.5–8.1) 0.90
Total Fish intake, g/day 11.7 (5.6–17.5) 12.0 (6.8–17.4) 11.6 (5.2–17.5) 0.87
Total Fish fat intake, g/day 1.14 (0.53–1.75) 1.16 (0.58–1.74) 1.10 (0.48–1.77) 0.50
Total Fish fat intake (En%) 0.52 (0.24–0.88) 0.49 (0.23–0.77) 0.57 (0.26–1.01) 0.01
Fatty acid status in plasma TG
Myristic acid, mol% 1.87 (1.40–2.48) 1.98 (1.49–2.68) 1.74 (1.35–2.35) <0.001
Pentadecanoic acid, mol% 0.30 (0.25–0.35) 0.29 (0.24–0.35) 0.30 (0.25–0.35) 0.27
Heptadecanoic acid, mol% 0.49 (0.41–0.59) 0.48 (0.39–0.58) 0.52 (0.44–0.62) <0.001
Trans-Palmitoleic acid, mol% 0.03 (0.02–0.04) 0.03 (0.02–0.04) 0.03 (0.02–0.04) 0.05
Vaccenic acid, mol% 0.10 (0.06–0.14) 0.10 (0.07–0.15) 0.10 (0.07–0.14) 0.30
Conjugated Linoleic acid, 
mol%
0.08 (0.05–0.10) 0.07 (0.05–0.10) 0.07 (0.05–0.10) 0.24
Fatty acid status in plasma PL
Myristic acid, mol% 0.49 (0.41–0.57) 0.47 (0.40–0.55) 0.50 (0.43–0.58) <0.001
Pentadecanoic acid, mol% 0.28 (0.24–0.33) 0.28 (0.24–0.33) 0.29 (0.25–0.33) 0.09
Heptadecanoic acid, mol% 0.40 (0.36–0.44) 0.39 (0.35–0.44) 0.40 (0.36–0.45) 0.08
Trans-Palmitoleic acid, mol% 0.02 (0.01–0.03) 0.02 (0.01–0.02) 0.02 (0.02–0.03) 0.002
Vaccenic acid, mol% 0.09 (0.07–0.12) 0.09 (0.06–0.11) 0.09 (0.07–0.12) 0.002
Conjugated Linoleic acid, 
mol%
0.03 (0.02–0.04) 0.03 (0.02–0.04) 0.03 (0.02–0.04) 0.01
Data are presented as mean ± SD, median (25–75th percentile) or number (%). Differences between 
gender were tested by independent t-test, Mann-Whitney U or Chi-square test. Abbreviations: SD, 
standard deviation;; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; 
TG, Triglycerides; TG/HDL-c ratio, Total Triglycerides/HDL cholesterol ratio; HbA1C, Hemoglobin A1C; 
hs-CRP, High sensitivity C-reactive protein; FFQ, Food Frequency Questionnaire; Kcal, Kilocalories; PL, 
Phospholipids. 1.Hs-Crp was available in n = 412, uric acid was available in n = 348.
Biomarkers for Dairy Fat or Fish Fat
To investigate whether the fatty acids in plasma TG and PL were dairy fat biomarkers, fish fat 
biomarkers or both, linear regression analyses were carried out. Firstly, the association with dairy 
fat intake was explored. After adjustment for energy intake, fatty acids in both plasma TG and 
PL, except C17:0 in plasma TG, were significantly associated with dairy fat intake (Figure 1). In 
plasma TG, C15:0 and trans-C18:1 (n-7) had the strongest association with dairy fat intake (both 
std.β = 0.25, P <0.001). In plasma PL, trans-C18:1 (n-7) and CLA had the strongest association 
with dairy fat intake (both std.β = 0.24, P <0.001), followed by C14:0 and C15:0 (std.β = 0.20, P 
<0.001; std.β = 0.19, P <0.001). Additional adjustments for age, sex, education, smoking habits, 




and cholesterol did not alter the associations between circulating fatty acids and dairy fat intake 
(Supplemental Table 1). If dairy fat intake was expressed as En%, associations with fatty acid 
biomarkers did not materially differ from associations found for dairy fat intake with adjustment 
for energy intake by means of linear regression.
Figure 1: Association between circulating fatty acids from plasma triglycerides and phospholipids and dairy 
fat intake, adjusted for energy intake. *Equal or below significance level P ≤0.05. Abbreviations: β, beta; 
C14:0, Myristic acid; C15:0, Pentadecanoic acid; C17:0, Heptadecanoic acid; T-C16:1 (n-7), Trans-Palmitoleic 
acid; T-C18:1 (n-7), Vaccenic acid; CLA, Conjugated Linoleic acid; TG, Triglycerides; PL, Phospholipids.
Secondly, the association with fish fat intake was explored. After adjustment for energy 
intake, only C14:0, C17:0 and CLA in plasma TG were significantly associated with fish fat intake 
(Figure 2). C14:0 and CLA were inversely associated (std.β = −0.10, P = 0.01; std.β = −0.09, 
P = 0.01, respectively), while C17:0 was positively associated with fish fat intake (std.β = 0.08, 
P = 0.03). The association with C14:0 and C17:0 disappeared after additional adjustments for 
age, sex, BMI, , and total serum triglycerides and cholesterol (Model 7, Supplemental Table 2). 
After adjustment for energy intake, fatty acids measured in plasma PL were not associated with 
fish fat intake. As a sensitivity analysis, the association of EPA and DHA with fish fat intake was 
explored as well. After adjustment for energy intake, age, sex, education and smoking habits, 
EPA and DHA in both plasma TG and PL were significantly associated with fish fat intake (plasma 
TG EPA: std.β = 0.27 and DHA: std.β = 0.45; plasma PL EPA: std.β = 0.25 and DHA: std.β = 0.46; 
P <0.001) (Supplemental Table 3). If fish fat intake was expressed as En%, associations with 
fatty acid biomarkers did not materially differ from associations found for fish fat intake with 
adjustment for energy intake by means of linear regression.
153
Biomarkers for dairy or fish and their association with CVD
Figure 2:. Association between circulating fatty acids from plasma triglycerides and phospholipids and fish 
fat intake, adjusted for energy intake. *Equal or below significance level P ≤0.05. Abbreviations: β, beta; 
C14:0, Myristic acid; C15:0, Pentadecanoic acid; C17:0, Heptadecanoic acid; T-C16:1 (n-7), Trans-Palmitoleic 
acid; T-C18:1 (n-7), Vaccenic acid; CLA, Conjugated Linoleic acid; TG, Triglycerides; PL, Phospholipids.
Circulating Fatty Acids in Plasma TG and Cardiovascular Risk Factors
The second aim of the study was to investigate whether the circulating fatty acids were associated 
with cardiovascular risk factors. Overall, C14:0 and C17:0 showed the strongest associations 
with cardiovascular risk factors (Table 2). C14:0 was positively associated with weight, waist 
circumference and BMI, while C15:0 and C17:0 showed an inverse association with weight, 
waist circumference and BMI. Additionally, C14:0 was positively associated with glucose and 
HbA1c% (std.β = 0.14, P <0.001; std.β = 0.12, P <0.01, respectively), while C17:0 was inversely 
associated with glucose (std.β = −0.13, P <0.001). Furthermore, C15:0 and C17:0 were inversely 
associated with serum hs-CRP (std.β = −0.11, P <0.05; std.β = −0.17, P <0.01; respectively) and 
uric acid (std.β = −0.14, P <0.05; std.β = −0.25, P <0.001; respectively), and remained associated 
after adjustment for age and sex. Trans-C16:1 (n-7) and trans-C18:1 (n-7) became inversely 
associated with uric acid after adjustment for age and sex (std.β = −0.12, P <0.05; std.β = −0.11; 
P <0.05; respectively). C14:0 and C17:0 had a strong positive association with total triglycerides 
(std.β = 0.40, P <0.001; std.β = −0.56, P <0.001; respectively), and these associations remained 
after adjustment for age and sex. The age and sex adjusted analyses where therefore also adjusted 
for total triglycerides (Supplemental Table 4). The association with weight, waist circumference 
and BMI remained for C15:0, but disappeared for C14:0 and C17:0. Additionally, the association 
with hs-CRP remained for C15:0 and C17:0, and the inverse association with uric acid remained 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Biomarkers for dairy or fish and their association with CVD
As an extra analyses, we adjusted the age and sex adjusted analyses for fatty acids from the 
de novo lipogenesis DNL instead of for total triglycerides. Interestingly, trans-C16:1 (n-7) and 
trans-C18:1 (n-7) became inversely associated with BMI (std.β = −0.11 and std.β = 0.10, both P 
<0.05; respectively) and waist circumference (std.β = −0.101 and std.β = −0.07, both P <0.05; 
respectively).
Circulating Fatty Acids in Plasma PL and Cardiovascular Risk Factors
Besides fatty acids in plasma TG, the association between fatty acids from plasma PL and 
cardiovascular risk factors were also investigated. Overall, most associations were found with 
C17:0 and trans-C18:1 (n-7) (Table 3). C15:0, C17:0, trans-C16:1 (n-7) and trans-C18:1 (n-7) were 
inversely associated with weight and waist circumference. Additionally, C17:0 and trans-C18:1 
(n-7) were inversely associated with BMI and glucose (std.β = −0.10, P <0.05; std.β = −0.08, P 
<0.05, respectively). Furthermore, C17:0 and trans-C18:1 (n-7) were inversely associated with 
hs-CRP (std.β = −0.22, P <0.001; std.β = −0.16, P <0.01, respectively), and all fatty acids, except 
for CLA, were inversely associated with uric acid, for which the strongest associations were found 
for C17:0 (std.β = 0.27, P <0.001) and trans-C18:1 (n-7) (std.β = −0.24, P <0.001). Associations 
remained after adjustments for age and sex.
C15:0, C17:0, trans-C16:1 (n-7) and trans-C18:1 (n-7) were inversely associated with 
total triglycerides (std.β = −0.16, P <0.001; std.β = −0.24, P <0.001; std.β = −0.15, P <0.001; 
std.β = −0.10, P <0.01, respectively), and these associations remained after adjustment for age 
and sex. To stay in line with the analyses carried out for plasma TG, the age and sex adjusted 
analyses were also adjusted for total triglycerides. Additionally, we adjusted the analyses for total 
cholesterol, since it is known that the fatty acids from PL are closely related to the fatty acids of 
plasma CE [31] (Supplemental Table 5). The inverse association of C17:0 and Trans-C18:1 (n-7) 
with waist circumference and BMI remained. The association between CLA and BMI became 
inversely associated (std.β = −0.09, P <0.05). C17:0 and trans-C18:1 (n-7) remained inversely 
associated with hs-CRP, while trans-C16:1 (n-7) became inversely associated with hs-CRP. Only 
C14:0, C17:0 and trans-C18:1 (n-7) remained inversely associated with uric acid. As an extra 
analyses, we adjusted the age and sex adjusted analyses for fatty acids from the DNL instead of 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Biomarkers for dairy or fish and their association with CVD
Dairy Fat Intake, Fish Fat Intake and Cardiovascular Risk Factors
The association of dairy fat, fish fat and cardiovascular risk factors was investigated as an extra 
analysis. Dairy fat intake was significantly associated with age (std.β = 0.36, P <0.001) and sex 
(std.β = 0.08, P <0.05) (Supplemental Table 6). Furthermore, dairy fat intake was significantly 
associated with waist circumference, systolic and diastolic blood pressure, total, HDL and LDL 
cholesterol, glucose and HbA1c%. However, these associations disappeared after adjustment 
for age and sex. Dairy fat intake was inversely associated with uric acid, even after adjustment 
for age, sex, education, smoking habits, BMI, fish fat intake, and total carbohydrate and total 
fat intake. In addition to dairy fat intake, fish fat intake was also significantly associated with 
age (std.β = 0.08, P ≤0.05), but not with sex (Supplemental Table 7). Furthermore, fish fat intake 
was positively associated with HDL cholesterol (std.β = 0.10, P <0.01), and inversely associated 
with total triglycerides (std.β = -0.12, P <0.01) and the TG/HDL-c ratio. The associations remained 
after adjustments for age, sex, education, smoking habits, BMI, total dairy fat intake, total 
carbohydrate and total fat intake.
DISCUSSION
The current paper showed that C14:0, C15:0, C17:0, trans-C16:1 (n-7), trans-C18:1 (n-7) and CLA 
were solid biomarkers to predict dairy fat intake in the general population, while in contrast, 
C15:0 and C17:0 were not confirmed as strong biomarkers for fish fat intake. The dairy fatty 
acids C15:0 and C17:0 in plasma TG and C15:0, C17:0 and trans-C18:1 (n-7) in plasma PL had an 
inverse association with cardiovascular risk factors such as weight, waist circumference and BMI. 
Additionally, dairy fat biomarkers were also inversely associated with diabetes-related outcomes, 
the inflammatory marker hs-CRP and the kidney marker uric acid.
For many years now the saturated fatty acids C15:0 and C17:0, and to a lesser extend 
C14:0 have been described as biomarkers to predict dairy and dairy fat intake [5,12,15,32–36]. 
Additionally, the trans fatty acids trans-C16:1 (n-7), trans-C18:1 (n-7) and CLA were added to the 
list of biomarkers [5,15,36–38]. In line with the previous studies, we also found that the current 
mentioned biomarkers are predictors of dairy fat intake in the general population, of which the 
strongest associations were found with TG C15:0, TG trans-C18:1 (n-7), PL trans-C18:1 (n-7) and 
PL CLA. Associations of dairy fat intake with trans-C18:1 (n-7) and CLA have hardly been explored. 
One study investigated the association between dairy fat intake and erythrocyte trans-C18:1 
(n-7), but found no significant association [36]. Furthermore, associations between CLA and 
dairy fat intake are more commonly investigated in adipose tissue. A case-control study that 
investigated the association between CLA and the risk of myocardial infarction demonstrated 
that CLA was significantly associated with dairy intake in the Costa Rican population (r = 0.31) 
[37]. In contrast to trans-C18:1 (n-7) and CLA, the association between dairy fat intake and 




study of Lund-Blix et al., it was for example found that plasma PL C15:0 and total dairy fat were 
significantly associated with an r of 0.39 [14].
Besides dairy fat, the saturated fatty acids C15:0 and C17:0 have also been described as 
potential fish fat biomarkers. The fatty acids can be found in marine water fish and have recently 
found to be related to DHA [18,19]. C15:0 and C17:0 were therefore presumed to be invalid dairy 
fat biomarkers in a population with a high fish consumption. Participants from the current study 
showed a low intake of fish (11.7 g/day) and a high intake of dairy (322 g/day). Subsequently, 
C15:0 and C17:0, and the other dairy fat biomarkers were not confirmed as strong biomarkers 
for fish fat intake. C15:0, C17:0 and the other circulating fatty acids are therefore valid dairy fat 
biomarkers for the general population in the northern part of the Netherlands.
In the current study, significant associations were found between dairy fat biomarkers 
and cardiovascular risk factors. The association between the circulating dairy fat biomarkers 
C14:0, C15:0, C17:0 and trans-C16:1 (n-7) and cardiovascular health has been investigated 
before and an illustrative overview of papers investigating this association can be found in 
Supplemental Table 8. One of the main interesting outcomes of the current paper is the inverse 
association of the saturated fatty acids C15:0 and C17:0 with weight, waist circumference and 
BMI. A Swedish prospective study regarding risk factors for ischemic heart disease in 62 70-
year old men found data that was in line with the current findings. Researchers showed an 
inverse association between plasma CE C15:0 and weight (r2 = −0.36), waist circumference 
(r2 = −0.28) and BMI (r2 = −0.39)[32]. A more recent Swedish study on the effect of dairy fat 
biomarkers and the risk to develop myocardial infarction in an adult population demonstrated 
an inverse association of plasma PL C15:0, PL C17:0 and PL C15:0 + C17:0 with BMI (r = −0.08, 
r = −0.14 and r = −0.14 respectively) [6]. Additionally, serum PL C15:0 and C17:0 were inversely 
associated with abdominal obesity (r = −0.22 and r = −0.30, respectively) as was found in a 
cross-sectional study with 301 healthy 63-year old men [39]. The inverse association between 
the saturated fatty acids and adiposity markers are in line with a recent published paper on 
dairy and overweight [40]. Moreover, the authors used data from the Lifelines Cohort also. 
However, while we investigated the association between dairy fat biomarkers and adiposity, 
they investigated the association between dairy fat products and adiposity. The investigators 
found an inverse association between full-fat dairy product intake and BMI-defined overweight 
(≥25–30 kg/m2) and obesity (≥30 kg/m2). Additionally, age and sex adjusted multivariate linear 
regression analyses identified inverse associations of full-fat dairy product intake (per 100g) with 
waist circumference (β = −0.39) and BMI (β = −0.23). In line with this paper, a systematic review 
of observational studies on the relationship between dairy intake and obesity, cardiovascular, 
and metabolic disease found an inverse association between high fat dairy consumption and 
measurements of adiposity in 11 out of 16 studies [41].
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The ruminant derived trans fatty acids were also found to be related to weight, waist 
circumference and BMI in the Lifelines Cohort. The plasma PL trans fatty acids trans-C16:1 (n-7) 
and trans-C18:1 (n-7) were inversely related to weight and waist circumference. Additionally, 
trans-C18:1 (n-7) was also inversely associated with BMI. In secondary analyses, plasma TG 
trans fatty acids trans-C16:1 (n-7) and trans-C18:1 (n-7) became inversely associated with 
waist circumference and BMI after adjustment for the fatty acids from DNL. The cardiovascular 
health study, a prospective cohort study from the U.S. including 3736 adult participants 
investigated the association between trans-C16:1 (n-7) and metabolic risk and diabetes type 2 
[42]. The researchers found a significant reduction of 1.8% (across quintiles) in BMI and waist 
circumference. Furthermore, a study in which the intake of ruminant derived trans fat was 
measured by FFQs also suggested a favorable effect on cardiovascular health. Results from 
this cohort showed an inverse association between intake of ruminant derived trans fat and 
changes in weight [43].
Concerning the effect on diabetes-related outcomes, plasma TG C14:0 was positively 
associated with glucose and HbA1c%, however this association did not remain after adjustment 
for total serum triglycerides. Plasma TG C17:0, PL C17:0 and PL trans-C18:1 (n-7) were inversely 
associated with glucose. Additionally, trans-C18:1 (n-7) was inversely associated with HbA1c%. 
All other dairy fat biomarkers were not associated with the diabetes-related outcomes. In a 
cross-sectional study with 17 men and women without nonalcoholic fatty liver disease, it was 
found that serum PL C15:0, C17:0 and trans-C16:1 (n-7), and free fatty acid C15:0 and C17:0 were 
inversely related to fasting plasma glucose, the area under the curve for glucose during an oral 
glucose tolerance test (OGTT) and liver fat [44]. Additionally, a prospective, case-control study 
with Swedish adults demonstrated that serum PL C17:0 and C15:0 + C17:0, but not C15:0, were 
inversely associated with fasting glucose (r = −0.13 and r = −0.16, respectively) [6]. Moreover, 
a cross-sectional study with 795 elderly men showed an inverse association between adipose 
tissue C17:0 and insulin sensitivity, but not between adipose tissue C15:0 and insulin sensitivity 
[45]. While data from the Lifelines Cohort demonstrated an inverse association between dairy 
fat biomarkers and diabetes-related outcomes, an opposite association of high-fat dairy product 
intake with pre-diabetes and newly diagnosed type 2 diabetes was actually found in the same 
cohort [46]. The authors suggested that the positive association between dairy fat intake and 
diabetes-related outcomes may potentially not depend on the ‘fat content’ of a dairy product, 
but to the individual dairy product intake.
Little is known about the mechanism behind the inverse association between dairy fat 
biomarkers and cardiovascular risk factors such as weight, waist circumference and BMI. One 
potential mechanism by which dairy fat may exert beneficial effects on cardiovascular risk 
factors, may be via reducing chronic inflammation and lipid peroxidation [41,47]. This mechanism 




that serum C15:0 and C17:0 were inversely associated with inflammation markers and oxidative 
stress in the overweight group [47]. The inverse association between dairy fat biomarkers and 
inflammation was confirmed in the current study, and in earlier published papers [47,48]. While 
it is commonly known that inflammatory markers and oxidative stress are positively related with 
cardiovascular risk factors [47,49–51], dairy fat biomarkers may actually reduce inflammatory 
markers, and subsequently cardiovascular risk factors.
In addition to the potential mechanism ascribed above, uric acid may also be involved in this 
process. Uric acid was found to be inversely related with dairy fat biomarkers in plasma TG and 
PL. The strongest associations were found with plasma PL C17:0 and PL trans-C18:1(n-7). Inverse 
associations between these dairy fat biomarkers and uric acid remained after adjustment for 
age, sex, education, smoking habits, total serum triglycerides and serum cholesterol. In addition 
to the dairy fat biomarkers, there was also an inverse association observed between dairy fat 
intake measured by FFQ, and uric acid and has been observed in the literature before [52]. While 
an increased uric acid level may increase the risk for the development of cardiovascular diseases 
[53,54], perhaps by activating a complex mechanism involving inflammatory and oxidative 
related mechanisms [55,56], it can be hypothesized that the opposite may actually reduce the 
risk for the development of cardiovascular risk. Overall, more research warrants an investigation 
of the potential mechanism between dairy fat biomarkers, uric acid levels, inflammation and 
cardiovascular health.
Interestingly, the associations between circulating fatty acids and cardiovascular risk factors 
were less strong in plasma TG compared to plasma PL. This might probably be due to the fact 
that the association between plasma TG trans fatty acids and cardiovascular risk factors can be 
influenced by recent dietary intakes and de novo lipogenesis, whereas this is less for plasma PL 
[57]. In our cohort, the association between fatty acids from de novo lipogenesis (i.e., C14:0, 
C16:0, C16:1 (n-7)) measured in plasma TG) were significantly associated with total triglycerides. 
Additionally, adjusting for the fatty acids from de novo lipogenesis changed associations between 
circulating dairy fat biomarkers and cardiovascular risk factors. Our results therefore also suggest 
that it is preferable to measure fatty acids in phospholipids to investigate associations with 
cardiovascular risk factors.
A main strength of this paper is the inclusion of the relatively large amount of participants. 
Furthermore, the association between circulating fatty acids and cardiovascular risk factors 
were investigated. Lifelines is building a biobank and database and for this purpose, Lifelines 
has collected and is still collecting information via questionnaires, physical examinations and 
biological samples, including information on several cardiovascular risk factors. This huge 
collection of data and samples allowed us to investigate a brought range of cardiovascular health 
aspects in relation to dairy fat biomarkers, dairy fat intake and fish fat intake. A third strong 
point is that we measured the fatty acids in two different compartments, i.e., plasma TG and 
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PL, providing the opportunity to investigate whether the association of dairy fat biomarkers 
with cardiovascular risk factors were consistent in plasma lipid classes with widely differing 
functions and half-lives.
Some limitations of this study should be addressed. First, given the observational nature 
of this study, it is impossible to draw a definite conclusion about the causality of the association 
of the circulating fatty acids with dairy fat, fish fat and cardiovascular risk factors. Secondly, 
the Lifelines cohort study uses an FFQ to measure dietary intake of the participants which is a 
method based on self-report, and therefore subject for recall bias. It is possible that the intakes 
of dairy and fish fat are over- or underreported. However, since there is no gold standard for 
measuring dietary intakes so far, FFQs are still seen as one of the best methods since they 
are able to capture usual, individual, long-term dietary intakes. Additionally, the burden for 
the participant is low [58,59]. Thirdly, we used Hoving’s method for the fatty acid analyses. 
The coefficients of variation for measuring circulating fatty acids in plasma was relatively 
high. Despite this limitation, we still found several associations between circulating fatty acids 
and cardiovascular risk factors. Potentially, using a method that allows for measurement of 
circulating fatty acids with lower coefficients of variation, such as Glaser’s method, might have 
given stronger associations between circulating fatty acids and cardiovascular risk factors [60].
CONCLUSIONS
This paper confirmed that the current known dairy fatty acid biomarkers are solid biomarkers 
to predict dairy fat intake in the general population of the Netherlands. Additionally, the fat 
biomarkers were inversely associated with adiposity, diabetes and inflammatory outcomes, 
suggesting that dairy fat intake may have a beneficial effect on cardiovascular health. Longitudinal 
studies are needed to further investigate the influence of dairy fat intake on cardiovascular risk 
and overall health.
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Biomarkers for dairy or fish and their association with CVD
Supplemental Table 3: Association between the circulating fatty acids EPA and DHA and fish fat intake
Omega-3 fatty acids
Total fish Fat (g/d) EPA DHA
β p-value β p-value
Plasma TG
Model 1 0.277 <0.001 0.425 <0.001
Model 2 0.283 <0.001 0.440 <0.001
Model 3 0.272 <0.001 0.445 <0.001
Plasma PL
Model 1 0.256 <0.001 0.457 <0.001
Model 2 0.258 <0.001 0.465 <0.001
Model 3 0.248 <0.001 0.464 <0.001
Model 1: Crude model; Model 2: Adjusted for model 1 + energy intake; Model 3: Adjusted for Model 2 + 
age and sex, education and smoking
Dependent: fish fat intake, independent: fatty acids. Associations between fatty acid status and fish fat 
intake are reported as standardized β’s.





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplemental Table 6: Association between dairy fat intake and cardiovascular risk factors
Dairy fat intake (g/d)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Age (years) 0.355***
Sex 0.083*
Weight (kg) -0.003 0.022 0.043 0.037 0.043 0.042
Waist circumference 0.094* 0.007 0.023 0.014 0.023 0.025
BMI (kg/m2) 0.048 -0.022
SBP (mmHg) 0.103* -0.043 -0.048 -0.044 -0.048 -0.046
DBP (mmHg) 0.108** 0.021 0.023 0.012 0.024 0.024
Total C (mmol/L) 0.118** -0.003 0.006 0.000 0.006
HDL-c(mmol/L) 0.112** 0.051 0.051 -0.004 0.053 0.036
LDL-c (mmol/L) 0.086* -0.015 -0.003 0.012 -0.003 -0.011
Total TG 0.009 -0.024 -0.026 -0.009 -0.028
TG/HDL-c ratio -0.037 -0.038 -0.039 -0.006 -0.041 -0.014
Glucose (mmol/L) 0.085* -0.036 -0.024 -0.055 -0.024 -0.018
HbA1c (%) 0.215*** 0.020 0.027 0.030 0.027 0.031
Hs-CRP (mg/L)1 0.001 0.005 -0.008 0.004 -0.007 -0.012
Creatinine (umol/L) -0.030 -0.020 -0.026 -0.030 -0.027 -0.023
Uric acid (mmol/L)1 -0.172** -0.122* -0.107* -0.106* -0.101 -0.058
Ureum (mmol/L)1 0.188** 0.183** 0.186** 0.184** 0.186** 0.184**
Model 1: Adjusted for energy intake; Model 2: Model 1 + age, sex, education and smoking; Model 3: 
Model 1 + age, sex and BMI; Model 4: Model 3 + total carbohydrates and total fat; Model 5: Model 3 + 
total fish fat intake; Model 6: Model 3 + total triglycerides and total cholesterol.
Dependent: cardiovascular risk factors, independent: dairy fat intake. Associations between dairy fat 
intake and cardiovascular risk factor are reported as standardized β’s. P-value: * = ≤ 0.05, ** = < 0.01, 
*** = < 0.001. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; Total C; total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, Low density 
lipoprotein cholesterol; Total TG, total triglycerides; TG/HDL-c ratio, total triglycerides/HDL cholesterol; 
HbA1c, Hemoglobin A1C; Hs-CRP, High sensitive C-reactive protein. 1. Hs-CRP data was available in 
n = 412, Uric acid and ureum data were available in n = 348
173
Biomarkers for dairy or fish and their association with CVD
Supplemental Table 7: Association between fish fat intake and cardiovascular risk factors
Fish fat intake (g/d)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Age (years) 0.077*
Sex 0.004
Weight (kg) -0.041 -0.036 0.007 0.003 0.007 0.003
Waist circumference -0.022 -0.035 0.000 -0.001 0.001 0.007
BMI (kg/m2) -0.045 -0.048
SBP (mmHg) 0.032 0.014 0.013 0.013 0.012 0.022
DBP (mmHg) 0.041 0.020 0.029 0.012 0.029 0.038
Total C (mmol/L) 0.019 -0.015 0.001 -0.011 0.002
HDL-c(mmol/L) 0.100** 0.080* 0.075* 0.042 0.076* 0.018
LDL-c (mmol/L) 0.018 0.043 0.007 0.009 0.007 -0.001
Total TG -0.117** -0.120** -0.109** -0.110** -0.109**
TG/HDL-c ratio -0.126*** -0.121*** -0.110*** -0.098** -0.111*** -0.006
Glucose (mmol/L) 0.000 -0.030 -0.006 -0.014 -0.006 0.016
HbA1c (%) 0.016 -0.026 -0.013 -0.004 -0.012 0.001
Hs-CRP (mg/L)1 -0.085 -0.079 -0.047 -0.047 -0.047 -0.033
Creatinine (umol/L) -0.013 -0.012 -0.015 -0.021 -0.016 -0.002
Uric acid (mmol/L)1 0.097 0.102* 0.081 0.079 0.076 0.102**
Ureum (mmol/L)1 -0.030 -0.019 -0.012 -0.015 -0.001 -0.011
Model 1: Adjusted for energy intake; Model 2: Model 1 + age, sex, education and smoking; Model 3: 
Model 1 + age, sex and BMI; Model 4: Model 3 + total carbohydrates and total fat; Model 5: Model 3 + 
total dairy fat intake; Model 6: Model 3 + total triglycerides and total cholesterol.
Dependent: cardiovascular risk factors, independent: fish fat intake. Associations between dairy fat 
intake and cardiovascular risk factor are reported as standardized β’s. P-value: * = ≤ 0.05, ** = < 0.01, 
*** = < 0.001. Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; Total C; total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, Low density 
lipoprotein cholesterol; Total TG, total triglycerides; TG/HDL-c ratio, total triglycerides/HDL cholesterol; 
HbA1c, Hemoglobin A1C; Hs-CRP, High sensitive C-reactive protein. 1. Hs-Crp data was available in 
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Supplementation with n-3 fatty acids may improve long-term outcomes of renal transplant 
recipients (RTR). Recent evidence suggests that eicosapentaenoic (EPA) and docosahexaenoic 
(DHA) acids have different outcomes compared with α-linolenic acid (ALA). We examined the 
prospective associations of EPA-DHA and ALA intakes with graft failure and all-cause mortality 
in 637 RTR. During 3.1 years (Interquartile range (IQR) 2.7, 3.8) of follow-up, 41 developed 
graft failure and 67 died. In age and sex adjusted analyses, EPA-DHA and ALA intakes were not 
associated with graft failure. EPA-DHA intake was not significantly associated with mortality 
(Hazard ratio (HR)=0.79; 95% CI 0.54, 1.15 per 0.1 Energy% difference). ALA intake was 
significantly associated with mortality (HR=1.17; 95% CI 1.04, 1.31 per 0.1 Energy% difference). 
This association remained following adjustments for BMI, proteinuria and intakes of fat, 
carbohydrate and protein. RTR in the highest tertile of ALA intake exhibited an about two fold 
higher mortality risk (HR=2.21; 95% CI 1.23, 3.97) compared to the lowest tertile. In conclusion, 
ALA intake may be associated with increased mortality in RTR. Future RCTs are needed to confirm 
these results.
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INTRODUCTION
The prevalence of end-stage renal disease (ESRD) is increasing worldwide [1]. In the United 
States the incidence of ESRD in 2012 was as high as 400 cases per million residents per year [2]. 
The preferred treatment for most ESRD patients is renal transplantation. Compared to dialysis 
treatment it is less expensive, improves quality of life and increases survival [3,4]. Although 90% 
of the allografts survives at least one year [5,6], more than half of these grafts do not last longer 
than 10-12 years [6]. This is largely due to graft failure and premature mortality [6]. Thus there 
is a great need for approaches to improve survival.
Many randomized controlled trials have investigated whether n-3 fatty acid supplements 
reduce cardiovascular risk and improve graft survival in renal transplant recipients (RTR). A 
meta-analysis from 2007 concluded that it cannot be excluded that RTR may benefit from 
such supplements [7]. In this respect it is important to realize that the effects of the marine-
derived n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and 
the plant-derived n-3 fatty acid α-linolenic acid (ALA) may differ. For example, in the general 
population it has been found that supplementation with EPA and DHA was protective, whereas 
supplementation with ALA was not [8]. Importantly, in a large Swedish study in more than 2000 
men aged 50 years or older, it was suggested that exposure to ALA has an adverse effect on 
mortality [9]. In RTR, it is unclear whether marine-derived and plant-derived n-3 fatty acids differ 
in effects on long-term outcome.
In the present study, we aimed to investigate the association of marine-derived and plant-
derived n-3 fatty acids with long-term outcome in stable outpatient RTR. For this purpose, we 
examined EPA-DHA and ALA intakes separately, and analyzed whether the intakes of these n-3 
fatty acids are associated with graft failure and all-cause mortality.
METHODS
Design and study population
We performed a post-hoc analysis in an existing prospective cohort study on RTR in which 
baseline food frequency questionnaire data were available that were suitable to address our 
research question. The study took place at the University Medical Center Groningen between 
November 2008 and March 2011 [10]. All RTR (≥ 18 years of age) had a functioning graft for 
at least 1 year, no alcohol or drug addiction and sufficient knowledge of the Dutch language. 
In total, 817 RTR were invited for the study, of whom 707 (87%) provided written consent to 
participate. In the current study, patients with missing dietary data were excluded from the 
analyses, resulting in 637 RTR for analysis. The study was approved by the Institutional Review 
Board (METc 2008/186). Dietary intake and clinical parameters were assessed once at baseline. 




RTR did not receive dietary recommendation regarding n-3 fatty acid intake. Patients were taking 
standard immunosuppressive and antihypertensive drugs.
Outcome parameters
The primary long-term outcomes of the study were graft failure and all-cause mortality. Graft 
failure was defined as return to dialysis or re-transplantation. The patients were followed until 
30 April 2013, with no loss to follow-up.
Dietary assessment
Dietary intake was assessed with a semi-quantitative validated Food Frequency Questionnaire 
(FFQ) that was developed at Wageningen University [11]. The questionnaire consisted of 177 
food items to record intake during the last month, expressed in times per day, week or month. 
The number of servings was recorded in natural units (for example, slice of bread or apple) or 
household measures (for example, cup or spoon). Patients had to fill in the questionnaire at 
home. All FFQs were checked by a trained researcher and verified with the patients in case of 
inconsistent answers. The results of the FFQ were converted into total energy and nutrient intake 
by using the Dutch Food Composition Table of 2006 [12].
Clinical parameters
All measurements were performed during a morning visit to the outpatient clinic. Patients were 
instructed to collect a 24-hour urine sample the day before the visit. In the morning, blood 
was drawn after a fasting period of 8-12 hours. Body weight and height were measured with 
patients wearing indoor clothing without shoes. Body mass index (BMI) was calculated as weight 
in kilograms divided by height in meters squared (kg/m2), and body surface area (BSA) was 
measured as meters squared (m2). Diabetes was defined as use of antidiabetic medication or 
fasting serum glucose ≥ 7.0 mmol/L [13]. Fasting blood pressure, heart rate and mean arterial 
pressure (MAP) were determined with a semi-automatic device (Dinamap 1846; Critikon). Blood 
pressure and heart rate were measured every minute for 15 minutes, and the last three were 
averaged [14]. Renal function was assessed by the eGFR (estimated glomerular filtration rate) 
[15]. Serum creatinine levels were measured with a modified version of the Jaffé method (MEGA 
AU 510; Merck Diagnostica). Total urinary albumin concentration was analyzed by nephelometry 
(Dade Behring Diagnostics), while total urinary protein concentration was determined using the 
Biuret reaction (MEGA AU 150; Merck Diagnostica). Serum cholesterol, glycated hemogloblin 
(HbA1C) and high-sensitive C-reactive protein (hs-CRP) were measured according routine 
laboratory methods. Proteinuria was defined as urinary protein excretion ≥ 0.5 g/24 h.
Information on patient health status, medical history, and medication use was obtained 
from patient records. Information on smoking habits and alcohol intake was collected as well. 
Patients were divided into current smokers, former smokers or never smokers. In addition, 
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patients were also divided into four groups according to their alcohol intake (g ethanol/d) (no 
alcohol, 0-10 g/d, 10-30 g/d and >30g/d). Smoking behavior and alcohol intake were based on 
self-report.
Statistical analyses
Data analysis was performed using SPSS version 22.0 software (SPSS, Inc.) and R version 3.2.3. 
Data are presented as the mean (SD) or median (Inter Quartile range (IQR)) unless stated 
otherwise. N-3 fatty acid intake was measured as percentage of the total energy intake (En%). 
For initial exploration, EPA-DHA and ALA intake were divided into tertiles, which were compared 
by means of ANOVA, Kruskal-wallis or Chi-square test depending on whether the distribution of 
data was normal, skewed or categorical respectively. Linear regression analyses with intake of 
n-3 fatty acids as a dependent variable were carried out to compare strengths of associations 
of different baseline variables with n-3 fatty acids. For these analyses, categorical variables 
were divided into 2 or more dummy variables. Baseline characteristics with a P-value < 0.10 for 
the association with intake of n-3 fatty acids were selected as potential explanatory variables 
in subsequent Cox regression analyses. Cox regression analyses were also used to test whether 
there were interactions between n-3 fatty acid intake and potential explanatory variables (age, 
sex, BMI, smoking habits, alcohol intake, intake of protein, fat and carbohydrates, proteinuria, 
blood pressure). In prospective analyses, we investigated the associations EPA-DHA and ALA 
intake with graft failure and all-cause mortality in RTR. Analyses were performed with adjustment 
for age and sex (model 1) and further cumulative adjustments for BMI (model 2), alcohol intake, 
smoking behavior (model 3), total fat intake, total protein intake, total carbohydrate intake 
(model 4), and proteinuria and diastolic blood pressure (DBP) (model 5). Analyses were each time 
initially performed for EPA-DHA and ALA intake as continuous variables and repeated for EPA-
DHA and ALA intake as tertiles. Cox regression analyses with restricted cubic splines was carried 
out to show the association between ALA intake and all-cause mortality. A two-sided P-value < 
0.05 was considered statistically significant. Since there were only a small number of statistical 
tests related to our a priori hypotheses, correction for multiple testing is not required [16,17].
In secondary analyses, n-3 fatty acid intake was measured in gram per day (g/d) instead of 
En%. For this analysis, n-3 fatty acid intake was adjusted for total energy intake according to the 
residual method, which is based on the isoenergetic principle [18]. In addition, we calculated both 
the intake of EPA-DHA and the intake of ALA as a proportion of the total intake of fatty acids. As 
sensitivity analyses, we repeated the Cox regression analyses after elimination of patients with 
extreme intakes of n-3 fatty acids outside of 3 SD from the mean value, i.e. an EPA-DHA intake 





Population characteristics of RTR are presented in Table 1. Median time after transplantation 
was 5.6 (1.8 - 12.1) years. The mean age of the study population was 53 (SD 13) years, and 57% 
was male. The participants were slightly overweight (mean BMI of 26.6) and 24% had diabetes. 
Mean blood pressure of RTR was within normal boundaries (136/83 mmHg). It should, however, 
be noted that 88% of the 637 participants were using antihypertensive drugs. Mean serum total 
cholesterol was 5.1 (SD 1.1) mmol/l, while statins were taken by 53% of the recipients. Calcineurin 
inhibitors were used in 57.1% of the RTR, and 83.3% were using proliferation inhibitors. Mean 
eGFR was 49 ml/min per 1.73m². The median urinary protein excretion was 0.19 (0-8.91) mg/24h, 
with 139 (22%) RTR having proteinuria.
Table 1: Baseline characteristics of 637 RTR.
Characteristics Mean SD Range (min-max)
Demographics
 Age, yr
 Gender (% male)
 BMI, kg/m2
 BSA, m2











































 Proliferation inhibitors (%)
 mTor (%)












Omega-3 fatty acids and long-term outcome in RTR
Table 1: Continued
Characteristics Mean SD Range (min-max)
Renal function parameters
 Time after transplantation, yr
 Median
 IQR
 Serum creatinine, µmol/l
 Median
 IQR
 eGFR, ml/min per 1.73 m2
 Proteinuria ≥0.5 g/d (%)
 n
 %
 Protein excretion, mg/24h
 Median
 IQR























 LDL cholesterol, mmol/l

































 Total fat intake, g/d
 Total protein intake, g/d
 Total carbohydrates, g/d





















N-3 fatty acid intake
 EPA-DHA intake, mg/d
 Median
 IQR
 Relative amount (En%)
 ALA intake, g/d
 Median
 IQR









Abbreviations: BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, Diastolic 
blood pressure; MAP, mean arterial pressure; CNI, calcineurin inhibitor; mTor, mammalian target of 
rapamycin; FFQ: Food Frequency Questionnaire; eGFR, estimated glomerular filtration rate; LDL, low 
density lipoprotein; HDL, High density lipoprotein; HbA1c, glycated hemoglobin ; Hs-CRP, High-sensitive 





Energy intake was 9117 (SD 2664) KJ/d (2175 (SD 637) kcal/d). Of the total intake, 36 en% 
was derived from fat (saturated fat: 13 en%; monounsaturated fat: 12 en%; polyunsaturated 
fat: 8 en%), 15 en% from proteins and 46 en% from carbohydrates. Median intakes of EPA-DHA 
and ALA were 92 (28-205) mg/d (0.04 (0.01-0.09) En%) and 1.2 (0.9-1.7) g/d (0.5 (0.4-0.7) En%) 
respectively. According to the European Food Safety Authority (EFSA), intake of EPA and DHA 
was below the recommended combined intake of 250 mg of EPA plus DHA per day in 524 RTR 
(82%), while intake of ALA was in accordance with the guidelines (0.5 En%) in 352 RTR (55%) 
[19]. Patient characteristics according to tertiles EPA-DHA and ALA intake (En%) are shown in 
Supplementary Table 1 and Supplementary Table 2 respectively.
The associations of baseline characteristics with intake of n-3 fatty acids are shown in 
Table 2. Age was found to be positively associated with the marine-derived n-3 fatty acids 
(β = 0.094, p = 0.02), while age was inversely associated with intake of plant-derived ALA 
(β = -0.093, p = 0.02). In addition, moderate alcohol intake (β = 0.197 p < 0.001) and former 
smoking habits (β = 0.128 p = 0.01) were positively associated with EPA-DHA intake, while there 
was no association with ALA intake. Furthermore, total fat intake (β = -0.157 p < 0.001) and total 
carbohydrate intake (β = -0.272, p < 0.001) were inversely associated with EPA-DHA intake, while 
total fat intake (β = 0.318, p < 0.001) had a positive association with ALA intake. Carbohydrate 
intake was not associated with ALA intake. We found no significant interactions of n-3 fatty acid 
intake with potential explanatory variables for the association with graft failure and all-cause 
mortality.
For prospective analyses, median follow-up was 3.1 (2.7-3.8) years. During the follow-up period, 
41 RTR developed graft failure, while 67 died.
Results for Cox regression analyses for graft failure are shown in Table 3. Neither EPA-DHA 
nor ALA intake appeared to be associated with graft failure (hazard ratio (HR)= 0.83; 95% CI 0.50, 
2.27; and HR=0.90; 95% CI 0.74, 1.09 respectively per 0.1 En% difference) while treating intakes 
as continuous variables. Findings were similar when intakes were treated as tertiles.
Results of Cox regression analyses for all-cause mortality are shown in Table 4. In age 
and sex adjusted analyses, with EPA-DHA intake treated as a continuous variable, there was no 
association with all-cause mortality (HR=0.79; 95% CI 0.54, 1.15 per 0.1 En% difference), while 
ALA intake was significantly associated with increased all-cause mortality risk (HR=1.17; 95% CI 
1.04, 1.31 per 0.1 En% difference) (Model 1) (Figure 1A). Moreover, RTR in the highest tertile of 
ALA intake (> 0.60 En%) were at 2-fold higher risk of all-cause mortality (HR=2.21; 95% CI 1.23, 
3.97) than those in the lowest tertile (reference tertile) (< 0.45 En%). Associations remained 
materially unchanged after cumulative adjustment for potential explanatory variables, including 
BMI, diastolic blood pressure, alcohol intake, smoking behavior, fat, protein and carbohydrate 
intake, and proteinuria.
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Table 2: Regression coefficients for the association between baseline EPA-DHA and ALA intakes with baseline 


















 Heart rate, bpm
Dietary intake (FFQ)
 Total fat intake, g/d
 Total protein intake, g/d
 Total carbohydrates, g/d





 Antihypertensives (% yes)
 Statines (% yes)
Renal function factors
 Serum creatinine, µmol/l
 eGFR, ml/min per 1.73m2
 Albuminuriaa , mg/24h























































































































Abbreviations: BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, Diastolic 
blood pressure; MAP, mean arterial pressure; CNI, calcineurin inhibitor; mTor, mammalian target of 
rapamycin; FFQ: Food Frequency Questionnaire; eGFR, estimated glomerular filtration rate; LDL, low 
density lipoprotein; HDL, High density lipoprotein; HbA1c, glycated hemoglobin; Hs-CRP, High-sensitive 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In secondary analyses, the association of ALA intake with all-cause mortality was analyzed using 
g/d instead of En%. In age- and sex-adjusted analyses, RTR in the highest tertile of ALA intake 
(> 1.45 g/d) were at almost 2-fold higher risk of all-cause mortality (HR=1.90 95% CI 1.07, 3.37) 
compared to the lowest tertile (reference tertile) (< 1.14 g/d). Our findings did not change after 
further cumulative adjustment for potential explanatory variables. We also calculated the intake 
of ALA as a proportion of the total intake of fatty acids. It remained that there was no association 
of ALA intake (now expressed as proportion of total fatty acid intake) with graft failure (HR=0.93; 
95% CI 0.80, 1.08 per 0.1% difference). It also remained that there was an association of ALA 
intake (now expressed as proportion of total fatty acid intake) with increased risk for mortality 
(HR=1.14; 95% CI 1.02, 1.27 per 0.1% difference, p = 0.02).
In sensitivity analyses, we excluded patients with extreme intakes of n-3 fatty acids. Hazard 
ratios of EPA-DHA and ALA intakes for graft failure and all-cause mortality remained materially 
unchanged, with no associations for graft failure, and HR=0.78; 95% CI 0.50, 1.22 and HR=1.21; 
95% CI 1.06, 1.37 per 0.1 En% difference for the associations of EPA-DHA and ALA intake with 
all-cause mortality respectively (Figure 1B).
DISCUSSION AND CONCLUSION
Our study is, to the best of our knowledge, the first to separately investigate the associations of 
the marine-derived n-3 fatty acids EPA and DHA and the plant-derived n-3 fatty acid ALA with 
long-term outcome in a large cohort of RTR. Both EPA-DHA and ALA intake were not associated 
with graft failure. Additionally, EPA-DHA intake was not associated with all-cause mortality, while 
ALA intake was positively associated with all-cause mortality.
The n-3 fatty acids EPA, DHA and ALA are long-chain polyunsaturated fatty acids (PUFAs). 
EPA and DHA are mainly found in fatty fish, whereas vegetable oils, such as linseed, soybean and 
rapeseed oils, are main sources of ALA. [20,21]. According to the EFSA, the combined intake of 
EPA plus DHA was found to be below the recommended intake in 82% of RTR, while 45% had an 
inadequate intake of ALA. Various recommendations for PUFA intakes are circulating around the 
world [22]. For instance, the ALA intake recommendation in Australia is 2.0 g/d (1 En%), while 
in the USA and Canada the recommended ALA intake is 1.35 g/d (0.7 En%) [23]. According to 
these international guidelines the number of RTR with an ALA intake below the recommended 
daily intake increases enormously.
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Figure 1: Restricted cubic spline showing the association between ALA intake (En%) and all-cause mortality 
in 637 RTR (a) and 632 RTR (b). The line in the graph represents the age and sex adjusted risk for all-cause 




At least two meta-analyses of randomized controlled trials have investigated whether 
fish oil supplementation may improve renal function, rejection rates, and patient and graft 
survival in renal transplant recipients [7,24]. Both these meta-analyses reported that there 
was insufficient evidence to conclude that fish oil has a beneficial effect on either of these 
outcomes. It was mentioned that the meta-analyses were hampered by methodological 
problems, including different doses of fish oils, different duration and timing of treatment, 
studies with small numbers of patients, inadequate randomization and lack of blinding [7]. 
Recently, two studies in a large observational cohort, with 569 allograft failures and 406 deaths 
in 1990 RTR that were followed for 6.8 years, showed significant inverse associations of plasma 
phospholipid concentrations of marine derived n-3 fatty acids with graft failure and mortality 
in renal transplant recipients [25,26]. Interestingly, in a large systematic review of the effects 
of n-3 fatty acids on cardiovascular disease in the general population it was concluded that 
EPA-DHA intake reduces the rates of all-cause mortality, cardiac and sudden death and possibly 
stroke [8]. These authors analyzed ALA separately from EPA-DHA and found that ALA was not 
associated with these positive findings [7,8]. In another systematic review, it was concluded 
that supplementation of EPA and DHA or fish oil has a consistent beneficial effect on serum 
lipids, while this is not the case for supplementation with ALA [27]. This pattern of decrease 
in risk associated with high intake of EPA-DHA, and increase in risk associated with high intake 
of ALA seems also present in studies including biomarkers. A recent study in which circulating 
levels of EPA, DHA and ALA were measured in 60-year old adults showed that high circulating 
concentrations of EPA and DHA were found to be associated with low risk of all-cause mortality, 
while it was found that there was a trend towards an association of high circulating levels of ALA 
with an increased risk for all-cause mortality [28].
In our cohort, there was no association of EPA-DHA intake with all-cause mortality, while a 
high ALA intake was associated with a significantly increased risk of all-cause mortality. The fact 
that the association between the marine-derived n-3 fatty acid intakes and all-cause mortality 
did not reach significance may have been the consequence of the relatively small number of 
cases (67 deaths in a cohort of 637 RTR during a follow-up period of 3.1 years). Indeed, in 
a recent analysis of a cohort study, with 406 deaths in 1990 RTR that were followed for 6.8 
years, it was found that circulating levels of marine n-3 fatty acid in plasma phospholipids were 
inversely associated with all-cause and cardiovascular mortality after renal transplantation [26]. 
Other than in size and duration of follow-up, this study differed from our study with respect to 
percentage of males (67 in de study by Eide et al. vs 57% in our study), percentage of diabetics 
(18.2 vs 24.2%), percentage of former smokers (36.2 vs 45.8%) and eGFR (57 vs 49 ml/min per 
1.73m2), while age (52 vs 53 years), BMI (24.8 vs 26.6 kg/m2) and percentage of current smokers 
(16.0 vs 12.9%) were less dissimilar. Another difference between the studies is the way in which 
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n-3 fatty acid exposure was assessed (i.e. a status marker (n-3 fatty acids in plasma phospholipids) 
in the study by Eide et al. vs intake (FFQ) in our study).
Results regarding the effect of EPA-DHA and ALA intake on graft failure are inconsistent. 
As mentioned before, meta-analyses of randomized-controlled trials on this subject found no 
effect of EPA-DHA on graft failure [7,24], what is in line with our finding of a virtual absence of an 
association of EPA-DHA and ALA intakes with graft failure in RTR. An intervention study in 2344 
post-myocardial infarction patients suggests, however, that a combined intake of 400 mg/d of 
EPA and DHA provides a small beneficial effect on renal function, while this was not the case 
for ALA [29]. A positive effect of EPA-DHA was also suggested by a study of circulating levels of 
EPA and DHA. In an observational cohort study from Norway it was described that high levels 
of marine derived n-3 fatty acids in plasma phospholipids were associated with better allograft 
survival. The authors showed an 11% reduction in risk of graft loss for every 1.0 wt% increase 
in EPA-DHA level [25].
Recently, two authoritative meta-analyses in the field of n-3 fatty acid intake and mortality 
investigated whether there is a threshold for the relation of EPA-DHA intake with outcome 
[30,31]. These studies found that there was a decline in CHD [30,31] and total mortality [31] with 
increasing EPA-DHA intake in the range of EPA-DHA intake from zero to 250 mg/d, while there 
was no further decline in CHD and total mortality with increasing intake beyond 250 mg/d. In our 
cohort, the median EPA-DHA intake was 92.1 (28.2-204.8) mg/d, with only 18% of the population 
consuming more than 250 mg of EPA-DHA per day. So, the EPA-DHA intake in our cohort is rather 
low compared to the threshold determined in the previous meta-analyses.
The reason why a higher ALA intake is associated with increased risk of all-cause mortality 
in RTR is unknown. ALA can be metabolized via at least two pathways. First, ALA is a preferred 
substrate for β-oxidation, with either complete oxidation to CO
2
 and water or incomplete 
conversion to intermediates that may subsequently be employed for the synthesis of fatty acids 
and cholesterol [32,33].
A second route is by conversion of ALA into EPA and subsequently into DHA [32,34]. 
Rate limiting in this pathway are the activities of Δ5 and Δ6 desaturases [35,36]. In renal 
transplant recipients, this route, but also β-oxidation, could be affected by glucocorticoids, 
a class of immunosuppressive drugs used to protect the transplanted kidney from rejection 
[37,38,38]. In our cohort, 99% of the renal transplant recipients were treated with prednisolone. 
Glucocorticoids can depress the activities of ∆5 and ∆6 desaturases, giving rise to altered fatty 
acid precursor/metabolic ratios, possibly including the ALA/EPA-DHA ratio [35,39].
Finally, it is also possible that the association of ALA intake with high mortality risk might 
not be through the intake of ALA itself but rather via its decomposed products produced during 
the baking or frying of ALA rich food [40]. ALA can be found in various widely used vegetable 




hazardous to health and adverse effects may possibly become amplified in susceptible patients, 
such as renal transplant recipients [40].
Strength of the current study is the large population included in the analyses. In total, data 
of 637 RTR were used for analyses what made the results reliable. Another strength of the study 
is the prospective analyses with Cox regression in RTR using 3 year follow-up information of 
patients. Currently, studies on the long-term effects of n-3 fatty acids are especially carried out 
in the general population. In our study we were able to identify specific long-term association 
in our target group that nevertheless needs further investigations of causality. Third strong 
point is the inclusion of intake of ALA in the prospective study. Most studies in the field of n-3 
fatty acids predominantly focus on EPA-DHA intake, while ALA intake might be important as 
well. We analyzed the EPA-DHA and ALA intakes separately, to investigate the specific effects of 
the marine-derived and plant-derived n-3 fatty acids and found a difference between the two.
We acknowledge that our study also has some limitations. The study is an observational 
epidemiological study which may only suggest biological significance. Another limitation of our 
study is the use of an FFQ for measuring dietary intake. Measurements of intake were based on 
self-report which may lead to misclassification, underreporting and overreporting. Furthermore, 
intakes were only measured once at baseline, while changes in intake and clinical parameters 
may appear during the 3-years of follow-up. Last, dietary intake and status form complementary 
information on n-3 fatty acid exposure. The current study made use of dietary n-3 fatty acid 
intake, but not status. A next study should therefore focus on n-3 fatty acid biomarkers also.
In conclusion, in RTR, the EPA-DHA and ALA intakes showed no clear association with graft 
failure. The EPA-DHA intake showed no association with all-cause mortality, while the ALA intake 
was associated with increased all-cause mortality. Although the association between ALA intake 
and all-cause mortality was strong, a causal relationship in RTR is as yet questionable. Further 
investigation on the long-term outcome of n-3 fatty acids, particularly ALA, in RTR is warranted.
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The effect of marine-derived omega-3 polyunsaturated fatty acids (n-3 PUFA) on long-term 
outcome in renal transplant recipients (RTR) remains unclear. We investigated whether marine-
derived n-3 PUFA intake is associated with all-cause and cardiovascular (CV) mortality in RTR. 
Intake of eicosapentaenoic acid plus docosahexaenoic acid (EPA-DHA) was assessed using a 
validated Food Frequency Questionnaire. Cox regression analyses were performed to evaluate 
the associations of EPA-DHA intake with all-cause and CV mortality. We included 627 RTR (age 
53 ± 13 years). EPA-DHA intake was 102 (42–215) mg/day. During median follow-up of 5.4 years, 
130 (21%) RTR died, with 52 (8.3%) due to CV causes. EPA-DHA intake was associated with lower 
risk of all-cause mortality (Hazard Ratio (HR) 0.85; 95% confidence interval (95% CI) 0.75–0.97). 
Age (p = 0.03) and smoking status (p = 0.01) significantly modified this association, with lower 
risk of all-cause and CV mortality particularly in older (HR 0.75, 95% CI 0.61–0.92; HR 0.68, 95% 
CI 0.48–0.95) and non-smoking RTR (HR 0.80, 95% CI 0.68–0.93; HR 0.74, 95% CI 0.56–0.98). 
In conclusion, marine-derived n-3 PUFA intake is inversely associated with risk of all-cause and 
CV mortality in RTR. The strongest associations were present in subgroups of patients, which 
adds further evidence to the plea for EPA-DHA supplementation, particularly in elderly and 
non-smoking RTR.
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INTRODUCTION
Renal transplantation offers superior survival, quality of life, and cost-effectiveness in comparison 
with chronic dialysis treatment [1-8]. Thus, it is considered the “gold standard” treatment for 
most patients with end-stage renal disease. However, compared to age-matched controls in the 
general population, the survival of renal transplant recipients (RTR) continues to be significantly 
lower [9], with cardiovascular (CV) disease as the most important contributor to excess of 
mortality in RTR [10,11].
The consumption of polyunsaturated fatty acids may reduce the CV risk profile. 
Consequently, several countries and organizations such as the World Health Organization have 
made population-based diet recommendations for omega-3 polyunsaturated fatty acids (n-3 
PUFA) intake. Fish are the major food source of the n-3 PUFAs docosahexaenoic acid (DHA, C22:6 
n-3) and eicosapentaenoic acid (EPA, C20:5 n-3). Thus, recommendations of EPA-DHA intake can 
easily be met by following dietary guidelines such as those of the American Heart Association, 
which advises consumption of at least two fish meals per week [11,12].
Evidence from both epidemiologic and interventional studies have shown that EPA and DHA 
may exert beneficial effects on all-cause and CV mortality in both patients with pre-existing CV 
disease as well as in healthy populations [13-19]. Prospective epidemiological studies have shown 
that weekly fish intake is associated with lower rates of coronary heart disease (CHD) mortality 
in men [20-22]. It has also been shown in women that intake of fish and n-3 PUFA are inversely 
associated with risk of CHD death [23]. Furthermore, in a study conducted across 36 countries, 
fish intake was associated with a reduced risk from all-cause and ischemic heart disease mortality 
[24]. In addition, interventional studies have reported a reduction in all-cause mortality in male 
survivors of a myocardial infarction (MI), who were advised to increase their dietary intake of 
oily fish [25]. The largest randomized control trial testing the efficacy of n-3 PUFA for secondary 
prevention of CHD so far included 11.324 patients. It showed a 15% reduction in the primary 
end point of death, nonfatal MI, and nonfatal stroke, and a 20% reduction in all-cause mortality 
in patients receiving n-3 PUFA supplementation [26].
In RTR, a recent observational cohort study performed in a total of 1990 Norwegian 
patients found that high levels of plasma phospholipid marine n-3 PUFA were independently 
associated with better long-term survival late after renal transplantation [27]. However, this 
study was on plasma biomarker status and not on intake per se. Hence, a recent systematic 
report from The Cochrane Collaboration concluded that there is still insufficient evidence to 
recommend fish oil supplementation to improve survival of RTR [28]. Nonetheless, in a recent 
study with relatively short follow-up, we found a trend towards an inverse association of intake 
of marine-derived n-3 PUFA with all-cause mortality in RTR [29].
We therefore set out to update data on intake of marine-derived n-3 PUFA and to extend 




n-3 PUFA intake with all-cause and CV mortality in the cohort of stable outpatient RTR. For this 
purpose, we investigated the intake of EPA and DHA, and evaluated its association with risk of 
all-cause and CV mortality in RTR.
METHODS
Study Design
An observational prospective study was conducted in a large single center RTR cohort [30]. All 
adult (≥18 years old) RTR with a functioning allograft for at least one year after transplantation 
and without known or apparent systemic illnesses (i.e., malignancies, opportunistic infections) 
who visited our outpatient clinic between November 2008 and March 2011 were invited to 
participate in this prospective cohort study. From a total of 817 RTR invited to be enrolled, 707 
(87%) patients signed informed consent. We excluded all patients missing dietary or laboratory 
data, resulting in 627 RTR eligible for the statistical analysis. The present study was conducted 
according to the guidelines settled in the Declaration of Helsinki, and the Institutional Review 
Board approved the study protocol (METc 2008/186).
The primary long-term endpoints of the current study were all-cause and CV mortality 
in RTR. The continuous surveillance system of the outpatient program ensures up-to-date 
information on patient status. We contacted general practitioners or referring nephrologists 
in cases the status of a patient was unknown. The patients were followed until 30 September 
2015, with no loss to follow-up.
Renal Transplant Characteristics
RTR were all transplanted in the University Medical Center Groningen and had no history of drug 
or alcohol addiction according to their patient files. RTR were on standard antihypertensive and 
immunosuppressive therapy. Except for discouraging excess sodium intake and encouraging 
losing weight in overweight individuals, no specific dietary counseling was included as a routine 
regimen, nor was dietary recommendation regarding n-3 PUFA intake advised to participants. 
Relevant characteristics including recipient age, gender, CV history, and transplant information 
were extracted from patient records. Self-report questionnaires were used to obtain information 
on smoking behavior and alcohol intake. Physical activity was assessed using the Short 
Questionnaire to Assess Health-Enhancing Physical Activity (SQUASH) score in time multiplied 
by intensity [31].
Dietary Assessment
Dietary intake was assessed with a semi-quantitative validated food frequency questionnaire 
(FFQ) that was developed at Wageningen University [32]. The questionnaire inquired about intake 
of 177 food items during the last month. For each item, the frequency was documented in times 
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per day, week, or month. The number of servings was recorded in natural units (for example, 
slice of bread or apple) or household measures (for example, cup or spoon). The questionnaire 
was self-administered and filled in at home. All FFQ were checked for completeness on the day 
of the visit to the outpatient clinic by a trained researcher. The results of the FFQ were converted 
into total energy and nutrient intake by using the Dutch Food Composition Table of 2006 [33].
Measurements
All measurements were performed once at baseline during a morning visit to the outpatient 
clinic. Body weight and height were measured with patients wearing indoor clothing without 
shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared (kg/m2), and body surface area (BSA) was estimated in meters squared (m2) [34]. 
Blood pressure, heart rate, and mean arterial pressure were measured according to a strict 
protocol and determined with a semi-automatic device (Dinamap 1846, Critikon, Tampa, FL, 
USA). Blood pressure and heart rate were measured every minute for 15 min, and the last three 
measurements were averaged [35].
Blood was drawn after a fasting period of 8–12 h, which included no medication intake. 
Diabetes was defined as use of antidiabetic medication, fasting plasma glucose ≥7.0 mmol/L 
[36] or glycated hemogloblin (HbA
1C
) higher than 6.5 as proposed by Shabir et al. [37]. Serum 
creatinine levels were measured with a modified version of the Jaffé method (MEGA AU 510, 
Merck Diagnostica, Darmstadt, Germany). Serum cystatin C concentrations were measured by 
Gentian Cystatin C Immunoassay (Gentian AS, Moss, Norway) on a Modular analyzer (Roche 
Diagnostics, Mannheim, Germany). Renal function was assessed by the estimated glomerular 
filtration rate (eGFR) based on the CKD-EPI equation of creatinine/cystatine C developed as 
proposed by Terpos et al. [38].
Serum albumin, high-sensitivity C-reactive protein (hs-CRP), HbA
1C
, triglycerides, low-
density lipoprotein (LDL)-, high-density lipoprotein (HDL)-, and total cholesterol were measured 
according to routine laboratory methods. According to a strict protocol, all RTR were asked 
to collect a 24-h urine sample during the day before their visit to the outpatient clinic. Total 
urinary protein concentration was determined using the Biuret reaction (MEGA AU 150, Merck 
Diagnostica, Darmstadt, Germany). Proteinuria was defined as urinary protein excretion ≥0.5 
g/24 h.
Statistical Analyses
Data analysis was performed using SPSS version 22.0 software (IBM Corp., Armonk, NY, USA), 
STATA version 13 (StataCorp LP, College Station, TX, USA) and R version 3.2.3 (R Foundation for 
Statistical Computing, Vienna, Austria). In all analyses, a two-sided p < 0.05 was considered 
significant. Continuous variables were summarized using mean (standard deviation, SD) 




(interquartile range (IQR)); percentages were used to summarize categorical variables. Marine-
derived n-3 PUFA intake was accounted as the sum of EPA and DHA intake (100 mg/day) adjusted 
for total energy intake (kJ/day) according to the residual method [39].
Linear regression analyses were performed to evaluate the association of marine-derived 
n-3 PUFA intake with baseline characteristics. Natural log transformation was used for analyses 
of variables with a skewed distribution. Schoenfeld residuals of EPA-DHA intake (per 100 mg) 
were checked: the assumption of proportional hazards was not violated (p = 0.65).
In prospective analyses, Cox-proportional hazard regression analyses were performed 
to investigate the associations of marine-derived n-3 PUFA intake as continuous variable, with 
all-cause and CV mortality in RTR. Analyses were performed with adjustment for age and sex 
(Model 1) and additional adjustment for eGFR, proteinuria, and time between transplantation 
and baseline measurement (Model 2). To avoid the inclusion of too many variables for the 
number of events, further models were performed with additive adjustments to model 2. We 
performed additional adjustment for smoking status, alcohol use, and physical activity (Model 
3); for BMI, diabetes mellitus, and CV history (Model 4); for LDL-, total cholesterol, triglycerides 
concentration, and systolic blood pressure (Model 5); for hs-CRP and albumin concentration 
(Model 6). Hazard ratios (HR) of Cox-regression models are reported with 95% confidence interval 
(CI).
In secondary analyses, we performed stratified analyses according to subgroups of age, sex, 
BMI, diabetes, cardiovascular history, renal function, smoking status, alcohol use, and physical 
activity. We also tested for interaction to identify potential effect modification.
RESULTS
Baseline Characteristics
Baseline characteristics of RTR are shown in Table 1. A total of 627 patients were included. At a 
median (IQR) of 5.7 (2.0-12.2) years after transplantation, participants were 53 ± 13 years old and 
56.3% were male. The patients were slightly overweight (BMI 26.6 ± 4.7), and 152 (24.2%) had 
diabetes. Mean blood pressure of RTR was within normal boundaries (136 ± 17/83 ± 11 mmHg). 
It should, however, be noted that 552 (88%) of the 627 participants were using antihypertensive 
drugs. Mean eGFR was 45 ± 19 mL/min/1.73 m2 and 139 (22.2%) patients had proteinuria. Mean 
serum total cholesterol was 5.1 ± 1.1 mmol/L, while statins were taken by 333 (53.1%) of the 
RTR. Eighty-seven percent of RTR reported the use of alcohol and 12.3% were current smokers. 
Smoking status was unknown in 25 (4.0%) of RTR. Total energy intake was 8756 (7224–10,636) 
kJ/day. EPA, DHA, and DHA-EPA intake were 39 (13–85), 60 (28–129), and 102 (42–215) mg/day, 
respectively.
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Table 1: Baseline characteristics of RTR, and association of energy adjusted EPA-DHA intake across clinical 
parameters.
Clinical Variables All Patients EPA-DHA Intake (100 mg/Day)
Std. β P
No. of patients 627 - -
DHA, mg/day 60 (28 - 129) - -
EPA, mg/day 39 (13 - 85) - -
EPA-DHA, mg/day 102 (42 - 215) - -
Demographics
Age, years 53 ± 13 0.13 0.001
Ethnicity (Caucasian), n (%) 625 (99.7) 0.03 0.46
Sex (male), n (%) 353 (56.3) 0.04 0.39
Body mass index, kg/m2 26.6 ± 4.7 0.08 0.04
Body surface area, m2 1.9 ± 0.2 0.01 0.78
Cardiovascular history, n (%) 251 (40.0) 0.04 0.28
Renal transplantation characteristics
Pre-emptive transplantation, n (%) 102 (16.3) 0.003 0.93
Time between transplantation and 
baseline, years
5.7 (2.0 – 12.2) - 0.002 0.95
Hemodynamic parameters
Systolic blood pressure, mmHg 136 ± 17 0.001 0.98
Diastolic blood pressure, mmHg 83 ± 11 0.03 0.41
Mean arterial pressure, mmHg 108 ± 15 0.02 0.71
Hearth rate, beats per minute 69 ± 12 0.01 0.78
Antihypertensives, n (%) 552 (88.0) - 0.04 0.34
Renal function parameters
Creatine, umol/L 123 (99 - 159) 0.005 0.91
Cystatine-C, mg/L 1.7 (1.3 – 2.2) - 0.06 0.13
eGFR, ml/min/1.73 m2 45 19 - 0.01 0.83
Proteinuria ≥0.5 g/day, n (%) 139 (22.2) - 0.02 0.55
Glucose homeostasis
Glucose, mmol/L 5.3 (4.8 – 6.0) 0.06 0.14
HbA1c, % 5.8 (5.5 – 6.2) 0.05 0.27
Diabetes, n (%) 152 (24.2) 0.02 0.60
Antidiabetic medication, n (%) 98 (15.6) 0.02 0.67
Serum parameters
Albumin, g/L 43 ± 3.0 - 0.02 0.67





Clinical Variables All Patients EPA-DHA Intake (100 mg/Day)
Std. β P
Lipids
Total cholesterol, mmol/L 5.1 ± 1.1 0.08 0.06
LDL cholesterol, mmol/L 3.0 ± 0.9 0.06 0.13
HDL cholesterol, mmol/L 1.3 (1.1 – 1.7) 0.07 0.10
Triglycerides, mmol/L 1.7 (1.2 – 2.3) - 0.01 0.75
Statin use, n (%) 333 (53.1) 0.02 0.57
Health lifestyle
Current smoker, n (%) 77 (12.3) - 0.008 0.85
Alcohol consumer, n (%) 547 (87.2) - 0.14 < 0.001
Physical activity, intensity x hours 5250 (2400 - 8160) 0.03 0.41
Total energy intake, kj/day 8756 (7224 – 10,636) - -
Abbreviations: RTR, renal transplant recipients; EPA, eicosapentaenoic acid; DHA, docosahexaenoic 
acid; eGFR, estimated glomerular filtration rate; HbA1C, glycated hemoglobin; hs-CRP, high-sensitivity 
C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; kJ, kilojoule.
Association between Intake of Marine-Derived n-3 PUFA with Clinical Baseline 
Characteristics
The association between EPA-DHA intake with clinical baseline characteristics is shown in Table 1. 
EPA-DHA intake was positively associated with age (std.β = 0.13, p = 0.001) and BMI (std.β = 0.08, 
p = 0.04), and was negatively associated with alcohol use (std.β = −0.14, p < 0.001).
Results of multivariate Cox-proportional hazard regression analyses are shown in Table 2. 
During follow-up of 5.4 (4.9–6.0) years, 130 (20.7%) RTR died. EPA-DHA intake was associated 
with lower risk of all-cause mortality (Model 2: HR 0.85; 95% CI 0.75–0.97, p = 0.02) independent 
of potential confounders including age, sex, eGFR, proteinuria, and time between transplantation 
and baseline. This inverse association remained significant after additional adjustment for other 
potential confounders. The association of EPA-DHA intake with CV mortality was of similar 
magnitude, but did not reach statistical significance (Model 2: HR 0.83, 95% CI 0.68–1.02, 
p = 0.08).
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Table 2: Prospective analysis of EPA-DHA intake (100 mg/day) on all-cause and CV mortality in RTR.
Model EPA-DHA Intake, 100 mg/Day
HR (95% CI) P
All-Cause Mortality
Model 1 0.87 (0.77 – 0.99) 0.03
Model 2 0.85 (0.75 – 0.97) 0.02
Model 3 0.87 (0.77 – 1.00) 0.04
Model 4 0.87 (0.76 – 0.99) 0.03
Model 5 0.84 (0.73 – 0.96) 0.01
Model 6 0.85 (0.74 – 0.97) 0.02
CV Mortality
Model 1 0.85 (0.69 – 1.05) 0.13
Model 2 0.83 (0.68 – 1.02) 0.08
Model 3 0.86 (0.70 – 1.07) 0.18
Model 4 0.84 (0.68 – 1.03) 0.10
Model 5 0.81 (0.64 – 1.01) 0.06
Model 6 0.82 (0.65 – 1.03) 0.08
Abbreviations: RTR, renal transplant recipients; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; 
CV, cardiovascular.
Model 1: adjustment for age and sex. Model 2: model 1 + adjustment for estimated glomerular filtration 
Rate, proteinuria, and time between transplantation and baseline measurement. Model 3: model 2 + 
adjustment for smoking status, alcohol use, and physical activity. Model 4: model 2 + adjustment for 
body mass index, diabetes mellitus and cardiovascular history. Model 5: model 2 + adjustment for total 
cholesterol, low-density lipoprotein-cholesterol, triglycerides concentration, and systolic blood pressure. 
Model 6: model 2 + adjustment for high-sensitivity C-reactive protein and albumin concentration.
In secondary analyses, we found effect modification of age (p = 0.03) and smoking status 
(p = 0.01) on the association of EPA-DHA intake with all-cause mortality, independent of age 
and sex (Figure 1). Consequently, we proceeded with further prospective stratified-analyses by 
subgroups of age (< or ≥63 years old) and smoking status (non-smokers or smokers), as depicted 




Figure 1. Stratified-analysis of the association of EPA-DHA intake with all-cause mortality in RTR. Hazard 
ratios adjusted for age and sex are shown. Subgroups with p-interaction < 0.05 were considered effect 
modifiers on the association of EPA-DHA intake with all-cause mortality.
EPA-DHA intake was associated with lower risk of all-cause mortality within the older subgroup of 
patients (Model 2: HR 0.75; 95% CI 0.61–0.92, p = 0.01) but not within the younger subgroup of RTR 
(Model 2: HR 0.98; 95% CI 0.85–1.18, p = 0.8). Likewise, EPA-DHA intake was associated with lower risk of 
CV mortality within the older subgroup of RTR (Model 2: HR 0.68; 95% CI 0.48–0.95, p = 0.02), but not in 
the younger subgroup of patients (Model 2: HR 1.02; 95% CI 0.80–1.29, p = 0.9).
DISCUSSION
In this study, we show that marine-derived n-3 PUFA intake is inversely associated with risk of 
all-cause mortality in a large cohort of stable outpatients RTR, and we show an association of 
similar magnitude—though not statistically significant—of marine-derived n-3 PUFA intake on 
the risk of CV mortality in RTR. We also show that age and smoking status are effect-modifiers 
of the association of marine-derived n-3 PUFA intake with all-cause mortality. Accordingly, 
further prospective age-stratified analysis shows that marine-derived n-3 PUFA intake is inversely 
associated with risk of all-cause and CV mortality within the older (cut-off point 63 years old), 
but not the younger subgroup of RTR. Likewise, prospective smoking status-stratified analysis 
shows that marine-derived n-3 PUFA intake is inversely associated with risk of all-cause and CV 
mortality within the non-smoker patient subgroup, but not within the subgroup of smoker RTR.
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In the general population, it has been largely shown that marine-derived n-3 PUFA 
intake may exert beneficial effects on both CV endpoints and all-cause mortality [13-19]. The 
mechanisms by which increased ingestion of n-3 PUFAs exert favorable effects on CV health 
are not fully known; however, it has been proposed that reducing susceptibility of the heart to 
ventricular arrhythmia, retarding growth of atherosclerotic plaques, reducing adhesion molecule 
expression, reducing platelet-derived growth factor, promoting nitric oxide-induced endothelial 
relaxation and anti-inflammatory effects may be underlying mechanisms involved [13].
Up-to-date results regarding their potential beneficial effects on survival after renal 
transplantation remain controversial thus far. Previously, Eide and colleagues reported that in a 
cohort of 1990 Norwegian RTR with 406 deaths events at a median follow-up of 6.8 years, higher 
plasma phospholipid marine n-3 PUFA levels were independently associated with better patient 
survival in RTR [40]. Importantly, this study was not performed on intake per se, but on plasma 
biomarker status of marine-derived n-3 PUFA, which is a resultant of intake and metabolism. 
However, a recent systematic report from the Cochrane Collaboration concluded that there is 
still insufficient evidence to recommend fish oil supplementation to improve survival of RTR 
[28]. On the basis of the latter statement, it seems that the beneficial effect of marine-derived 
n-3 PUFA on survival of RTR remains under discussion. Importantly, it is critical to consider that 
inconsistent results across the three randomized control trials accounted in this systematic 
review (for the outcome of mortality in RTR) may arise from methodological problems such as 
differing doses of fish oils, duration and timing of treatment, small number of patients, and a 
number of events too low to establish definitive conclusions. Previously, we reported a trend 
towards an inverse association of intake of marine-derived n-3 PUFA with all-cause mortality 
in RTR, with relatively short follow-up of RTR [29]. The current study updated data on n-3 PUFA 
intake and extended follow-up of our cohort. The findings of the current study support the 
notion [17,18,19,27] that marine-derived n-3 PUFAs exert beneficial effects on long-term survival 
after renal transplantation. Moreover, our findings support that favorable outcomes offered by 
marine-derived n-3 PUFA intake may vary among different subgroups of RTR according to age 
and smoking status.
It is not completely understood which are the underlying mechanisms that explain the 
effect modification of age on the association of n-3 PUFA intake with mortality. Despite the 
fact that chronic low-grade inflammation remains after renal transplantation and that many of 
the beneficial effects of n-3 PUFA have been attributed to their anti-inflammatory properties 
[41], we did not find an association of n-3 PUFA intake with inflammatory biomarkers. However, 
it has been shown that independently of any influence on inflammation, n-3 PUFA may be an 
effective intervention against anabolic resistance [42-45], which is known to be one of the main 
causes of age-related sarcopenia. Animal studies have shown that n-3 PUFAs improve whole-




maintain whole-body protein metabolism via mTOR signaling pathways [47]. In healthy young 
adults, n-3 PUFA supplementation has been shown to increase the anabolic response [43], and 
particularly in older adults, an increase of muscle protein synthesis has been reported [42]. 
Thus, one might speculate that the effect modification of age on the association of n-3 PUFAs 
with mortality could be at least partly explained through the beneficial effect of n-3 PUFAs on 
muscle protein synthesis.
Regarding smoking status as an effect modifier, it should be noted that it has previously 
been suggested that oral supplementation of marine-derived n-3 PUFA may have effects that 
are distinct between smokers and non-smokers [48]. Research regarding biomarkers of n-3 
PUFA has already shown that n-3 PUFA biomarkers are lower in smokers. It is noteworthy that 
this relationship was independent of dietary intake of n-3 PUFAs [49]. Furthermore, it has been 
suggested that smoking may affect fatty acid absorption and metabolism [50], including increased 
n-3 lipid peroxidation in smokers [51,52]. Future studies are needed to better understand the 
effect of smoking on the metabolism of n-3 PUFAs.
The strengths of our study include a median follow-up of 5.4 years with all-cause and 
CV mortality as clinically relevant endpoints, without loss of participants due to follow-up. 
Furthermore, our study included a large sample size of the specific setting of stable outpatient 
RTR. Moreover, data was extensively collected, which allowed adjustment for many potential 
confounders of the main results. On the other hand, we acknowledge that the current study 
has several limitations; for example, marine-derived n-3 PUFA intake was measured using a self-
reporting FFQ, which could lead to possible over- or under-reporting of dietary intake. Moreover, 
dietary intake was only measured on baseline and therefore changes in dietary intake during 
the follow-up period might not be accounted for in our analysis. The higher the intra-individual 
variation of n-3 PUFA intake along the follow-up period would be, the greater one would expect 
the benefit of repeated measurement for prediction of outcomes [53,54]. Plasma biomarkers of 
n-3 PUFA were not available in this cohort study. Data regarding plasma status of marine-derived 
n-3 PUFA could have provided better understanding of the relation between dietary intake with 
plasma levels of marine-derived n-3 PUFA biomarkers. Further, CV complications or interventions 
were not documented; therefore, we were unable to assess the effect of dietary intake of n-3 
PUFA on non-fatal CV-events. Additionally, our study population consisted predominantly of 
Caucasian people, which calls for prudence to extrapolate our results to different populations 
with regard to ethnicity. Finally, since the current study is observational by design, no conclusions 
of causality can be drawn from our results.
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CONCLUSIONS
In conclusion, marine-derived n-3 PUFA intake is inversely associated with a lower risk of all-
cause mortality in RTR. Furthermore, according to effect modifiers of this association, the 
beneficial effects of marine-derived n-3 PUFA intake are different over subgroups of RTR. Thus, 
marine-derived n-3 PUFA intake is inversely associated with all-cause and CV mortality in the 
older but not the younger subgroup of patients. In turn, marine-derived n-3 PUFA intake is 
associated with lower risk of all-cause and CV mortality in the non-smoker but not in the smoker 
subgroup of RTR. Our findings support the protective effect of marine-derived n-3 PUFA intake 
on all-cause and CV mortality that has been previously reported. We provide relevant data on 
intake complementary to existing data on plasma biomarkers, further adding to the evidence 
that they are protective. However, due to methodological heterogeneity across different studies, 
further design of multicenter, randomized, double-blind, placebo-controlled trials aimed at 
testing the beneficial effects of marine-derived n-3 PUFA supplementation on mortality of RTR 
are still lacking.
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Supplemental Table 1: Prospective age-stratified analysis of EPA-DHA intake (100 mg/day) on all-cause 
and CV mortality in RTR.
Type EPA-DHA Intake, 100 mg/day
<63 years old ≥63 years old
No. of subjects 474 153
HR (95 % CI) p HR (95 % CI) p
No. of events 65 65
Model 1 0.98 (0.84–1.14) 0.8 0.77 (0.63–0.95) 0.01
Model 2 0.98 (0.84–1.15) 0.8 0.75 (0.61–0.91) 0.01
Model 3 0.98 (0.86–1.17) 0.9 0.78 (0.63–0.96) 0.02
Model 4 0.98 (0.84–1.15) 0.8 0.75 (0.61–0.93) 0.01
Model 5 0.97 (0.82–1.14) 0.7 0.73 (0.59–0.90) 0.004
Model 6 0.98 (0.83–1.17) 0.8 0.73 (0.58–0.91) 0.004
No. of events 25 27
Model 1 1.01 (0.80–1.27) 0.9 0.70 (0.50–1.00) 0.05
Model 2 1.02 (0.80–1.29) 0.9 0.68 (0.48–0.95) 0.02
Model 3 1.04 (0.82–1.32) 0.8 0.68 (0.47–0.99) 0.05
Model 4 1.01 (0.80–1.26) 0.9 0.66 (0.47–0.95) 0.02
Model 5 0.97 (0.74–1.26) 0.8 0.67 (0.46–0.98) 0.04
Model 6 1.02 (0.78–1.31) 0.9 0.65 (0.44–0.96) 0.03
Abbreviations: RTR, renal transplant recipients; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; 
CV, cardiovascular. Model 1: adjustment for age and sex. Model 2: model 1 + adjustment for estimated 
Glomerular Filtration Rate, proteinuria and time between transplantation and baseline measurement. 
Model 3: model 2 + adjustment for smoking status, alcohol use, and physical activity. Model 4: model 
2 + adjustment for body mass index, diabetes mellitus and cardiovascular history. Model 5: model 2 
+ adjustment for total cholesterol, low-density lipoprotein-cholesterol, triglycerides concentration, 
and systolic blood pressure. Model 6: model 2 + adjustment for high-sensitivity C-reactive protein and 
albumin concentration.
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Supplemental Table 2: Prospective smoking status-stratified analysis of EPA-DHA intake (100 mg/day) on 
all-cause and CV mortality in RTR.
Type EPA-DHA Intake, 100 mg/day
Non-smokers Smokers
No. of subjects 525 77
HR (95 % CI) p HR (95 % CI) p
All-cause mortality
No. of events 104 18
Model 1 0.81 (0.69–0.95) 0.01 1.12 (0.89–1.41) 0.3
Model 2 0.80 (0.68–0.93) 0.01 1.15 (0.89–1.48) 0.3
Model 3 0.81 (0.70–0.96) 0.01 1.15 (0.88–1.50) 0.3
Model 4 0.80 (0.68–0.94) 0.01 1.18 (0.88–1.57) 0.3
Model 5 0.80 (0.68–0.94) 0.01 1.11 (0.82–1.50) 0.5
Model 6 0.78 (0.66–0.92) 0.003 1.23 (0.91–1.66) 0.2
CV mortality
No. of events 38 9
Model 1 0.76 (0.57–1.01) 0.05 1.15 (0.85–1.57) 0.4
Model 2 0.74 (0.56–0.98) 0.04 1.16 (0.80–1.69) 0.4
Model 3 0.76 (0.57–1.00) 0.05 1.24 (0.83–1.84) 0.3
Model 4 0.73 (0.55–0.97) 0.03 1.17 (0.79–1.73) 0.4
Model 5 0.76 (0.57–1.02) 0.06 1.03 (0.64–1.67) 0.9
Model 6 0.68 (0.50–0.94) 0.02 1.21 (0.76–1.92) 0.4
Abbreviations: RTR, renal transplant recipients; EPA, Eicosapentaenoic acid; DHA, Docosahexaenoic acid; 
CV, cardiovascular. Model 1: adjustment for age and sex. Model 2: model 1 + adjustment for estimated 
Glomerular Filtration Rate, proteinuria and time between transplantation and baseline measurement. 
Model 3: model 2 + adjustment for alcohol use, and physical activity. Model 4: model 2 + adjustment for 
body mass index, diabetes mellitus and cardiovascular history. Model 5: model 2 + adjustment for total 
cholesterol, low-density lipoprotein-cholesterol, triglycerides concentration, and systolic blood pressure. 
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Background: Glucocorticoid treatment decreases liver insulin sensitivity and may modify fatty 
acid metabolism. We investigated the influence of oral prednisolone on indices for de novo 
lipogenesis (DNLi), stearoyl-CoA desaturase (SCDi) and Δ6-desaturase (D6Di) activity in healthy 
males. In addition, we explored whether the changes may be associated with prednisolone-
induced changes in glucose and lipid metabolism and insulin sensitivity.
Methods: Thirty-two healthy young males (mean ± SD age 22±3 years, BMI 22.4 ± 1.7 kg/m2) were 
allocated to receive prednisolone 7.5 mg/day (PRED7.5; n=12), prednisolone 30 mg/day (PRED30; 
n=12), or placebo (n=8) in a randomized double-blind fashion for 2 weeks. Fatty acid compositions 
of plasma cholesteryl esters (CE), phospholipids (PL) and triglycerides (TG) were measured at 
baseline and on day 14. DNLi, SCDi and D6Di were estimated from product/precursor ratios 
in CE, with DNLi primary deriving from 16:1ω7/18:2ω6, SCDi from 16:1ω7/16:0 and D6Di from 
22:6ω3/20:5ω3. Ratios were also assessed in PL and TG.
Results: In CE, PRED30 increased DNLi by 51.2 [95%CI 14.8 ; 87.6], increased SCDi by 48.6 [18.7 
; 78.5]%, and decreased D6Di by 57.7 [-91.8 ; -23.5]% (p ≤ 0.01 for all, compared to placebo). 
The prednisolone-induced increases in DNLi and SCDi were positively correlated with insulin 
sensitivity (r = 0.35 and 0.50, respectively). Similar results were found in PL and TG.
Conclusion: Prednisolone dose-dependently increases DNLi and SCDi and decreases D6Di in 
plasma CE, PL and TG in healthy males after 2 weeks. The observed unfavorable effects on fatty 
acid metabolism were related to the induction of glucocorticoid-induced insulin resistance.
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INTRODUCTION
Glucocorticoids (such as prednisolone) are anti-inflammatory drugs commonly used to 
treat both acute and chronic inflammatory diseases, including gout, pulmonary infection, 
rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and psoriasis [1,2]. Intake 
of glucocorticoids is high, especially in the US, where the prevalence of oral glucocorticoids in 
the general population is around 1.2% [3]. Glucocorticoid treatment is associated with multiple 
adverse effects, including systemic hypertension, impaired glucose metabolism and overt 
diabetes, dyslipidemia, osteoporosis, muscle and skin atrophy and increased susceptibility 
to infections [4-9]. Furthermore, chronic exposure to increased glucocorticoid levels, e.g. as 
observed in patients with Cushing’s disease, causes unfavorable body fat distribution and 
increased cardiometabolic risk [10].
Glucocorticoids alter metabolic processes. Our previous study indicated that even short 
term use of low-dose glucocorticoids may impair insulin sensitivity in the liver, and modify fatty 
acid metabolism in healthy subjects [11]. Glucocorticoids also stimulate gluconeogenesis which 
could eventually result in an increase in hepatic de novo lipogenesis (DNL) [12-14]. Animal studies 
suggested that glucocorticoids influence other processes of the fatty acids acid metabolism as 
well, i.e. an increase in the activity of stearoyl-CoA desaturase (SCD; also named Δ9 desaturase) 
and a decrease in the activity of Δ6-desaturase (D6D) [15,16]. Whether this also occurs in humans 
is unknown.
DNL via fatty acid synthase ends in the production of palmitic acid (16:0), which can 
subsequently become elongated to stearic acid (18:0) [17]. 16:0 and 18:0 may subsequently 
become desaturated to palmitoleic (16:1ω7), oleic (18:1ω9) and vaccenic (18:1ω7) acids (Figure 
1a) [18,19]. SCD catalyzes the desaturation of 16:0 and 18:0 to 16:1ω7 and 18:1ω9, respectively 
[18]. D6D is a key enzyme in the conversion of 18:2ω6 to arachidonic acid (20:4ω6) and of 
alpha-linolenic acid (18:3ω3) to eicosapentaenoic (20:5ω3) and docosahexaenoic (22:6ω3) acids 
(Figure 1b) [15,16]. An indirect manner to estimate DNL, and the activities of SCD and D6D is by 
calculating their product/precursor ratios, which provide indices for their respective activities.
Studies investigating the effects of oral glucocorticoids on fatty acid metabolism in humans 
have mainly focused on adipose tissue and lipolysis [14,20-22]. To the best of our knowledge, 
there are few studies investigating the effects of glucocorticoids on lipogenesis (DNLindex; DNLi) 
by measuring whole body DNL using indirect calorimetry, but there are no reports from human 
studies on the SCD index(SCDi) and the D6D index (D6Di). In this study, we conducted a post-hoc 
analysis of a 2-week randomized, placebo-controlled, double-blind trial, in which the dose-
dependent effect of oral prednisolone on fatty acid metabolism was investigated in healthy young 
males. As a secondary aim, we investigated whether the changes in fatty acid metabolism may 
be associated with prednisolone-induced changes in fasting metabolic parameters (circulating 




Figure 1a: Major saturated and monounsaturated fatty acids produced by the de novo lipogenesis (DNL). 
1.16:0, 18:0, 16:1ω7, 18:1ω7 and 18:1ω9 dilute the pool of 18:2ω6.
Primary measurements and data analyses were done in plasma CE (DNLi: 16:1ω7/18:2ω6, SCDi: 
16:1ω7/16:0), while secondary measurements and data analyses were performed in plasma PL and 
TG. Extra analyses (CE, PL, TG) DNLi: 16:0/18:2ω6, 18:0/18:2ω6, 18:1ω7/18:2ω6, 18:1ω9/18:2ω6; SCDi: 
18:1ω7/16:0 and 18:1ω9/18:0.
Abbreviations: Acetyl CoA, Acetyl-coenzyme A; CE, cholesteryl esters; DNL, De novo lipogenesisindex; PL, 
phopholipids; TG, triglycerides; SCDi, Stearoyl Coenzym Aindex.
Figure 1b: Elongations and desaturation of polyunsaturated fatty acids by D5D and D6D activities.
Primary measurements and data analyses were done in plasma CE (D6Di: 22:6ω3/20:5ω3), while 
secondary measurements and data analyses were performed in plasma PL and TG. Extra analyses (CE, PL, 
TG) D6Di: 18 :3ω6/18:2ω6; D5Di: 20:4ω6/20:3ω6. Abbreviations: AA, Arachidonic acid; ALA, α-Linolenic 
acid; CE, cholesteryl esters; D5Di, Delta-5-Desaturase index; D6Di, Delta-6-Desaturase index; DHA, 
Docosahexaenoic acid; DPA, Docosapentaenoic acid; EPA, Eicosapentaenoic acid; LA, Linoleic acid; PL, 
phospholipids ; TG, triglycerides.
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PATIENTS AND METHODS
Study design and population
A post-hoc analysis was performed of a randomized placebo-controlled, parallel-group, 
double-blind dose-response intervention study, conducted at the Diabetes Center of the VU 
University Medical Center, and the Metabolic Research Unit of the Academic Medical Center in 
Amsterdam, The Netherlands [11]. Briefly, 32 healthy Caucasian young men were recruited via 
local advertisements. Inclusion criteria included: age 18-35 years; BMI 20-25 kg/m2; and normal 
glucose metabolism defined as fasting plasma glucose (FPG) < 5.6 mmol/l and 2 h glucose < 7.8 
mmol/l following a 75-g oral glucose tolerance test (OGTT). Subjects with a history of any disease, 
use of medication, first-degree relative with type 2 diabetes, smoking history or current smoking, 
shift work, a history of glucocorticoid use and sporting activities more than twice/week were 
excluded from the study. Furthermore, participants with unstable weight in the past 3 months 
were also excluded.
Participants were allocated to receive either prednisolone 7.5 mg once-daily (PRED7.5; 
n=12), prednisolone 30.0 mg once-daily (PRED30; n=12), or placebo (n=8) for a period of 2 
weeks using block randomization. Before randomization and on day 13 of drug-exposure, body 
composition, body fat distribution and liver fat content were quantified. At baseline and on 
day 14 of drug-exposure, glucose kinetics and lipolysis were measured. All measurements were 
conducted following a 12 h overnight fast. Participants refrained from drinking alcohol for a 
period of 24 h before testing and did not perform strenuous exercise for a period of 48 h before 
the study days. The study protocol was approved by an independent ethics committee and 
conducted in accordance with the Declaration of Helsinki. This trial is registered in the ISRCTN 
registry (ID: ISRCTN83991850). All participants provided written consent before participation.
Study Medication
Prednisolone tablets were purchased from Pfizer (Sollentuna, Sweden) and matching placebo 
tablets were obtained from Xendo Drug Development (Groningen, The Netherlands). The tablets 
were encapsulated in order to allow the treatment to be blinded. Study medication was taken 
orally at 08:00 h for 2-weeks, except on days 13 and 14, when it was ingested at 06:00 h.
Clinical parameters
Bodyweight and height were measured at baseline. Body mass index (BMI) was calculated 
as weight in kilograms divided by height in meters squared (kg/m2). Systolic and diastolic 
blood pressure were measured manually by a single experienced investigator following a 30 




performed with 5 min intervals, was used for further analyses. Body composition was measured 
by dual energy X-ray absorptiometry (DEXA) scans (Delphi A; Hologic, Waltham, MA, USA) [23,24].
Metabolic variable analyses
Fasting state blood samples were drawn for the determination of basal glucose, non-esterified 
fatty acid (NEFA), insulin and glucagon concentrations. Plasma glucose concentrations were 
measured with the glucose oxidase method using a Biosen C-line Plus glucose analyser (EKF 
Diagnostics, Barleben/Magdeburg, Germany). Plasma NEFA concentrations were measured with 
an enzymatic colorimetric method (NEFA-C test kit; Wako Chemicals, Neuss, Germany). Insulin 
was determined with an Immulite 2000 system (Diagnostic Products, Los Angeles, CA, USA) that 
employs a chemiluminescent immunometric assay. Glucagon was determined with the Linco 125I 
radioimmunoassay (St Charles, MO, USA). Homeostatic model assessment – Insulin resistance 
(HOMA-IR) was calculated to estimate insulin resistance by using the following equation: (fasting 
glucose (mmol/l) x fasting insulin (µU/l))/22.5 [25].
Fatty acid analyses
EDTA-plasma samples were collected at baseline and after 2-weeks drug-exposure. Analyses of 
fatty acids were performed at the Department of Laboratory Medicine of the University Medical 
Center Groningen, The Netherlands using the methodology as described by Hoving et al. [26]. 
Total lipids were extracted by the method of Folch et al., using 3.75 ml of chloroform-methanol 
(2:1) and a 100 µl EDTA-plasma sample [27]. A shortened version of the method of Kaluzny et 
al. was used to isolate cholesteryl esters (CE), phospholipids (PL) and triglycerides (TG), using 
aminopropyl SPE columns for the separation of the plasma lipid classes (Isolute, Biotage) [28]. 
Fatty acids were transmethylated with methanolic-HCL into fatty acid methyl esters (FAME). The 
samples were extracted with hexane and eventually redissolved into 100 µl hexane. 100 µl of an 
internal standard for the quantification of fatty acids in CE (17:0) (50.1 mg/100 ml chloroform-
methanol, 2:1 v/v) and TG (19:0) (19.9 mg/100 ml chloroform-methanol, 2:1 v/v), both obtained 
from Sigma-Aldrich (Zwijndrecht, The Netherlands), were added before isolation of classes. For 
the quantification of fatty acids in PL, 100 µl of free fatty acid 17:0 (50.0 mg/100 ml methanol), 
obtained from Larodan (Solna, Sweden), was added after isolation of classes. 100 µl Butylated 
Hydroxytoluene (1 g/100 ml methanol) from Sigma-Aldrich (Zwijndrecht, The Netherlands) was 
added to prevent fatty acid oxidation.
Aliquots of 2 µl were injected into an Agilent model 6890 gas chromatography equipped 
with a 50 m x 0.2 mm x 0.11 µm apolar column (CMS WCOT capillary column) and detected with 
an Agilent 7683 series flame ionization detector. FAME were identified by comparing retention 
times with those of known standards. Fatty acids were eventually calculated into mol%. DNLi, 
SCDi and D6Di were primary assessed in plasma CE and secondary in plasma PL and TG.
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Parameters of DNLi, SCDi and D6Di
DNLi, SCDi and D6Di at baseline and after 2-weeks drug-exposure were estimated from their 
product/precursor ratios (PPR) or the ratio of the product to a fatty acid with relatively stable 
status. DNLi was primary assessed as 16:1ω7/18:2ω6. 16:1ω7 is one of the products of DNL and 
might be a more specific marker than 16:0, which is the end product of fatty acid synthase activity 
commonly used for PPR calculations reflecting DNL [22]. An increase in DNL may be expected to 
increase 16:1ω7 and other DNL-derived fatty acids and thereby dilute the relative amount of the 
essential fatty acid 18:2ω6. SCDi was primary assessed as the 16:1ω7/16:0 ratio, a PPR commonly 
used as a marker of SCDi [22,29,30]. D6Di was primary assessed as the 22:6ω3/20:5ω3 ratio. 
Although this is not a direct marker for D6Di, D6D is widely considered to be rate limiting in the 
conversion of 20:5ω3 to 22:6ω3 [16,31,32].
In additional analyses, DNLi, was calculated as 16:0/18:2ω6, 18:0/18:2ω6, 18:1ω7/18:2ω6 
and 18:1ω9/18:2ω6, SCDi as 18:1ω7/16:0 and 18:1ω9/18:0, and D6Di as 20:3ω6/18:2ω6 and 
18:3ω6/18:2ω6 [32]. Furthermore, another desaturase activity enzyme (Delta-5-desaturase 
index; D5Di), operational in e.g. AA (20:4ω6) synthesis, was calculated as 20:4ω6/20:3ω6 
[16,30,33].
Statistical analyses
Data analyses were performed using SPSS statistics (Version 22.0; IBM SPSS Inc. Chicago, IL) and 
GraphPad Prism (Version 5.03; Graphpad Software, La Jolla, CA). Data are presented as mean 
± SD or median (interquartile range (IQR)) in case of skewed data. The change in plasma fatty 
acids (mol%) after 2-week prednisolone or placebo was calculated as Delta% ([Fatty acid study 
end - Fatty acid baseline]/[Fatty acid Baseline] * 100%). The change in DNLi, SCDi and D6Di after 
2-week prednisolone or placebo was also calculated as Delta% ([PPR study end – PPR baseline]/
[PPR baseline] * 100%). Between group changes of fatty acids (mol%) and PPRs were tested with 
ANCOVA, with change in fatty acids or PPR (Delta%) as continuous variable and baseline fatty 
acids or PPR as covariate. PRED7.5 and PRED30 were compared against placebo by post-hoc 
testing. Notable outliers (defined as: 1) values < Quartile 1 (Q1) – 3 * IQR, or 2) values > Quartile 
3 (Q3) + 3 * IQR) were removed before analyses. Between group changes in fasting plasma 
glucose, insulin, glucagon, NEFA, circulating TG (cTG) and HOMA-IR were calculated and tested 
using the same statistical methods. Univariate correlations between change in fasting plasma 
glucose, insulin, glucagon, NEFA, cTG and HOMA-IR, and change in DNLi, SCDi and D6Di were 
assessed using Spearman correlation. All primary analyses were done with data from plasma CE, 
while secondary analyses were performed with data from plasma PL and TG. A P-value < 0.05 





Demographic and clinical characteristics were generally well balanced between groups at 
inclusion (Table 1). Lean body mass (LBM) and total fat mass percentages were on average 81.2 
± 6.1 % and 15.8 ± 3.6 %, respectively. No treatment-related side effects were reported.
In plasma CE, prednisolone did not affect the saturated fatty acids 16:0 and 18:0 
(Supplemental Table 1A). Prednisolone affected the fatty acids 16.1ω7, 18:3ω6 and 20:5ω3. 
Both administration of PRED7.5 and PRED30 resulted in increases of 16:1ω7 by 35.1 [5.0 ; 65.1]% 
(p = 0.02) and 59.9 [95%CI 28.5 ; 90.1]% (p = 0.004), respectively. PRED30, but not PRED7.5, 
resulted in an increase of 18:3ω6 by 60.0 [25.6 ; 94.3]% (p = 0.001) and an increase of 20:5ω3 
by 55.9 [23.2 ; 88.7]% (p = 0.002). In secondary analyses, PRED30, but not PRED7.5, increased 
both 16:0 and 18:0 in plasma TG and 16.1ω7 in plasma PL and TG, while 20:5ω3 in plasma PL was 
increased by both PRED7.5 and PRED30 (Supplemental Table 1B, 1C).
Table 1: Baseline characteristics
Characteristics Placebo PRED7.5 PRED30
n 8 12 12
Age (years) 22 ± 3 22 ± 2 22 ± 3
Weight (kg) 76.9 ± 8.7 74.8 ± 7.2 77.0 ± 5.4
BMI (kg/m2) 22.7 ± 2.1 22.2 ± 1.9 22.4 ± 1.2
LBM (%) 78.6 ± 7.9 82.1 ± 3.9 80.7 ± 2.5
Fat Mass (%) 16.9 ± 4.7 15.9 ± 2.8 14.8 ± 3.5
Systolic BP (mmHg) 117 ± 11 125 ± 9 127 ± 9
Diastolic BP (mmHg) 74 ± 14 72 ± 14 79 ± 13
FPG (mmol/L) 5.1 ± 0.3 5.0 ± 0.2 5.0 ± 0.4
2 h OGTT (mmol/L) 4.2 ± 0.8 4.7 ± 0.9 4.2 ± 1.1
Cholesterol (mmol/L) 4.1 ± 0.9 4.3 ± 0.8 4.1 ± 0.8
HDL-cholesterol (mmol/L) 1.6 ± 0.4 1.4 ± 0.3 1.4 ± 0.3
LDL-cholesterol (mmol/L 2.1 ± 0.6 2.5 ± 0.9 2.4 ± 0.9
Triglycerides (mmol/L) 0.9 (0.6-1.0) 0.6 (0.5-1.0) 0.6 (0.5-0.7)
Data are mean ± SD or median (IQR). Abbreviations: BP, blood pressure; BMI, body mass index; FPG, 
fasting plasma glucose; HDL, high density lipoprotein; IQR, interquartile range; LBM, lean body mass; 
LDL, low density lipoprotein; OGTT, oral glucose tolerance test; PRED7.5, prednisolone 7.5 mg group; 
PRED30, Prednisolone 30 mg group; n, amount.
Prednisolone resulted in a dose-dependent increase in DNLi (p = 0.03), an increase in SCDi 
(p = 0.01) and a decrease in D6Di (p = 0.01) in plasma CE (Table 2). PRED30 resulted in an increase 
of DNLi by 51.2 [14.8 ; 87.6]% (p = 0.01) and an increase of SCDi by 48.6 [18.7 ; 78.5]% (p = 0.003). 
PRED7.5 did cause a numerical increase in DNLi and SCDi, however, this trend was not significantly 
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different compared to placebo. PRED7.5 and PRED30 resulted in dose-dependent decreases of 
D6Di by -44.4 [-77.3 ; -11.5]% (p = 0.01) and -57.7 [-91.8 ; -23.5]% (p = 0.002), respectively. DNLi 
and SCDi were positively correlated (r = 0.83, p < 0.001). DNLi and SCDi were each inversely 
correlated with D6Di (r = -0.71 and -0.63, respectively, both p < 0.001). In secondary analyses, 
the increase in DNLi and decrease in D6Di were also found in PL and TG. The increase in SCDi 
was found in PL, but not in plasma TG (Supplemental Table 2(A-C).
DNLi, SCDi and D6Di were additionally evaluated from other PPRs (Supplemental Table 
2(A-C). PRED30, but not PRED7.5, resulted in increases in DNLi in TG, as observed from the PPRs 
16:0/18:2ω6 and 18:0/18:2ω6. Only PRED30 resulted in an increase of 18:3ω6/18:2ω6 in CE, 
while only a trend towards an increase was found in PL and TG. Prednisolone did not influence 
D5Di in plasma CE, PL and TG.
Overall between-group differences in metabolic variables were observed for FPG, FPI, 
fasting glucagon and cTG (Table 3). PRED7.5 and PRED30 increased FPG by 5.9 [0.9 ; 10.9]% 
(p = 0.02) and 15.0 [9.6 ; 20.4]% (p <0.001) respectively. PRED30, but not PRED7.5, significantly 
increased FPI by 127.3 [54.4 ; 200.2]% (p < 0.001), fasting glucagon by 37.0
[9.8 ; 64.3]% (p = 0.01) and cTG by 65.2 [15.5 ; 114.8]% (p = 0.01). After a 2-week drug-exposure 
an overall difference was found between the three groups in HOMA-IR (p < 0.001). HOMA-IR 
increased in the PRED30 by 172.3 [112.9 ; 231.9]% (p < 0.001).
The prednisolone-induced changes in DNLa, SCDa and D6Da in plasma CE, PL and TG were 
related to prednisolone-induced changes in several metabolic variables (Supplemental Table 3). 
In CE, DNLi and SCDi were positively correlated with FPG (DNLa: r = 0.48, p = 0.01; SCDa: r = 0.60, 
p < 0.001) (Figures 2a and 2b), while D6Di correlated inversely with FPG (r = -0.37; p = 0.05) 
(Figure 2c). FPI was only significantly correlated with SCDi (SCD: r = 0.49, p = 0.01). DNLi and SCDi 
were positively correlated with cTG (DNLi: r = 0.38, p = 0.03, SCDa: r = 0.42, p = 0.02) (Figures 2d 
and 2e), while the D6Da correlated inversely with cTG (r = -0.37, p = 0.05) (Figure 2f). DNLi and 
SCDi were positively correlated with HOMA-IR (DNLi: r = 0.35, p = 0.05; SCDi: r = 0.50, p = 0.01) 
(Figures 2g and 2h), while D6Di did not correlate with HOMA-IR (r = - 0.27, p = 0.17) (Figure 2i). 
Correlations with the DNLi, SCDi and D6Di in PL and TG showed the same overall results. D6Di 
in PL showed an even stronger association with FPG and HOMA-IR compared to the activity in 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Correlations of prednisolone-induced DNLi, SCDi, and D6Di in plasma CE with alterations in fasting 
metabolic parameters and insulin sensitivity. Figures a-c represent correlations between FPG and DNLi (a), 
SCDi (b) and D6Di (c). Figures d-f represent correlations between fasting circulating triglycerides (cTG) and 
DNLi (d), SCDi (e) and D6Di (f). The figures g-i represent correlations between insulin sensitivity measured 
as HOMA-IR and DNLi (a), SCDi (b) and D6Di (c). Abbreviations: CE, plasma cholesteryl esters; cTG, fasting 
circulating triglycerides; D6Di, Delta-6 desaturase index; DNLi, de novo lipogenesis index; FPG, fasting plasma 
glucose; HOMA-IR, homeostatic assessment model – Insulin resistance; PL, plasma phospholipids; SCDi, 
stearoyl-CoA desaturase index.
DISCUSSION AND CONCLUSIONS
To the best of our knowledge, this is the first study that has investigated the effect of 
glucocorticoids on specific parameters of fatty acid metabolism in humans. We determined 
the effects of two doses of oral prednisolone for two weeks on DNLi, SCDi and D6Di in healthy 
young males. Prednisolone administration caused increases in both DNLi and SCDi, while D6Di 
decreased. The increase in DNLi and the decrease in D6Di were observed in plasma CE, PL and 
TG, while the increase in SCDi was only found in CE and PL. The observed prednisolone-induced 
changes in fatty acid metabolism were correlated to alterations in metabolic parameters and 
estimated insulin sensitivity. This study shows that glucocorticoids influence human fatty acid 
metabolism, probably as a consequence of the glucocorticoid-induced changes in metabolic 
parameters.
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Not only at high doses, but also at low doses, glucocorticoid therapy has been shown to 
influence fatty acid metabolism. Prednisolone administration was dose-dependently associated 
with increases in DNLi and SCDi, and a decrease in D6Di. The increases in DNLi and SCDi were 
primary assessed in plasma CE, and confirmed in plasma PL, while plasma TG showed an increase 
in DNLi only. Additional analyses revealed that DNLi in TG also increased, as derived from the 
ratios 16:0/18:2ω6 and 18:0/18:2ω6. Literature data on the effects of glucocorticoids on DNL 
and SCD are scarce. In animals, injections with the synthetic glucocorticoid dexamethasone 
influenced lipid metabolism in broiler chickens by increasing hepatic DNL, as compared to 
saline injection [34]. Two other preclinical experiments showed an increase in SCD following 
exogenous glucocorticoid administration [35,36]. A glucocorticoid-induced increase in SCD was 
also demonstrated in liver microsomal preparations of rats by means of increased conversion 
of 16:0 to 16:1ω7 [37].
We demonstrated that 2-week prednisolone reduces the 22:6ω3/20:5ω3 ratio in CE, which 
was confirmed by subsequent analyses in PL and TG. Experiments performed as early as in 1979 
showed that synthetic glucocorticoids, such as triamcinolone and dexamethasone, depress D6D 
in liver microsomes [37]. More recent studies in rat and cell cultures confirmed that D6D can be 
inhibited by this type of medication [15,36,38,39].
Our findings that prednisolone-induced changes in fatty acid metabolism were strongly 
correlated with alterations in fasting metabolic parameters and changes in insulin sensitivity 
suggests that administration of glucocorticoids may lead to changes in fatty acid metabolism 
through alterations in metabolic parameters. The link between fatty acid metabolism and 
metabolic parameters is in line with several animal and human studies. In an animal study 
conducted in 2004, it was suggested that a local increase of glucocorticoids promotes insulin 
resistance as well as hepatic steatosis and hepatic lipid synthesis [39]. An experiment in broiler 
chickens has been carried out to investigate the influence of dexamethasone on hepatic lipid 
metabolism and the role of insulin in this process. The authors concluded that glucocorticoids 
together with the induced hyperinsulinemia are responsible for the up-regulated hepatic 
lipogenesis [34,40]. In addition, it was shown that an inverse correlation between intrahepatic 
TG content and hepatic insulin sensitivity in 42 non-diabetic obese subjects existed [41]. Another 
study in overweight adolescents showed that elevated intrahepatic TG content is associated with 
insulin resistant glucose metabolism in the liver [42].
Glucocorticoids influence metabolic processes, such as gluconeogenesis, insulin sensitivity 
and insulin secretion [43]. Glucocorticoids may increase gluconeogenesis by stimulating the 
production of the gluconeogenic precursor glycerol through enhanced lipolysis, and by stimulating 
amino acid release through enhanced proteolysis [11,14,43-45]. Furthermore, glucocorticoids 
stimulate the transport and hepatic uptake of these gluconeogenesis precursors, induce 




hormones on gluconeogenesis [43]. The increased gluconeogenesis in the liver causes excessive 
glucose production, resulting in stimulated hepatic DNL [14]. Concomitant upregulation of SCD 
leads to the production of 16:1ω7, 18:1ω7 and 18:1ω9 [19,46]. Upregulated DNL and SCD are thus 
ultimately responsible for lipid accumulation in the liver. Glucocorticoids may increase insulin 
secretion and reduce insulin sensitivity directly, or indirectly by stimulated gluconeogenesis 
[43]. Reduced insulin sensitivity is among the diabetogenic effects of glucocorticoids and might 
eventually, in combination with beta-cell failure, result in overt diabetes [44].
Administration of glucocorticoids in this study was found to decrease D6Di, as derived 
from the ratio 22:6ω3/20:5ω3, suggesting lower conversion of EPA to DHA (Figure 1b). However, 
other product/precursor ratios (i.e. 18:3ω6/18:2ω6), that may also reflect D6Di, did not confirm 
this result. The discrepancy might point at the omission that the conversion of EPA to DHA 
does not merely reflect D6Di, but also elongation and β-oxidation, while the conversion of 
18:2ω6 to 18:3ω6 depends on D6Da only. In our study, a 2-week prednisolone treatment 
resulted in an increase of EPA in all three compartments, while DHA did not change. Based on 
the observed reduction of the 22:6ω3/20:5ω3 ratio and the accumulation of EPA, we speculate 
that glucocorticoids may influence elongation and/or β-oxidation.
This study has some limitations. Plasma fatty acid levels fluctuate in parallel with the feed/
fast cycle. A high or low fat diet consumed on the day before or during the study may differentially 
influence fasting levels of fatty acids in plasma at baseline and study end. One limitation of the 
study is therefore that we did not standardize food intake, or assessed fatty acid intake, on the 
days before testing. However, we did statistically correct for baseline fatty acid status by using 
the ANCOVA test. Another limitation of the study is the use of healthy volunteers. The results 
of this study may therefore not be generalizable to a patient population. A third limitation is 
that we measured DNL and indices of SCD and D6D by calculating the product/precursor ratios 
rather than by measuring activities of DNL, SCD and D6D by methods in which labeled fatty 
acids are added. The indices have been criticized since they can be influenced by factors like diet 
(e.g. MUFA/SFA ratio), lifestyle factors (e.g. exercise training) or hormones (e.g. estrogens) [47]. 
Nevertheless, fatty acid indices are considered a reasonable alternative to investigate changes 
in DNL, SCD and D6D when direct measurements are not feasible [22,48].
Prednisolone-induced changes in fatty acid metabolism were less pronounced in plasma 
TG compared to plasma CE and PL, which may be contra-intuitively. We speculate that this could 
be due to the use of blood samples that were drawn following a 12 h fast. In the postprandial 
state, VLDL-TG carry dietary- and de novo synthesized fatty acids from the liver to peripheral 
tissues resulting in higher VLDL-TG levels. As the half-life of VLDL is about 3- to 4 h [49], these 
higher VLDL-TG levels have normalized after an overnight fast, when residing VLDL-TG fatty acids 
might predominantly derive from adipose tissue. Consequently, postprandial DNL and other 
parameters of hepatic lipid metabolism might be better demonstrable from non-fasting TG.
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The study has several strong points. Most studies in this field investigated the acute or 
chronic effects of prednisolone treatment in patients using a single drug-dose. In the current 
study we exposed healthy young volunteers to two different doses of prednisolone with a 
placebo control, allowing us to investigate the specific effects of prednisolone on metabolic 
parameters and fatty acid metabolism at both low and high doses without any background 
of pathophysiological effects. Another strong point of our study is that we measured fatty 
acid metabolism in three different compartments (i.e. plasma CE, PL and TG), providing the 
opportunity to investigate whether the prednisolone-induced changes in fatty acid metabolism 
were consistent in plasma lipid classes with widely differing functions and half-lives.
In conclusion, 2-week prednisolone administration in healthy young males dose-
dependently increased DNLi and SCDi, and decreased D6Di. In addition, we demonstrated that 
the prednisolone-induced changes in fatty acid metabolism are associated with glucocorticoid-
induced alterations of the metabolic parameters. Further research is necessary to confirm our 
results and understand this complex mechanism in more detail.
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General discussion and conclusions
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Chapter 9
Dairy intake has been suggested to have a positive effect on various cardiovascular risk factors, 
including BMI, fasting glucose and insulin resistance[1,2]. High intake of dairy has also been 
linked to a reduced risk of cardiovascular disease. Cardiovascular disease is still a common cause 
of death worldwide[3,4]. It is well recognized that multiple dietary factors contribute[5]. Fatty 
acids have been proposed as one of these dietary factors. Examples are the industrially produced 
trans fatty acids, which can for instance be found in baked goods and fast food. Fatty acids can, 
however, also have a positive influence on cardiovascular health. For instance, saturated odd-
chain fatty acids from dairy products have been suggested to improve cardiovascular health[6-9]. 
Dairy fat is therefore an interesting target for further research to reduce cardiovascular risk in 
the general population.
One difficult issue concerning investigation of the association between dairy fat intake and 
cardiovascular health is that a perfectly objective measure for dairy fat intake is missing. Usually, 
investigations make use of dietary assessment tools such as food frequency questionnaires, 
which are not fully objective and prone to bias. Fatty acid biomarkers measured in blood might 
be a solution, since these are more objective. However, these methods have not been fully 
investigated. This is especially the case for the trans fatty acid biomarkers trans-C18:1(n-7) and 
CLA. A second issue is that some of the potential dairy fat biomarkers have also been proposed 
as fish fat biomarkers (i.e. C15:0 and C17:0). An important part of this thesis therefore concerns 
the investigation of potential dairy fat biomarkers in the general population. We explored the 
literature for existing biomarkers and investigated a potential new method to be able to measure 
the less common biomarkers. We also explored whether the association between dairy fat 
biomarkers and dairy fat intake was independent of fish fat intake, so that the potential reduction 
in cardiovascular risk factors can mainly be attributed to dairy fat intake. Since former studies 
especially described a reduction in cardiovascular risk due to fish fat intake and the omega-3 
fatty acid supplements EPA and DHA, a minor part of this thesis concerns the effects of the fish 
fat biomarkers on cardiovascular disease, with special attention to the effects in renal transplant 
recipients, which is a patient group with a particularly high risk of cardiovascular disease.
MEASURING DAIRY FAT INTAKE
The traditional way of measuring dairy fats is by using dietary assessment tools such as food 
frequency questionnaires (FFQs), food records or 24-h recalls. The FFQ is the most convenient 
one, since it can capture usual, individual, long-term dietary intakes[10,11]. The use of dietary 
assessment tools remains popular to date, since they are considered easy measurement tools, 
with a low burden for participants[11]. Although these methods provide specific information on 
dairy fat intake, the data are based on self-reporting, and therefore subjective and often biased. 
The methods also rely on memory and may be subject to socially desirable answers[11,12]. This 
may lead to misclassification, underreporting and/or overreporting of dietary fat intake[11,13]. 
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Therefore, in Chapter 2-5 of this thesis, we explored alternative or complementary methods 
for measuring dairy fat intake. In these chapters, we focused on fatty acids as biomarkers for 
dairy fat intake. These biological markers are considered to provide more objective information 
of the dairy fat intake.
In previous years, several papers have reported that the fatty acids C14:0, C15:0, C17:0, trans-
C16:1(n-7), trans-C18:1(n-7) and CLA may be useful biomarkers to predict dairy fat intake[14-
16]. However, up to now, a clear overview of fatty acids that can be used as biomarkers of 
dairy and dairy fat intake was lacking. Therefore, in Chapter 2, we carried out a systematic 
review and meta-analysis to examine which fatty acids are suitable as biomarkers of dairy and 
dairy fat intake in the general population. We reviewed observational studies that assessed the 
association of dairy fatty acids measured in plasma/serum, erythrocytes and adipose tissue with 
dairy and dairy fat intake by a traditional dietary assessment tool (FFQ, Food record, 24-recall). 
The systematic review identified C14:0, C15:0, C17:0, trans-C16:1(n-7), trans-C18:1(n-7) and CLA 
in plasma/serum, erythrocytes and adipose tissue as potential dairy fat biomarkers in the general 
population. Additionally, the meta-analysis confirmed C14:0, C15:0, C17:0 and trans-C16:1(n-7) 
as biomarkers of dairy and dairy fat intake. C15:0 was found to be one of the strongest markers 
among the set of biomarkers investigated in this review. Stronger associations were found with 
dairy fat intake compared to dairy intake as a whole.
In Chapter 2 we identified several limitations concerning the use of fatty acid biomarkers 
for estimation of dairy intake. Firstly, we found that the fatty acids trans-C18:1(n-7) and CLA 
were hardly explored as biomarkers of dairy and dairy fat intake, while these are also thought 
to mainly originate from dairy derived products[17]. Potentially, this might be due to suboptimal 
measurement techniques that are less capable of separating naturally occurring trans-C18:1(n-7) 
from other, often industrially produced, trans-C18:1 fatty acids. Secondly, we found that the 
correlations of dairy fat biomarkers with dairy intake and dairy fat intake were between the 0.10 
and 0.33, which is adjudicated as low. Thirdly, C15:0 and C17:0 can also be found in marine water 
fish and have recently found to be related to DHA, a common fatty acid found in fatty fish[18,19]. 
C15:0 and C17:0 might therefore be invalid biomarkers of dairy fat intake in a population with 
a high fish consumption.
In Chapters 3-5, we describe and use a method that we developed to improve the 
measurement of commonly and less commonly investigated biomarkers. Furthermore, we 
investigated whether the dairy fat biomarkers (single markers or a combination) were associated 
with dairy fat intake, independently of fish fat intake. To do so, we used data from the Lifelines 
Biobank and Cohort study, an observational study with initially healthy participants of the 




used fatty acids as biomarkers of dairy fat intake in plasma from a random subset of 864 
participants[20].
Development of a new method to measure dairy fat biomarkers
In Chapter 3, we described the development of a new method to measure both commonly 
investigated biomarkers and less commonly investigated biomarkers (i.e. trans-C18:1(n-7) and 
CLA) in plasma CE, TG and PL. Up to now, dairy fat biomarkers were mostly measured with a polar 
column with a length of up to 100 m. Such a column does, however, not have the separation 
efficiency to prevent co-elution of trans-C18:1(n-7) acid with other trans fatty acids, rendering an 
uncontaminated measurement of the potential dairy fat biomarker Trans-C18:1(n-7) impossible 
and associations with dairy fat intake impossible to calculate. We therefore developed a new 
method that consisted of a 200 m polar column. These columns are specifically developed to 
allow for better separation between trans-C18:1 fatty acids (i.e. trans-C18:1(n-9))[21]. Now, it 
was possible to measure both commonly and less commonly investigated dairy fat biomarkers 
within a single run. In Chapter 3, we also investigated whether the potential dairy fat biomarkers, 
and especially the less commonly investigated fatty acids trans-C18:1(n-7) and CLA, could be 
detected in all three fractions (plasma CE, TG and PL). In the literature, plasma PL was the most 
recommended fraction to measure fatty acids biomarkers[1,8,9,22-29], while, plasma TG was 
only used in one study[23]. In the LifeLines Cohort, we found that the less commonly investigated 
biomarkers were well-detectable both in plasma TG and plasma PL.
Although the new method has several strengths, it also has drawbacks. For instance, the 
runtime for one sample is almost two hours and analyzing both plasma TG and plasma PL of 
more than 864 samples was therefore a challenge. Furthermore, we measured the dairy fat 
biomarkers in both plasma TG and PL, but not in CE, since the biomarkers of interest were only 
detectable in the former and not in plasma CE. In literature, stronger associations between fatty 
acid intakes and fatty acid biomarkers have been suggested to be present for plasma CE and PL 
compared to plasma TG[27-29]. This might be due to the fact that plasma TG can be influenced 
by recent dietary intakes and de novo lipogenesis, whereas this is less true for plasma CE and 
PL[30]. Despite these limitations, there is up to now no better method to measure the commonly 
and less commonly investigated dairy fat biomarkers in plasma.
An alternative to plasma fatty acids biomarkers are fatty acids measured in adipose tissue. 
In literature, stronger associations between intake and biomarkers can be found when they are 
measured in this tissue[23]. Fatty acid biomarkers measured in adipose tissue reflect long-term 
intake, while fatty acid biomarkers measured in plasma are likely more influenced by short-term 
changes in the diet, especially plasma TG[31]. Given the fact that FFQs capture usual, long-term 
dietary intake, adipose tissue might be a better match compared to plasma. Adipose tissue 
261
Discussion and Conclusions
is, however, not always available in studies, as was also the case in the LifeLines Biobank and 
Cohort study.
Dairy fat biomarkers in the LifeLines BioBank and Cohort Study
In Chapter 4, we investigated the biomarkers trans-C18:1(n-7) and CLA as potential biomarkers 
of dairy and dairy fat intake and compared them with the more commonly used biomarkers. 
Secondly, we investigated whether a combination of biomarkers was a better predictor for dairy 
fat intake compared to single biomarkers.
C15:0, measured in both plasma TG and PL, was found to be one of the best biomarkers from 
the set of investigated biomarkers for the prediction of dairy fat intake, with standardized beta’s 
for the association with dairy fat intake of 0.29 in plasma TG and 0.22 in plasma PL. Significant 
associations with comparable magnitude have been found in the literature before[9,32]. For 
example, a study with more than 3,000 subjects found a correlation of 0.29 between plasma 
C15:0 and dairy fat intake[32]. An even higher correlation was reported in a study of 110 
children[8]. The researchers reported a Spearman rank correlation of 0.43 between the weighted 
percentage of plasma PL C15:0 and dairy fat intake. Significant associations between C15:0 and 
dairy fat intake have been confirmed in fractions such as erythrocytes and adipose tissue. Where 
the association in erythrocytes were slightly lower compared to plasma TG and PL[32,33], the 
associations found in adipose tissue were higher compared to plasma TG and PL[7,24,26]. For 
instance, one study even reported a correlation of 0.71 between adipose tissue C15:0 and dairy 
fat intake[26]. Unfortunately, adipose tissue samples were not available in the LifeLines Biobank 
and Cohort Study.
With regard to trans-C18:1(n-7), until now, only one study, apart from ours, investigated 
the association between plasma trans-C18:1(n-7) and dairy fat intake[14]. This other study found, 
however, no significant association between plasma trans-C18:1(n-7) and dairy fat intake. Most 
other studies used a cluster of trans-C18:1 fatty acids, which is a combination of the rumen-
derived (trans-C18:1(n-7)) and the industrially-derived trans fatty acid (trans-C18:1(n-9)), rather 
than trans-C18:1(n-7) alone[15,34,35]. These studies provided contradicting results, with some 
studies reporting positive correlations with dairy intake[34,35], and others reporting absence 
of a correlation with dairy intake[15].
Plasma CLA may be a predictor of dairy fat intake, alone or in combination with other 
biomarkers. In The LifeLines Biobank and Cohort study, CLA was associated with dairy fat 
intake, with associations stronger for plasma PL than for plasma TG. This is in line with the 
current literature, which mainly consists of research carried out with adipose tissue CLA. For 
instance, a study with 123 participants demonstrated that adipose tissue CLA was associated 
with milk fat intake (r = 0.43)[15]. Furthermore, a more recent study with 3,630 participants 




and demonstrated that adipose tissue CLA was associated with energy-adjusted dairy intake 
(r = 0.24, P < 0.001)[36].
Although in this chapter, we revealed several dairy fat biomarkers, there is also a critical 
note on how we identified these biomarkers. A common way to explore potential biomarkers is 
by comparing the biomarkers against a traditional dietary assessment. Like previous researchers, 
we associated fatty acid biomarkers in plasma with fat intake from the FFQ, which usually 
results in a relatively low correlation between the two[8,14,23,32,37,38]. Whether this is the 
consequence of the biomarker providing a poor reflection of intake, or the dietary assessment 
tool providing a poor reflection of intake, is not completely clear. In addition, it has been shown 
that some of the fatty acids in plasma are not only influenced by dairy fat intake, but can also 
be affected by metabolic processes (e.g. trans-C16:1(n-7) can be influenced by β-oxidation of 
trans-C18:1(n-7)), or by the intake of dietary fibers (e.g. C17:0 can be influenced by inulin), meat 
and coconut oil (e.g. C14:0) [39-42]. It should also be noted that the fatty acid composition 
of dairy fat can vary depending on factors such as cow genetics, forage content, production 
level, duration of lactation, physiological status of the animal, and seasonal variation[43-46]. 
Nevertheless, fatty acid biomarkers can provide an objective estimation of dairy fat intake, while 
this is not the case with the FFQ.
Dairy intake versus Dairy fat intake; unadjusted versus energy-adjusted dairy fat 
intakes
In Chapter 4, it was found that the biomarkers were more strongly associated with dairy fat 
intake compared to dairy intake. This is in line with recent studies. For instance, in a study with 
114 children serum C14:0, C15:0 and C17:0 were all more strongly related to dairy fat intake than 
to dairy intake as a whole[47]. Moreover, a study among 313 participants also demonstrated 
that C14:0, C15:0, C17:0 and trans-C16:1(n-7) were more strongly associated with dairy fat intake 
than with dairy intake as a whole[14]. In Chapter 4, we also found that the biomarkers were more 
strongly associated with energy-adjusted intakes compared to unadjusted intakes (dairy fat 
intake adjusted for energy-intake). That energy-adjusted intakes better relate to dairy and dairy 
fat intake may potentially be due to the fact that energy intake can operate as a confounding 
variable[48].
Are dairy fat biomarkers solid markers for dairy fat intake?
It has been doubted by some researchers whether the association between dairy (fat) intake 
and dairy fat biomarkers is always entirely attributable to dairy intake, because some of the 
dairy fatty acids can also be found in other foods. For example, C15:0 and C17:0 are fatty acids 
that can also be found in fish[19]. Table 1 shows the composition of some of the fatty acids that 
can be found in milk and fish according to the Dutch NEVO table. The question was therefore 
whether C15:0 and C17:0, and other dairy fat biomarkers are reliable solid markers for the 
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prediction of dairy fat intake in the LifeLines population. In Chapter 5, we explored whether 
C15:0 and C17:0 were solid markers of dairy fat intake in the general population. We therefore 
investigated whether the association between the dairy fat biomarkers and total dairy fat intake 
(according to the FFQ) was independent of fish fat intake. We repeated these analyses for other 
biomarkers that are considered dairy fat biomarkers (C14:0, trans-C16:1(n-7), trans-C18:1(n-7). 
We demonstrated that C14:0, C15:0, C17:0, trans-C16:1(n-7), trans-C18:1(n-7) and CLA were 
biomarkers for the prediction of dairy fat intake, while C15:0 and C17:0 appeared unrelated to 
fish fat intake. The same was true for the other investigated dairy fat biomarkers. The biomarkers 
therefore seem valid markers for dairy fat intake in the LifeLines population. Importantly, we 
found these results in a population with a high dairy and low fish fat intake. According to the 
Dutch Food Center (Voedingscentrum), the median intake of fish is approximately 70 g/week[49]. 
This reflects the intake of around 1x fish per two weeks. In the LifeLines population, we found 
a median intake of around 81.9 g/week, which was slightly higher compared to the numbers 
of the Dutch Food Center. The Dutch Food Center currently recommends the intake of one 
portion of fish per week. Potentially, our conclusion would have been different if we had chosen 
to investigate the fatty acids in plasma of populations eating large amounts of fish, such as the 
habitants of Greenland and Japan. The outcome of this study may therefore only apply for 
populations low in fish intake and high in dairy intake.
Table 1: Composition of fat from milk and fish (i.e. salmon and Herring) in the Netherlands
Milk Fish
Full-Fat Semi-Skimmed Skimmed Salmon Herring
g/100g
Total fat 3.4 1.5 0.1 10.8 10.01
SFA 2.2 1.0 0.1 2.5 2.5
MUFA 0.7 0.3 0 5.4 5.1
PUFA 0.1 0 0 2.1 1.8
TFA 0.1 0 0 0 0
% of total fat
C14:0 11.3 5.4 7.8
C15:0 1.0 0.4 0.5
C17:0 0.6 0.2 0.3
T-C16:1 0.2 0 0
T-C18:1 1.7 0 0
EPA 0.1 4.7 5.6
DHA 0 7.9 6.0
The fatty acid composition of the most common potential fat biomarkers in milk and fish.  In this table, 
full-fat, semi-skimmed and skimmed milk are compared to the two most common types of fish that 
are eaten in the Netherlands; i.e. salmon and herring. Numbers are from the online NEVO table 2016 
(https://nevo-online.rivm.nl).  
Abbreviations: C14:0, Myristic acid; C15:0, Pentadecanoic acid; C17:0, Heptadecanoic acid; EPA, 




DAIRY FAT INTAKE AND CARDIOVASCULAR HEALTH
Intake of dairy has been suggested to reduce cardiovascular disease and its risk factors. For 
example, a narrative review concluded that dairy consumption, despite its high saturated fat 
content, may have positive or neutral effects on cardiometabolic risk factors and cardiovascular 
diseases[50]. Additionally, evidence from a prospective cohort study with more than 42,000 
participants demonstrated that the intake of dairy products may reduce the risk of cardiovascular 
mortality[51]. In addition to total dairy intake, fat from dairy products may have beneficial effects 
on cardiovascular risk factors also, including saturated and trans fatty acids. A study with Swedish 
adults demonstrated that C15:0 was inversely associated with weight, waist circumference and 
BMI[1]. Two papers with data from 3,736 US adults found that trans-C16:1(n-7) was associated 
with higher insulin sensitivity, and lower levels of atherogenic dyslipidemia, circulating 
triglycerides, blood pressure and lower incidence of diabetes[52,53]. To investigate whether 
the fatty acids from dairy intake were also associated with a beneficial cardiovascular health 
profile in the Dutch population, we explored the association of commonly and less commonly 
investigated biomarkers with several cardiovascular risk factors in the Lifelines Biobank and 
Cohort study in Chapter 5 of this thesis.
Besides trans-C18:1(n-7), the dairy fatty acids C15:0 and C17:0 in both plasma TG and PL 
exhibited inverse associations with cardiovascular risk factors, especially waist circumference 
and BMI. Our results suggest that waist circumference and BMI may have a mediating effect. 
Furthermore, dairy fat biomarkers may improve cardiovascular health by reducing chronic 
inflammation and uric acid as well. Both hs-CRP and uric acid had strong associations with dairy 
fat biomarkers. 
Recently, two other papers have been published with data from the LifeLines Biobank 
and Cohort study. Where we investigated the association between dairy fat biomarkers and 
cardiovascular risk factors, they investigated the effects of dairy product intake on overweight, 
pre-diabetes and newly diagnosed type 2 diabetes[54,55].The investigators found an inverse 
association between full-fat dairy product intake and overweight (BMI ≥25-30 kg/m2) and obesity 
(BMI ≥30 kg/m2)[55], which is actually in line with our findings for C15:0 and C17:0. Interestingly, 
compared to our own data, the authors found an opposite association of high-fat dairy product 
intake with pre-diabetes and newly diagnosed type 2 diabetes[54].  While we found an inverse 
association between dairy fat biomarkers and diabetes related outcomes (including HbA1c and 
fasting glucose), they found an increase on the risk of pre-diabetes and newly diagnosed type 
2 diabetes with intake of high-fat dairy products. The authors suggested that the association 
between high fat dairy products and diabetes-related outcomes may potentially not depend 
on the ‘fat content’ of a dairy product, but could be related to other attributes of the products 
in the high fat dairy category.  
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FISH INTAKE, FISH FAT BIOMARKERS AND (CARDIOVASCULAR) HEALTH
In the general population, there is abundant evidence that fat from fish may reduce the risk to 
develop cardiovascular diseases[56-59], by reducing inflammatory markers[60]. Potentially, this 
could have been due to a higher intake of C15:0 and C17:0 as described in Chapter 5. However, 
both odd-chain fatty acids proved unrelated to fish fat intake and to fish intake as a whole in 
the LifeLines Cohort. Instead, a strong association was found of EPA and DHA with fish intake 
and fish fat intake. These results are in line with previous studies. In the NQplus study, another 
Dutch cohort with more than 350 adults included, it was found that the omega-3 fatty acids were 
significantly associated with fish intake[11]. Furthermore, EPA and DHA were also associated with 
fish in a cross-sectional study with 110 young children (age 3-10 years)[8]. In addition, a study 
with 192 Asian participants demonstrated that plasma EPA+DHA was significantly associated 
with fish and seafood[61]. Moreover, randomized controlled trials showed that the intake of fish 
oil supplements (which are rich in EPA and DHA) may increase the amount of EPA and DHA that 
incorporates into body compartments such as plasma phospholipids and erythrocytes[62-65]. 
Based on previous and current findings, it is safe to state that up to now, EPA and DHA are the 
best biomarkers of fish fat intake in a high and low fish eating population. 
Intake of fish, omega-3 fatty acids and (cardiovascular) health in renal transplant 
recipients
It has been suggested that omega-3 fatty acids may also have beneficial effects in a patient 
population such as renal transplant recipients (RTR). For instance, EPA and DHA supplements 
have been proposed  to improve renal function, rejection rates and patient survival in RTR, but 
convincing evidence whether it may also improve survival is still lacking[66,67],[68]. Besides 
the marine-derived omega-3 fatty acids EPA and DHA, there is also the plant-derived omega-3 
fatty acid, called α-linolenic acid (ALA)[69], which has only been investigated sporadically. Up to 
now, it was unknown whether both the marine-derived and plant-derived omega-3 fatty acids 
may reduce all-cause and cardiovascular mortality in RTR. In Chapter 6 and 7, we therefore 
aimed to investigate the association between the intake of EPA+DHA and ALA with all-cause 
and cardiovascular mortality in stable RTR patients.
In Chapter 6, EPA-DHA and ALA intakes were estimated separately, so that both the marine-
derived and plant-derived omega-3 fatty acids could be investigated. Firstly, we found a positive 
association between ALA intake and all-cause mortality. The reason why a higher ALA intake is 
associated with increased risk of all-cause mortality in RTR is unknown. However, we know that 
ALA may convert into EPA and subsequently into DHA[70,71]. Rate limiting in this pathway are 
the activities of Δ5 and Δ6 desaturases [72,73]. In renal transplant recipients, this route could be 
affected by glucocorticoids, a class of immunosuppressive drugs used to protect the transplanted 




Secondly, we found a trend towards an inverse association between EPA-DHA intake and 
all-cause mortality in RTR. The contrast between the intake of marine and plant-derived omega-3 
fatty acids is in line with findings reported for the general population[76]. However, the absence 
of an association between EPA-DHA intakes and all-cause mortality is not in line with literature 
on RTR[77,78]. Two observational studies showed a significant inverse association between EPA-
DHA intake or status and all-cause mortality in RTR. The studies included 1,990 Norwegian RTR 
and demonstrated that high levels of plasma phospholipid omega-3 fatty acids were inversely 
associated with mortality. Importantly, these studies were not on omega-3 fatty acid intake 
per se, but on plasma biomarker status of omega-3 fatty acids, which is the outcome of intake 
and metabolism. Furthermore, these studies had a longer follow-up period (6.8 years) with a 
large number of cases (569 developed graft failure and 406 died in a population of 1,990 RTR) 
compared to our study (follow-up period of 3.1 years, during which 41 developed graft failure 
and 67 died in a population of 637 RTR)[78,79]. Potentially, the association between omega-3 
fatty acid intake and all-cause mortality did not reach significance in the current study due to 
the relatively short follow-up period and small number of cases. Therefore, in Chapter 7, we 
updated our database on the intake of omega-3 fatty acids and extended the follow-up period 
(130 deaths in a cohort of 627 with a follow-up period of 5.4 years) to increase the power for the 
association of omega-3 fatty acid intake with all-cause and cardiovascular mortality.
In Chapter 7, we did demonstrate that intake of the omega-3 fatty acids EPA and DHA is 
inversely associated with all-cause mortality in stable outpatient RTR. Additionally, we showed 
an inverse, albeit not significant, association with cardiovascular mortality. This is in line with 
the Norwegian study in 1,990 RTR, which found a weak inverse association between plasma 
EPA-DHA levels and cardiovascular mortality[80]. Additionally, they showed that higher levels 
of plasma EPA-DHA were associated with lower levels of cardiovascular risk markers, including 
fasting plasma glucose and plasma triglycerides. 
Influence of drugs on omega-3 fatty acids
As previously mentioned in the literature, supplementation of the omega-3 fatty acids EPA and 
DHA increases the omega-3 status in humans and may thereby reduce cardiovascular risk[62-
65]. In addition, in this thesis, we discovered an inverse association between EPA and DHA 
status and cardiovascular risk. For instance, an increase in the status of omega-3 fatty acid 
has been suggested to decrease inflammation, and related chronic diseases[81-84]. Secondly, 
we found a positive association between the ALA status and the risk of mortality in RTR. It has 
been suggested that drugs such as glucocorticoids (i.e. prednisolone) may have influence on the 
fatty acid ratios in the body. Glucocorticoids may depress the conversion of ALA into EPA and 
DHA, which results in an inhibition of the EPA+DHA status and accumulation of ALA. Both may 
be related to an increase in cardiovascular risk factors. In addition, glucocorticoid treatment is 
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associated with impaired insulin sensitivity in the liver, diabetes, dyslipidemia and an unfavorable 
body fat distribution[85-88]. 
From animal studies, it has been suggested that glucocorticoids may decrease delta-6-
desaturase activity (D6D), and thereby decrease the formation of omega-3 fatty acids[72,89]. 
Whether this is also the case in humans is unknown. In Chapter 8, we therefore conducted a 
post-hoc analysis of a 2-week randomized, placebo-controlled, double-blind trial in which we 
investigated the dose-dependent influence of prednisolone on a surrogate marker of D6D activity 
in healthy young males. As a secondary aim, we investigated whether the changes in surrogate 
D6Da activity were related with prednisolone induced changes in fasting metabolic parameters 
and insulin sensitivity.
In Chapter 8, we demonstrated as one of the first investigators that a 2-weeks trial of 
prednisolone administration in healthy young males resulted in a dose-dependent decrease in 
surrogate D6D activity. In addition, we demonstrated that the prednisolone-induced changes 
in surrogate D6D activity were related to prednisolone-induced unfavorable alterations in 
metabolic parameters, including circulating triglycerides, fasting glucose and insulin resistance 
(HOMA-IR). The association between prednisolone-induced changes in fatty acid metabolism and 
metabolic parameters was in accordance with other human studies. First of all, a study carried 
out in 2008 showed an inverse correlation between intrahepatic TG content and hepatic insulin 
sensitivity in 42 non-diabetic obese subjects[90]. In addition, a study in overweight adolescents 
showed that an elevated intrahepatic TG content was associated with insulin resistant glucose 
metabolism in the liver[91]. The difference between these studies and our study is that they 
were performed in overweight and obese subjects, while we investigated the association in 
healthy young males.
A limitation of Chapter 8 is that the fatty acid ratios (product/precursor ratios) are not the 
perfect parameters for genuine DNL, SCD and D6D activities. The ratios have been criticized 
since they can be influenced by factors like diet, hormones and lifestyle factors (e.g. exercise)
[92]. An alternative for measuring proxies for the DNL, SCD and D6D activities is by using in vivo 
methods in which stable isotopically labeled fatty acids are employed, in conjunction with ex vivo 
stable-isotope techniques[93]. However, since this was not available in our dataset, calculation 
of product/precursor ratios was considered a reasonable surrogate[94]. 
CONCLUSIONS AND FUTURE PERSPECTIVES
Cardiovascular disease is a common cause of death in the general as well as diseased population. 
Several dietary components, such as fatty acids, may play a huge role in this. Particularly fatty 
acids from dairy and fish have been proposed to reduce the risk of cardiovascular disease. In 
this thesis we explored the association of fatty acids from dairy with overall and cardiovascular 




fat intake. Additionally, we tried to link these biomarkers to cardiovascular health and mortality. 
As a minor part of this thesis, we also investigated the association between omega-3 fatty acids 
and cardiovascular health.
In the LifeLines Dataset, we found that C14:0, C15:0, C17:0, trans-C16:1(n-7), trans-
C18:1(n-7) and CLA measured in plasma TG and PL can be useful biomarkers of dairy fat intake 
for the general population. The associations with dairy biomarkers were independent of fish fat. 
Furthermore, a combination of fatty acids, including at least C15:0 and trans-C18:1(n-7), may 
predict dairy intake even better. We therefore recommend to further investigate a combination 
of dairy fat biomarkers. Furthermore, future research should preferably include analyses of 
fatty acid biomarkers in adipose tissue since the amount of fatty acids in adipose tissue is often 
higher than can be found in plasma or erythrocytes which may therefore show even stronger 
associations between dairy fat intake and fatty acid biomarkers. Thirdly, we would recommend 
to further investigate the laboratory methodology of the dairy fat biomarkers to optimize and 
shorten the analyses. Potentially, measuring the fatty acid in adipose tissue on a 100 m column 
would improve and shorten the analyses due to higher output compared to the current method. 
Furthermore, use of a GC-MS (alone or in combination with a GC-FID) equipped with a 200 m 
column might be a good alternative for the current method. In comparison to the dairy fat 
biomarkers, C15:0 and C17:0 were not found to be strong biomarkers for fish and fish fat intake 
in the present cohort, but we confirmed EPA and DHA to be strong biomarkers for fish and fish 
fat intakes. 
In this thesis, using data from the LifeLines Biobank and Cohort study, we found that an 
increase in dairy fat biomarkers may be related to a decrease in cardiovascular risk factors. 
Associations were especially found for the dairy fat biomarkers C15:0, trans-C18:1(n-7) and CLA 
with BMI and waist circumference. An important limitation of the Lifelines Cohort is that the 
data are observational in nature and that other nutrients in milk and milk products (i.e. lactose, 
milk proteins and micronutrients), total energy intake and expenditure, percentage milk fat of 
total fat intake, and all potential interactions, might also explain some of the current results. 
It is therefore not possible to draw definite conclusions about the causality of the association 
of the fatty acids with cardiovascular risk factors. Furthermore, Lifelines only contained cross-
sectional data which means that data were collected at a single point in time. At the moment, 
LifeLines is collecting prospective data. It is expected that, based on prospective data from other 
cohort studies, that the inverse association between dairy fat biomarkers and risk to develop 
cardiovascular diseases would even be stronger in the prospective dataset of LifeLines. 
In addition to the dairy fat biomarkers, literature suggests that the traditional fish fat 
biomarkers EPA and DHA are related to a beneficial cardiovascular health profile. In addition, we 
found associations in a patient population such as renal transplant recipients. This was shown 
in a large single center RTR cohort in the University Medical Center Groningen. The results of 
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EPA-DHA were in contrast to the results found with ALA. In addition, earlier research suggested 
that in the general population ALA does not have a beneficial effect. Future studies should 
preferably investigate EPA-DHA separately of ALA because of the discrepancy between EPA-DHA 
and ALA found, otherwise this might have influence on the overall outcome. Interestingly, this 
thesis shows that high intake of ALA may even be associated with an increased risk of premature 
mortality in renal transplant recipients. What the mechanism is behind the inverse association 
is not known, however it may be suggested that the inverse association is not directly due to 
ALA status or intake. An explanation might be that the inverse association is actually due to 
the high intake of glucocorticoids. Glucocorticoids may have a negative influence on the ALA, 
EPA and DHA status; i.e. reduced conversion of ALA into EPA and DHA causing accumulation of 
ALA. Further research in this field is therefore necessary to unravel the underlying mechanism 
between the association of ALA status and (cardiovascular) mortality risk in RTR. It is also 
suggested that the inverse association might actually be due to oxidation of ALA during baking 
or frying of ALA rich foods (i.e. oils rich in ALA). Future studies should therefore also investigate 
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In de algemene bevolking komen veel mensen te overlijden door hart- en vaatziekten. 
Voedingscomponenten zijn belangrijke factoren bij de ontwikkeling van en bescherming tegen 
het ontstaan van hart- en vaatziekten. In dit kader worden vetzuren gezien als een belangrijke 
voedingscomponent. Vetzuren zijn onderdeel van een grote diversiteit aan voedselproducten, 
waaronder zuivel, vis en plantaardige oliën. Hiervan zijn vetzuren die voornamelijk in zuivel 
voorkomen bijzonder, omdat in zuivel de diversiteit van de vetzuren die er in voorkomen erg hoog 
is. Daarnaast worden verschillende van de vetzuren die er in voorkomen gezien als uniek voor 
deze voedingsbron. Het gaat hier vooral om twee vetzuren met een oneven ketenlengte (C15:0 
en C17:0), en de natuurlijke transvetzuren Vacceenzuur (Trans-C18:1(n-7)) en Linolzuur (CLA). 
Eén van de redenen waarom het moeilijk is om het verband tussen inname van zuivelvet en 
cardiovasculaire gezondheid te onderzoeken, is omdat een objectieve meetmethode om de 
inname van zuivelvet te meten momenteel ontbreekt. Tot op de dag van vandaag maken 
onderzoekers voornamelijk gebruik van methodes zoals voedselfrequentievragenlijsten of 
voedingsdagboekjes. Deze methodes zijn over het algemeen niet objectief, en kunnen daarom 
een vertekend beeld geven. Het meten van vetzuur biomarkers in het bloed geeft weliswaar 
geen directe informatie over de inname, maar geeft wel objectieve informatie. Tot op heden is 
deze methode nog maar weinig onderzocht. Een andere reden daarvan kan zijn dat biomarkers 
die met zuivelvet worden ingenomen, potentieel ook gezien kunnen worden als biomarkers voor 
visvet inname (vooral C15:0 en C17:0).
In dit proefschrift was ons eerste doel om reeds eerder geëvalueerde (C14:0, C15:0, C17:0 
en Trans-C16:1(n-7)) alsmede nog nauwelijks onderzochte biomarkers (Trans-C18:1(n-7) en CLA) 
voor het voorspellen van zuivel en zuivelvet inname in de algemene bevolking te onderzoeken. 
Hiervoor hebben we een nieuwe methode ontwikkeld waarmee we alle mogelijke biomarkers 
konden meten. Daarnaast hebben we onderzocht of het verband tussen de zuivelvet biomarkers 
en zuivelvet inname onafhankelijk was van visvet inname. Ons tweede doel van dit proefschrift 
was onderzoek te doen naar het verband tussen zuivelvet inname en risicofactoren voor de 
ontwikkeling van hart- en vaatziekten. Daarnaast hebben we ook onderzoek gedaan naar het 
verband tussen visvet inname en risicofactoren voor de ontwikkeling van hart- en vaatziekten. 
Dit hebben we gedaan, om te onderzoeken of een effect van vetzuren in zuivel eigenlijk het 
gevolg zou kunnen zijn van een verhoging van vetzuren in visvet, omdat eerdere publicaties 
vooral een reductie in risicofactoren van hart- en vaatziekten lieten zien naarmate men 
meer visvet at. We hebben hierbij niet alleen gericht op de algemene bevolking, maar ook 
op niertransplantatiepatiënten, omdat dit een patiëntengroep is waarbij het risico op hart- en 




Om te kijken of vetzuren in bloed kunnen dienen als biomarkers voor de inname van zuivel en 
zuivelvet in de algemene bevolking, hebben we in hoofdstuk 2 een systematische review en 
meta-analyse van observationele studies uitgevoerd. Hierbij werden observationele studies 
meegenomen welke het verband bekeken van zuivelvetzuren gemeten in plasma/serum, 
erythrocyten en vetweefsel met zuivel en zuivelvet gemeten met meer traditionele methoden 
(voedselfrequentievragenlijsten, voedingsdagboekjes en 24-uurs “recalls”). De systematische 
review identificeerde C14:0, C15:0, C17:0, trans-C16:1(n-7), trans-C18:1(n-7) en CLA in plasma/
serum, erythrocyten en vetweefsel als mogelijke biomarkers voor zuivelvet inname in de 
algemene bevolking. Daarnaast bevestigde de meta-analyse dat C14:0, C15:0, C17:0 en trans-
C16:1(n-7) als biomarkers voor de inname zuivel en zuivelvet kunnen worden gebruikt. C15:0 
werd geïdentificeerd als één van de sterkste biomarkers.
In het review waren er ook een aantal tekortkomingen die naar voren kwamen aangaande 
het gebruik van vetzuren als biomarkers voor het meten van de inname van zuivelvet. Als eerste 
kwamen we er achter dat trans-C18:1(n-7) en CLA amper waren onderzocht, mogelijk doordat 
de gebruikte meetmethode niet toeliet ze apart te identificeren. De meeste methodes voor 
het meten van vetzuren kunnen namelijk het natuurlijk transvetzuur (trans-C18:1(n-7)) niet 
onderscheiden van andere, voornamelijk industrieel gevormde C18:1 transvetzuren. Ten tweede 
zagen we dat de sterktes van de verbanden tussen de zuivelvetzuren en inname van zuivelvet 
op een schaal van -1.00 tot 1.00 lagen tussen de 0.10 en 0.33, wat gezien word als relatief 
zwakke verbanden. Een van de mogelijke oorzaken is dat biomarkers vaak afzonderlijk worden 
onderzocht, terwijl combinaties mogelijk  sterkere verbanden laten zien. Ten derde kunnen C15:0 
en C17:0 ook gevonden worden in vis. Beide biomarkers werden daarom aangemerkt als minder 
valide biomarkers voor de inname van zuivelvet in een populatie met hoge vis consumptie.
Door de observaties die wij hebben gedaan bij het maken van het review, zijn we in hoofdstuk 
3 begonnen met het ontwikkelen van een nieuwe methode voor het meten van zowel de reeds 
bekende zuivelvetzuren alsmede het meten van de nog veel minder onderzochte zuivelvetzuren 
trans-C18:1(n-7) en CLA in plasma cholesterol esters (CE), triglyceriden (TG) en fosfolipiden (PL). 
De metingen werden uitgevoerd in samples afkomstig uit de Lifelines Biobank. In dit hoofdstuk 
wordt de methode beschreven die we hebben ontwikkeld waarmee trans-C18:1(n-7) van de 
andere transvetzuren onderscheiden kan worden. Dit kon door gebruik te maken van een polaire 
gas chromatografie kolom met een lengte van 200 meter in plaats van de normaal gebruikte 
apolaire kolom met een lengte van 100 meter. De betreffende vetzuren bleken alleen meetbaar 
in plasma triglyceriden en fosfolipiden.
De nieuwe methode die beschreven werd in hoofdstuk 3, is toegepast in hoofdstuk 4. In 
dit hoofdstuk hebben we onderzoek gedaan naar mogelijke biomarkers voor zuivel en zuivelvet 
inname in de algemene bevolking. In dit hoofdstuk werden zowel de bekende als de tot nu 
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toe minder onderzochte biomarkers meegenomen. Ook in dit hoofdstuk is er gebruik gemaakt 
van samples en data van het Lifelines cohort, waarvan de deelnemers afkomstig zijn uit de 
noordelijke drie provincies van Nederland. Van de reeds eerder onderzochte biomarkers bleek 
C15:0 de sterkste enkelvoudige biomarker voor het voorspellen van de inname van zuivelvet 
in de algemene bevolking. De sterkte van het verband van C15:0 met de inname van zuivelvet, 
wederom afgemeten op een schaal die loopt van -1.00 tot 1.00, was 0.29 voor plasma TG en 
0.22 voor plasma PL. De minder onderzochte biomarkers, plasma trans-C18:1(n-7) en CLA, waren 
beide goede vetzuur biomarkers voor het voorspellen van zuivelvet inname (trans-C18:1(n-7): 
0.29 voor plasma TG en 0.27 voor plasma PL; CLA: 0.22 voor plasma TG en 0.27 voor plasma PL). 
Een combinatie van de bekende vetzuren samen met de tot nu toe minder onderzochte vetzuren 
leverde een betere voorspelling voor de inname van zuivelvet in de algemene bevolking dan 
enkelvoudige biomarkers.
Omdat sommige van de vetzuren die worden gezien als biomarkers voor de inname van 
zuivel ook kunnen voorkomen in vis (dit geldt vooral voor C15:0 en C17:0) en daarom soms gezien 
worden als visvet biomarkers, hebben we in hoofdstuk 5 onderzocht of het verband tussen 
inname van zuivelvet en biomarkers voor zuivelvet compleet toe te schrijven was aan inname 
van zuivelvet, of dat sommige biomarkers toch meer de inname van visvet zouden voorspellen. 
C14:0, C15:0, C17:0, trans-C16:1(n-7), trans-C18:1(n-7) en CLA bleken goede voorspellers voor 
de inname van zuivelvet, omdat het verband tussen de biomarkers en de inname van zuivelvet 
onafhankelijk was van de inname van visvet. C15:0 en C17:0 bleken geen goede voorspellers 
voor de inname van visvet.
Zuivelvet biomarkers en cardiovasculaire gezondheid
In de literatuur is terug te vinden dat vet afkomstig uit zuivelproducten risicofactoren van hart- 
en vaatziekten mogelijk kunnen verminderen. Risicofactoren voor het ontstaan van hart- en 
vaatziekten zijn onder meer gewicht, “body mass index”, bloeddruk en cholesterol, maar ook 
meer diabetes gerelateerde risicofactoren en de minder traditionele risicofactoren Hs-CRP 
(inflammatie marker) en urinezuur. In hoofdstuk 5 hebben we dan ook gekeken naar het verband 
tussen de zuivelvet biomarkers en verschillende traditionele, diabetes gerelateerde en minder 
traditionele risicofactoren voor hart- en vaatziekten. Er was duidelijk een gunstig verband 
gevonden tussen de zuivelvet biomarkers C15:0 en C17:0 in plasma TG en C15:0, C17:0 en trans-
C18:1(n-7) in plasma PL met traditionele risicofactoren zoals gewicht, buikomvang, en de “body 
mass index”. Daarnaast zagen we dat er een gunstig verband was tussen zuivelvet biomarkers 




Vis inname en (cardiovasculaire) gezondheid
Er is overvloedig bewijs dat een hoge inname van visvet het risico op hart- en vaatziekten in de 
algemene bevolking verlaagd. Zoals aangegeven in hoofdstuk 5, kon dit mogelijk het geval zijn 
door een gelijktijdige hoge inname van C15:0 en C17:0. Voor beide vetzuren werd een dergelijk 
verband tussen de vetzuren C15:0 en C17:0 met visvet inname echter niet gevonden in het 
Lifelines Cohort, en was het verband tussen de vetzuren en cardiovasculaire risicofactoren niet 
toe te schrijven aan visvet inname. Daarentegen was er een sterk verband tussen de omega-3 
vetzuren eicosapentaeenzuur (EPA) en docosahexaeenzuur (DHA), en de inname van vis en visvet. 
In de literatuur is eerder naar voren gekomen dat EPA en DHA mogelijk een positief effect hebben 
op de cardiovasculaire gezondheid. Dit is niet alleen het geval in de algemene bevolking, maar 
meer nog in patiëntengroepen zoals niertransplantatiepatiënten. Naast de omega-3 vetzuren uit 
vis, bestaat er ook een plantaardig omega-3 vetzuur α-Linoleenzuur (ALA), waar maar sporadisch 
afzonderlijk onderzoek naar is gedaan. Tot op heden was het onbekend of zowel de omega-3 
vetzuren uit vis, alsmede het plantaardige omega-3 vetzuur het risico op hart- en vaatziekten 
bij niertransplantatiepatiënten zou kunnen verkleinen. In de hoofdstukken 6 en 7 hebben we 
daarom onderzoek gedaan naar het verband tussen de inname van EPA+DHA en ALA met sterfte 
aan hart- en vaatziekten bij stabiele niertransplantatiepatiënten.   
In hoofdstuk 6 werd de inname van EPA+DHA en ALA apart vastgelegd, zodat beide typen 
omega-3 vetzuren apart konden worden onderzoekt. Ten eerste vonden we een positief verband 
tussen de inname van ALA en sterfte. Ten tweede zagen we een neiging naar een beschermend 
verband tussen de inname van EPA+DHA en sterfte. Mogelijk vonden we hier geen significant 
verband, doordat de patiënten nog relatief kort gevolgd waren (gemiddeld 3,1 jaar), wat er 
voor zorgde dat er maar weinig te onderzoeken gevallen waren (67 doden in een cohort van 
637 patiënten). Voor hoofdstuk 7 hebben we daarom de database aangevuld;  de patiënten 
werden langer gevolgd (gemiddeld 5,4 jaar), wat er toe leidde dat er meer te onderzoeken 
gevallen waren (130 doden in een cohort van 627). Het verband tussen de inname van omega-3 
vetzuren EPA+DHA en de kans op sterfte kreeg hierdoor meer kracht. We hebben in dit hoofdstuk 
dan ook gevonden dat er een beschermend verband was tussen de inname van de omega-3 
vetzuren EPA en DHA en sterfte in stabiele niertransplantatiepatiënten. Verder hebben we in dit 
hoofdstuk een neiging naar een beschermend effect voor het optreden van sterfte aan hart- en 
vaatziekten gevonden.
De reden waarom een hogere ALA inname in niertransplantatiepatiënten is verbonden 
met een verhoogde kans op voortijdig overlijden is niet bekend. Het is wel bekend dat ALA kan 
worden omgezet naar EPA, en vervolgens naar DHA. In niertransplantatiepatiënten kan deze 
omzettingsroute mogelijk worden geblokkeerd door het chronisch gebruik van glucocorticoïden. 
Glucocorticoïden hebben mogelijk een negatieve beïnvloeding op de EPA en DHA status, wat 
weer kan resulteren in een verslechtering van de cardiovasculaire gezondheid. Uiteindelijk kan 
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dit dan leiden tot een hogere kans op voortijdig overlijden. In hoofdstuk 8 hebben we onderzocht 
wat voor effect glucocorticoïden hebben op de EPA en DHA status bij gezonde jonge mannen. 
Daarnaast hebben we het verband tussen eventuele veranderingen en risicofactoren voor hart- 
en vaatziekten onderzocht. Informatie van dierexperimenten suggereert dat glucocorticoïden 
de activiteit van het enzym delta-6-desaturase negatief beïnvloeden, wat kan leiden tot 
een verminderde omzetting van ALA naar EPA en DHA. We hebben in een 2-weken durend 
onderzoek naar het effect van inname van het glucocorticoïd prednisolon bij gezonde jonge 
mannen inderdaad gevonden dat er een afname was van de activiteit van dit enzym. Deze afname 
was dosisafhankelijk, waarbij de hoogste dosis de grootste afname veroorzaakte. Er was een 
verband tussen de afname van de delta-6-desaturase activiteit en ongunstige veranderingen in 
risicofactoren voor hart- en vaatziekten en suikerziekte.
Conclusie en toekomstig onderzoek
In het eerste gedeelte van dit proefschrift hebben we gevonden dat C14:0, C15:0, C17:0, 
trans-C16:1(n-7), trans-C18:1(n-7) en CLA, gemeten in plasma TG en PL, goede biomarkers zijn 
voor het meten van de inname van zuivelvet in de algemene bevolking. Het verband tussen 
inname van zuivelvet en biomarkers voor zuivelvet was onafhankelijk van de inname van visvet. 
Daarnaast hebben we gevonden dat een combinatie van vetzuren, met tenminste de vetzuren 
C15:0 en trans-C18:1(n-7), de inname van zuivelvet nog beter kan voorspellen dan enkelvoudige 
biomakers. We raden toekomstige onderzoekers dan ook aan om een combinatie van vetzuren 
te gebruiken voor een optimale voorspelling van inname van zuivelvet. Daarnaast raden we aan 
om ook vetzuren te onderzoeken in vetweefsel, omdat mogelijk sterkere verbanden kunnen 
worden gevonden tussen inname van zuivelvet en biomarkers gemeten in vetweefsel dan in 
plasma. Als derde, zouden we willen aanraden om de meetmethode nog verder te optimaliseren, 
bijvoorbeeld door het gebruik van massaspectrometrie.
In het tweede gedeelte van dit proefschrift hebben we geprobeerd om de vetzuur 
biomarkers te verbinden aan gezondheid van hart- en bloedvaten. Hiervoor hebben we gebruik 
gemaakt van gegevens van de Lifelines Biobank en Cohort studie. Er was voornamelijk een 
gunstig verband van de vetzuren C15:0, trans-C18:1(n-7) en CLA met risicofactoren voor hart- en 
vaatziekten, waaronder de “body mass index” en de buikomvang. Naast een gunstig verband 
voor de biomarkers voor zuivelvet met risicofactoren voor hart- en vaatziekten, wordt dit ook 
veelvuldig gesuggereerd voor de traditionele visvetten EPA en DHA. In het laatste gedeelte 
van dit proefschrift hebben we gevonden dat de inname van EPA en DHA in een populatie 
niertransplantatiepatiënten mogelijk kan leiden tot een betere gezondheid met een verminderde 
kans op voortijdig overlijden. Daarentegen was de inname van ALA juist verbonden met een 
verhoogde kans op voortijdig overlijden. Toekomstige studies doen er daarom goed aan om de 
inname van EPA+DHA en ALA apart te onderzoeken. Het mechanisme dat verantwoordelijk is 
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voor het verhoogde risico op voortijdig overlijden bij een relatief grote inname van ALA is niet 
bekend. Mogelijk speelt de inname van gluccorticoïden bij de groep patiënten die is onderzocht 
een grote rol. Glucocorticoïden kunnen mogelijk leiden tot een verlaging van EPA en DHA, 
wat weer kan resulteren in een verslechtering van de gezondheid op het gebied van hart- en 
vaatziekten. Uiteindelijk kan dit dan leiden tot een hogere kans op voortijdig overlijden. Meer 
onderzoek is nodig om uit de zoeken wat precies de reden is waarom een verhoogde inname 




Eindelijk is het zover, tijd om te promoveren! Met het schrijven van dit dankwoord ga ik een 
ongelofelijk mooie periode afsluiten. Een periode waarin ik het doen van een PhD niet altijd 
even makkelijk vond, maar waar zeker ook genoeg mooie momenten voorbij zijn gekomen, die 
me ontzettend veel hebben opgeleverd. Alleen al van dit boekje kon ik voor de start van mijn 
PhD alleen maar dromen, en nu is deze er echt! Uiteraard had ik dit zonder de hulp van anderen 
nooit zo goed voor mekaar kunnen krijgen. En daarom zou ik ze hierbij graag willen bedanken.
Graag zou ik willen beginnen met het bedanken van mijn promotoren. Allereerst, Prof. dr. S.J.L. 
Bakker, beste Stephan, wat fijn dat jij me de kans hebt gegeven om aan dit promotietraject te 
starten. Hoewel ik in het begin nog wat sceptisch was, vooral door de hoeveelheid lab werk 
die me te wachten stond, heb je me uiteindelijk toch weten te overtuigen om dit te gaan doen 
(het aannemen van een analist doet wonderen). Fijn dat je dat toch hebt gedaan, want zonder 
jou was dit niet gelukt! Ik heb de afgelopen jaren ontzettend veel van je mogen leren en wil 
je dan ook bedanken voor je goede discussies, je optimisme en vertrouwen in mij en mijn 
onderzoek. Bedankt dat je me de mogelijkheid hebt gegeven om me ontwikkelen op het gebied 
van voedingswetenschap, epidemiologie maar ook in het lab. Ik heb de samenwerking als zeer 
prettig ervaren.
Prof. dr. I.P. Kema, beste Ido, bedankt dat je me de mogelijkheid hebt gegeven om mijn onderzoek 
mede bij Laboratorium Geneeskunde uit te voeren. Als nieuweling in het lab heb je geprobeerd 
mij wegwijs te maken bij de afdeling Klinische Chemie en kon ik altijd bij je terecht om te 
overleggen hoe we mijn vetzuur methode nog meer konden verbeteren. Dank voor de prettige 
samenwerking.
En dan Prof. dr. F.A.J. Muskiet, beste Frits, fijn dat we tijdens mijn promotietraject hebben mogen 
samenwerken. Ik heb de afgelopen jaren veel van je mogen leren op het gebied van voeding 
en ben dan ook blij dat je je kennis altijd graag met me wilde delen. Je kon altijd net even een 
andere kijk op de wetenschap geven, wat mijn onderzoek net dat beetje extra gaf. Halverwege 
mijn promotie ben je met pensioen gegaan, maar ik heb nog altijd input van je mogen ontvangen 
ondanks dat je niet meer in het UMCG rond liep. Heel veel dank daarvoor. Mijn thesis was zonder 
jou kennis nooit geworden tot wat deze nu is.
Uiteraard zou ik ook graag mijn begeleiders vanuit FrieslandCampina willen bedanken. Dr. 
S.J. W. H. Oude Elferink en dr. C.M. Singh-Povel, beste Stephanie en Cécile. Fijn dat jullie 
mij de mogelijkheid hebben gegeven om een onderzoek te doen in samenwerking met 
FrieslandCampina. Stephanie, ook al was de samenwerking vrij kort, je wetenschappelijke input 
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was van grote waarde. Cécile, dank voor de fijne samenwerking. Je kijk vanuit het bedrijfsleven 
is een waardevolle input geweest voor mijn manuscripts.
Graag zou ik de leescommissie, bestaande uit prof. dr. E. J.M. Feskens, prof. dr. Prof. dr. J.J. Homan 
van der Heide en prof. dr. R.A. de Boer, willen bedanken voor het lezen en kritisch beoordelen 
van het manuscript.
Daarnaast zou ik ook graag alle co-auteurs willen bedanken voor de bijdrage aan de studies die 
we hebben uitgevoerd. Hierbij zou ik in het bijzonder dr. E. Corpeleijn willen benoemen. Bedankt 
voor je onuitputtelijke epidemiologische en statische kennis. Jou adviezen hebben mijn stukken 
die gebruik maakten van Lifelines data nog beter gemaakt. Verder zou ik graag mijn co-auteurs 
vanuit het VUmc willen bedanken. Dr. D.H. van Raalte en Dr. M.A.H. Muskiet, beste Daniël en 
Marcel, fijn dat ik gebruik mocht maken van jullie dataset om onderzoek te doen naar het effect 
van glucocorticoïden op vetzuren in plasma. Het heeft geresulteerd in een mooi artikel dat een 
waardevolle bijdrage heeft geleverd aan mijn thesis.
Uiteraard zou mijn onderzoek niets zijn geworden zonder de deelnemers en medewerkers van 
Lifelines. Bedankt voor jullie bijdrage en ik ben zeer benieuwd wat voor resultaten dit grote 
cohort nog meer gaat opleveren.
Tijdens mijn promotie heb ik ontelbare dagen doorgebracht op het lab van Bijzondere Chemie 
voor het opwerken en doormeten van al mijn samples. Voor mij een hele nieuwe ervaring, maar 
wel eentje die ik zeker niet had willen missen. Ik wil daarom ook alle medewerkers van het lab 
bedanken. Zonder jullie hulp was ik er zeker niet gekomen! Claude, Alle, Henk, Gerrie, dank voor 
jullie hulp bij het ontwikkelen van de nieuwe vetzuurmethode. Ik weet dat het soms erg irritant 
was als ik weer eens vroeg om een kolom te laten verwisselen in de GC-FID, maar het werd zeer 
gewaardeerd! Door jullie heb ik vele vetzuur samples kunnen meten. Dorothea en Josien, dank 
voor jullie enorme interesse in mijn onderzoek. Herman, bedankt voor al je gezellige verhalen en 
de jaarlijkse kerstbroden die we bij je konden bestellen. Noura, fijn dat je me hebt willen helpen 
met de start van mijn promotieonderzoek. En tot slot, Ingrid, wat een kennis over vetzuren heb 
jij zeg! Ik vond het erg fijn om met je samen te werken, en van jou de kneepjes van het vak te 
leren. Ontzettend bedankt voor al je hulp!
Naast de medewerkers van het lab zou ik ook graag de studenten willen bedanken die hebben 
geholpen met het doormeten van de 1600! Lifelines samples. Larissa, jij was er bij vanaf het 
begin. Dankjewel voor het doormeten van de allereerste samples. Adrian, heel erg bedankt voor 
je hulp en heel veel succes met je eigen promotieonderzoek. Ik ben ontzettend benieuwd wat je 
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er van gaat maken. Dan, Anne-Margreet, wat een topper ben jij! Je hebt ontzettend veel werk 
voor me verricht en bewonder je enorm voor je kennis en doorzettingsvermogen. Het verbaasde 
me dan ook niks dat je na je stage verder bent gaan studeren aan het HBO. Kitty, dankjewel dat 
je me geholpen hebt bij de allerlaatste loodjes voor het Lifelines Cohort. Zonder jullie hulp had 
ik niet zo veel samples kunnen meten en stond ik waarschijnlijk nog steeds in het lab.
Wat zou mijn promotietijd zijn geweest zonder de ‘labrats’. Wat ben ik blij dat ik met jullie op een 
kamer heb gezeten. Bedankt voor de gezelligheid tijdens en na kantooruren. Zo heb ik enorm 
gelachen op onze kamer, maar kijk ik ook met veel plezier terug op onze borrels, Noorderzon 
uitje, de Escape room, de etentjes bij elkaar thuis en uiteraard mijn bruiloft. Naast dat we de 
leuke momenten met elkaar deelden, kon ik ook bij jullie terecht als het even wat minder ging. Ik 
had me geen betere groep promovendi kunnen wensen. Martijn, wat een kennis heb jij in huis! 
Werkelijk alles kan je aan jou vragen en vaak weet je het antwoord ook nog wel. Is het niet over 
labzaken, dan weet je wel te helpen met statistiek en ‘R’. Dankjewel voor al je hulp! Isidor, wat 
een doorzettingsvermogen heb jij en wat heb ik ontzettend met je gelachen, op kantoor maar 
ook tijdens de voedingscongressen in Heeze. Eline en Anna, bijna de hele promotietijd zat ik bij 
jullie op de kamer en konden we lief en leed delen tijdens de theekransjes! Wat een fijne tijd 
was dat. Succes met de laatste loodjes, ook jullie komen er wel! Carolien en Mark, dank voor de 
gezellige tijd, en veel succes met jullie onderzoeken.
Naast de collega’s van laboratorium geneeskunde maakte ik ook officieel deel uit van de 
‘Nefronerds’. Ondanks dat ik wat minder bij jullie aanwezig was, omdat mijn kantoor ergens 
anders in het UMCG was, heb ik me desalniettemin bij jullie zeer welkom gevoeld. Ik kon 
altijd bij jullie terecht voor vragen en gezelligheid. Dank jullie wel voor alle borrels, etentjes, 
volleybaltoernooien, sinterklaasvieringen en mijn allereerste kennismaking met congressen. 
Ik heb me zeer vermaakt bij de ASN in Philadelphia! Ineke, ex-nefronerd, dankjewel dat je 
me de vacature voor de PhD hebt toegestuurd. Zonder jou was ik hier nooit aan begonnen. 
Lianne, dankjewel dat je samen met mij in de postercommissie wilde voor de ASN. Lyanne en 
Dineke, mede-epidemiologen, dankjewel voor jullie enorme epi kennis! Coby, bedankt voor de 
samenwerking in het FrieslandCampina project, en succes met de vetzuur samples in je eigen 
project. Verder wil ik uiteraard de rest van de nefronerds ook bedanken. Zonder jullie zag mijn 
promotietijd er heel anders uit.
In mei 2018 ben ik met mijn nieuwe baan begonnen bij PPD in Bennekom. Dit zorgde er voor 
dat ik mijn thesis af moest ronden naast mijn nieuwe baan. Als eerste wil ik dan ook Viola 
bedanken dat ze me de kans heeft gegeven om een eerste stap te maken binnen het klinische 
onderzoek, maar daarnaast ook veel begrip heeft gehad voor het feit dat een thesis afronden 
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naast je baan niet altijd even makkelijk is. Verder, Marit (zonder jou zat ik niet bij PPD, ik ben blij 
dat je me geïntroduceerd hebt), Moniek R (ik kon me geen betere ‘buddy’ wensen), Moniek L, 
Julie, Madelon, Daphne, Liesbeth, mede-leden van de Accie en nog vele andere collega’s, dank 
jullie wel voor jullie steun en interesse! Ik weet dat ik soms wat heb zitten zeuren over mijn 
PhD schrijfweekenden, maar het heeft me wel erg geholpen om stoom af te blazen! Jullie zijn 
supercollega’s en zonder jullie had ik me niet zo fijn gevoeld bij PPD. Ik kijk nu al uit naar Glasgow 
en de prestaties van ons supervoetbal team, sowieso dat we die prijs binnenhalen!
Tot slot wil ik graag aangeven dat ik erg blij ben geweest met de interesse en ondersteuning van 
mijn vrienden en familie. Allereerst, de voedingsmiepjes! Lieve Aafke, Annelies, Bianca en Elles. 
Fijn dat we al jaren met elkaar bevriend zijn. Bedankt voor de gezelligheid die jullie brachten 
tijdens de studententijd in Wageningen, maar ook daarna. Ik heb genoten van onze etentjes, 
borrels, filmavonden, zwemavonden (of eerder een paar baantjes zwemmen, genieten van het 
bubbelbad en afsluiten met een Turks stoombad – avonden), bankhangdagen, vakanties en 
dagjes uit. Ook al wonen we nu allemaal in een andere uithoek van het land, toch fijn dat we 
elkaar nog regelmatig blijven zien. Jeske, ook jou heb ik leren kennen in Wageningen tijdens de 
opleiding, maar eigenlijk pas echt toen we samen het avontuur aan gingen in de USA! Superleuk 
dat we dit samen mochten beleven. Dankjewel voor de gezellige etentjes en squashavonden 
in Wageningen en niet te vergeten de leuke tijd in Zuid-Afrika. Veel succes met het afronden 
van je promotie en de voorbereiding van je bruiloft! Het jaar kan voor jou nu al niet meer stuk!
Lieve Sjoukje, we kennen elkaar al sinds groep 4 van de basisschool. Het is dan ook niet zo gek 
dat ik me naast jou altijd vertrouwd voel, ook al hebben we elkaar even niet gezien of gesproken. 
Wat hebben we veel beleefd samen (gek doen op de middelbare school, mooie en hilarische 
vakanties naar Parijs, Italië en Barcelona, borrelen in Groningen of Wageningen, etc). Ik denk 
er met plezier aan terug en ik ben blij dat we elkaar ook nu nog steeds zien. Dankjewel voor je 
jarenlange vriendschap, je humor, je interesse en gezelligheid.
Uiteraard wil ik mijn paranimfen niet vergeten te noemen. Annelies en Eline, heel fijn dat jullie 
aan mijn zijde willen staan tijdens mijn verdediging. Lieve Annelies, ik heb je leren kennen tijdens 
het eerste jaar van de opleiding ‘Voeding en Gezondheid’. Je bent een lieve vriendin die altijd 
aan iedereen denkt en bij wie je altijd terecht kunt. Dankjewel voor je steun en interesse in mijn 
PhD, alsmede de gezellige en humorvolle, hilarische uitjes en telefoontjes (want ja, als je elkaar 
even niet kan zien, dan moet je maar uren gaan bellen). Fijn dat we nu weer een stuk dichter bij 
elkaar wonen! Eline, mede labrat! Ik heb mijn hele promotietijd bij jou op de kamer gezeten, en 
wat was dat fijn! We deelden ons lief en leed met elkaar en aan humor op onze kamer ontbrak 
het zeker niet. Daarnaast heb ik genoten van de tripjes naar Stockholm en Stellenbosch, Zuid-
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Afrika! Ik had dit zeker niet willen missen. Lieve Eline, dankjewel dat ook jij aan mijn zijde wilt 
staan. Heel veel succes met de laatste loodjes van je eigen proefschrift, je kan het!
Dan mijn schoonfamilie, lieve Nicolette, Ruud, en Inge. Wat fijn dat ik jullie heb leren kennen. 
Bedankt dat jullie altijd interesse hebben gehad in mijn PhD en daarbuiten. Fijn dat ook jullie 
aanwezig zullen zijn bij mijn verdediging.
Lieve papa en mama (oftewel mum en dad), ik kan jullie in geen woorden omschrijven. Dank jullie 
wel voor alle interesse, steun, humor en liefde die jullie aan mij hebben meegegeven, zonder 
jullie was ik niet geworden wie ik nu ben! Lieve Arianna (Ari) en Nynke (Enke), lieve soul sisters, 
wat mag ik mezelf gelukkig prijzen met zulke lieven zussen! Ik kan met jullie lachen, leuke reisjes 
maken (Keulen, Gent, maar ook NZ en Australië), gezellig borrelen, concertjes bezoeken, maar 
ook bij jullie terecht als het even wat minder is. Jullie voelen haarfijn aan hoe het met me gaat, 
en daar hoeven we niet eens voor te praten. Nynke, ‘mijn kleine zusje’ wat ben ik trots op jou 
hoe je in het leven staat! Even als Ari, wat heb jij een moed om zomaar je droombaan achterna 
te gaan! Trouwens, je voorspelling is inderdaad uitgekomen, dr. & dr. van der Pol it is!
Lieve Edwin, wat ben ik blij dat ik jou heb leren kennen. Je gezelligheid, humor en liefde maken 
mijn dag altijd weer goed. Bedankt dat je me de steun hebt gegeven om deze PhD te volbrengen. 
Ook al was ik zo af en toe niet te genieten, jij wist precies hoe het zat en kon er altijd weer een 
positieve draai aan geven. Bedankt dat je er altijd voor me bent geweest! Nu dat deze missie 
is volbracht, is het tijd om verder te genieten van mooie reisjes, concertjes en het leven. Lieve 
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